

=> fil reg
FILE 'REGISTRY' ENTERED AT 16:26:34 ON 20 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 DEC 2006 HIGHEST RN 916029-54-4
DICTIONARY FILE UPDATES: 19 DEC 2006 HIGHEST RN 916029-54-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d que stat 16
L6 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 15
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M3 C M2 N AT 15

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE

=> fil hcap
FILE 'HCAPLUS' ENTERED AT 16:27:12 ON 20 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

December 20, 2006

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Dec 2006 VOL 145 ISS 26
 FILE LAST UPDATED: 19 Dec 2006 (20061219/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> d que nos 111
L6          STR
L8      1762424 SEA FILE=REGISTRY ABB=ON PLU=ON NCNC2/ESS
L10      479 SEA FILE=REGISTRY SUB=L8 SSS FUL L6
L11      12 SEA FILE=HCAPLUS ABB=ON PLU=ON L10
```

```
=> fil marpat
FILE 'MARPAT' ENTERED AT 16:27:31 ON 20 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)
```

FILE CONTENT: 1961-PRESENT VOL 145 ISS 25 (20061215/ED)



SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
 (COVERAGE TO THESE DATES IS NOT COMPLETE):

US	20060247444	02 NOV 2006
DE	102005020105	26 OCT 2006
EP	1717297	02 NOV 2006
JP	2006302757	02 NOV 2006
WO	2006116773	02 NOV 2006
GB	2425654	01 NOV 2006
FR	2884821	27 OCT 2006
RU	2286328	27 OCT 2006
CA	2545188	28 OCT 2006

Expanded G-group definition display now available.

```
=> d que 121
L15          STR
```



VPA 14-16/15/19 U

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

L21 21 SEA FILE=MARPAT SSS FUL L15

=> fil wpix

FILE 'WPIX' ENTERED AT 16:28:01 ON 20 DEC 2006

COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE LAST UPDATED: 18 DEC 2006 <20061218/UP>

MOST RECENT THOMSON SCIENTIFIC UPDATE: 200681 <200681/DW>

DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> YOU ARE IN THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:

http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE

<http://scientific.thomson.com/support/patents/coverage/latestupdates/>

PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE

http://www.stn-international.de/stndatabases/details/ipc_reform.html and

<http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf>



>>> FOR DETAILS ON THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX
PLEASE SEE

[<<<](http://www.stn-international.de/stndatabases/details/dwpi_r.html)

=> d que 128

L15

STR



VPA 14-16/15/19.U

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

L24 135 SEA FILE=WPIX SSS FUL L15

L25 4 SEA FILE=WPIX ABB=ON PLU=ON L24/DCR

L26 4 SEA FILE=WPIX ABB=ON PLU=ON (RADX2Z/DCN OR RADX3A/DCN OR
RADX31/DCN OR RADX33/DCN OR RADX34/DCN OR RADX35/DCN OR
RADX38/DCN OR RA5TKN/DCN OR RA5TKQ/DCN OR RA5TKS/DCN OR
RA5TKT/DCN OR RA5TKU/DCN OR RA5TKV/DCN OR RA5TKW/DCN OR
RA5TKX/DCN OR RA5TKY/DCN OR RA5TLA/DCN OR RA5TLB/DCN OR
RA5TLC/DCN OR RA5TLD/DCN OR RA5TLE/DCN OR RA5TLF/DCN OR
RA5TLG/DCN OR RA5TLH/DCN OR RA5TLI/DCN OR RA5TLJ/DCN OR
RA5TL0/DCN OR RA5TL1/DCN OR RA5TL2/DCN OR RA5TL3/DCN OR
RA5TL4/DCN OR RA5TL5/DCN OR RA5TL6/DCN OR RA5TL7/DCN OR
RA5TL8/DCN OR RA5TL9/DCN OR RA5URA/DCN OR RA5URB/DCN OR
RA5URC/DCN OR RA5URD/DCN OR RA5URE/DCN OR RA5URG/DCN OR
RA5URH/DCN OR RA5URI/DCN OR RA5URJ/DCN OR RA5URK/DCN OR
RA5URM/DCN OR RA5URN/DCN OR RA5URO/DCN OR RA5URP/DCN OR
RA5URQ/DCN OR RA5URR/DCN OR RA5URS/DCN OR RA5URT/DCN OR
RA5URU/DCN OR RA5URV/DCN OR RA5URW/DCN OR RA5URX/DCN OR
RA5URY/DCN OR RA5URZ/DCN OR RA5UR8/DCN OR RA5USA/DCN OR
RA5USB/DCN OR RA5USD/DCN OR RA5USF/DCN OR RA5USG/DCN OR
RA5USK/DCN OR RA5USL/DCN OR RA5USN/DCN OR RA5USR/DCN OR
RA5UST/DCN OR RA5USW/DCN OR RA5USY/DCN OR RA5US0/DCN OR
RA5US1/DCN OR RA5US4/DCN OR RA5US6/DCN OR RA5US7/DCN OR
RA5US8/DCN OR RA5US9/DCN OR RA5UTG/DCN OR RA5UTH/DCN OR
RA5UTI/DCN OR RA5UTR/DCN OR RA5UTT/DCN OR RA5UTU/DCN OR
RA5UTV/DCN OR RA5UTW/DCN OR RA5UTY/DCN OR RA5UUUA/DCN OR

RA5UUB/DCN OR RA5UUC/DCN OR RA5UUG/DCN OR RA5UUH/DCN OR
 RA5UUI/DCN OR RA5UUO/DCN OR RA5UUP/DCN OR RA5UUQ/DCN OR
 RA5UUS/DCN OR RA5UUT/DCN OR RA5UUV/DCN OR RA5UUY/DCN OR
 RA5UUZ/DCN OR RA5UU0/DCN OR RA5UU1/DCN OR RA5UU2/DCN OR
 RA5UU3/DCN OR RA5UU4/DCN OR RA5UU6/DCN OR RA5UU7/DCN OR
 RA5UU8/DCN OR RA5UU9/DCN OR RA5UVB/DCN OR RA5UVM/DCN OR
 RA5UVN/DCN OR RA5UVO/DCN OR RA5UVQ/DCN OR RA5UVR/DCN OR
 RA5UVS/DCN OR RA5UVV/DCN OR RA5UVW/DCN OR RA5UVX/DCN OR
 RA5UVY/DCN OR RA5UV1/DCN OR RA5UV2/DCN OR RA5UV3/DCN OR
 RA5UV5/DCN OR RA5UV9/DCN OR RA5UW0/DCN OR RA5UW1/DCN OR
 RA6LJH/DCN OR RA6LJO/DCN OR RA6LKI/DCN OR RA6LKJ/DCN OR
 RA6LKL/DCN)

L28 4 SEA FILE=WPIX ABB=ON PLU=ON L25 OR L26

=> dup rem 111 121 128
 FILE 'HCAPLUS' ENTERED AT 16:28:17 ON 20 DEC 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MARPAT' ENTERED AT 16:28:17 ON 20 DEC 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

FILE 'WPIX' ENTERED AT 16:28:17 ON 20 DEC 2006
 COPYRIGHT (C) 2006 THE THOMSON CORPORATION
 PROCESSING COMPLETED FOR L11
 PROCESSING COMPLETED FOR L21
 PROCESSING COMPLETED FOR L28
 L40 30 DUP REM L11 L21 L28 (7 DUPLICATES REMOVED)
 ANSWERS '1-12' FROM FILE HCAPLUS
 ANSWERS '13-29' FROM FILE MARPAT
 ANSWER '30' FROM FILE WPIX

=> d 140 ibib abs hitstr 1-12;d 140 ibib abs qhit 13-29;d 140 ibib abs hitstr 30

L40 ANSWER 1 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1
 ACCESSION NUMBER: 2003:376828 HCAPLUS Full-text
 DOCUMENT NUMBER: 138:368893
 TITLE: Preparation and use of substituted imidazoles as
 selective histamine H3 receptor agonists
 INVENTOR(S): Rudolf, Klaus; Hurnaus, Rudolf; Stenkamp, Dirk;
 Mueller, Stephan; Krist, Bernd
 PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Novo
 Nordisk A/S
 SOURCE: PCT Int. Appl., 92 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040106	A1	20030515	WO 2002-EP12305	20021105
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,			

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG

DE 10155202 A1 20030731 DE 2001-10155202 20011109

EP 1446385 A1 20040818 EP 2002-802645 20021105

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

JP 2005508986 T 20050407 JP 2003-542152 20021105


US 2003181479 A1 20030925 US 2002-290615 20021108

US 2004127718 A1 20040701 US 2003-741880 20031219

PRIORITY APPLN. INFO.: DE 2001-10155202 A 20011109
 US 2001-334209P P 20011129
 WO 2002-EP12305 W 20021105
 US 2002-290615 B1 20021108

OTHER SOURCE(S): MARPAT 138:368893

GI



AB The present invention relates to novel substituted imidazoles (shown as I; variables defined below; e.g. N-trityl-3-(5-methyl-1H-imidazol-4-yl)propan-1-ol), to the use of these compds. as medicaments, to pharmaceutical compns. comprising the compds., and to a method of treatment employing these compds. and compns. The present compds. show a high and selective binding affinity to the histamine H3 receptor indicating a histamine H3 receptor antagonistic or agonistic activity. As a result, the compds. are useful for the treatment of disorders related to the histamine H3 receptor. More particularly, the present compds. possess a histamine H3 receptor agonistic activity and are accordingly useful in the treatment of disorders in which a histamine H3 receptor activation is beneficial. IC₅₀ values for binding to the histamine H3 receptor were determined for 2 examples of I, e.g. <50 nM for 4-[3-(3-iodobenzyl)oxy]propyl]-5-methyl-1H-imidazole. Compds. I do not show a high affinity for histamine H1 and H2 receptors. Preparation methods are claimed and 17 example preps. plus characterization data for many more I are included. For example, 5-methyl-4-(3-phenoxypropyl)-1H-imidazole was prepared from N-trityl-3-(5-methyl-1H-imidazol-4-yl)propan-1-ol (5 mmol), Ph₃P (6 mmol), phenol (5 mmol) and di-Et azodicarboxylate (6 mmol) in THF; the trityl reactant was prepared in 3 steps starting from 5-methyl-1H-imidazole-4-carboxaldehyde and involving intermediates 3-(5-methyl-1H-imidazol-4-yl)propionic acid Me ester and its N-trityl derivative. For I: R1 is H or a functional group which can be converted into a H atom in vivo; R2 is a C1-6-alkyl, C3-7-cycloalkyl, aryl or aryl-C1-2-alkyl; n is 2, 3, 4 or 5; X is O, S, -CO-, -OCH₂- or -SOCH₂-; Ar is phenylene or naphthylene, a 5-membered heteroarylene linked via a C or N atom or a 6-membered heteroarylene group containing one or two N atoms, while the above-mentioned phenylene or 5- or 6-membered heteroarylene groups are optionally condensed via pairs of two adjacent C atoms with one or two saturated, unsatd. or aromatic carbocyclic or

heterocyclic groups, which are optionally substituted by one or two carbonyl or C1-3-alkyl groups, and the resulting condensed bi- or tricycles may be linked to X via the carbocyclic or heterocyclic moiety. Y is H, F, Cl, Br, I, hydroxy, cyano, C1-6-alkyl, C3-7-cycloalkyl, acetylene, C1-4-alkylacetylene, C1-4-alkylcarbonyl, C3-7-cycloalkylcarbonyl, -C(:NOH)CH₃, Ph, 5- or 6-membered heteroaryl, C1-6-alkyloxy or phenoxy; addnl. details are given in the claims. Claimed applications include treatment of ischemic arrhythmias, myocardial ischemia and myocardial infarction, asthma, chronic vasomotor rhinitis, pain or as a gastroprotective drug. Four pharmaceutical formulations and methods for preparing them are described.


IT 524011-59-4P, 6-[3-(5-Methyl-1H-imidazol-4-yl)propoxy]-3,4-dihydro-2H-naphthalen-1-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation and use of substituted imidazoles as selective histamine H₃ receptor agonists)

RN 524011-59-4 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[3-(5-methyl-1H-imidazol-4-yl)propoxy]-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 2 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2001:780862 HCAPLUS Full-text

DOCUMENT NUMBER: 135:331423

TITLE: Preparation of 5-substituted tetralones as inhibitors of ras farnesyl transferase for treatment of proliferative diseases

INVENTOR(S): Denny, William Alexander; Hutchings, Richard H.; Johnson, Douglas S.; Kaltenbronn, James Stanley; Lee, Ho Huat; Leonard, Daniele Marie; Milbank, Jared Bruce John; Repine, Joseph Thomas; Newcastle, Gordon William; White, Andrew David

PATENT ASSIGNEE(S): Warner-Lambert Co., USA

SOURCE: PCT Int. Appl., 358 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001079180	A2	20011025	WO 2001-US12490	20010416
WO 2001079180	A3	20020523		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,				

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
 RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 CA 2405696 A1 20011025 CA 2001-2405696 20010416
 BR 2001010142 A 20030121 BR 2001-10142 20010416
 EP 1276725 A2 20030122 EP 2001-927121 20010416
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2003531143 T 20031021 JP 2001-576781 20010416
 US 2004044057 A1 20040304 US 2003-257301 20030519
 US 6943183 B2 20050913
 PRIORITY APPLN. INFO.: US 2000-197485P P 20000417
 WO 2001-US12490 W 20010416

OTHER SOURCE(S): MARPAT 135:331423

GI



AB Title compds. I [wherein W = CH₂ or CH₂CH₂; R₃ = H, alkyl, or (un)substituted Ph; R_{3a} = H or alkyl; provided that R₃ and R_{3a} cannot both be H and that when R₃ = (un)substituted Ph, then R_{3a} = H; X = halo, NH₂, alkyl, alkenyl, heteroaryl, CH₂R₆, CH₂NR₆R_{6a}, CH₂SR₆, CH₂CH₂CO₂R₆, or (un)substituted aryl, or (hetero)arylalkyl; R₆ = H, (cyclo)alkyl, alkenyl, benzyl, or (un)substituted Ph; R_{6a} = H or alkyl; Y = O or S; R₅ = H, alkyl, or NH₂; and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof] were prepared and formulated as farnesyl transferase enzyme inhibitors. For example, coupling of 5-chloromethyl-6-hydroxy- 2,3,4-trihydronaphthalen-1-one with thiophenol using diisopropylamine in THF (58%), followed by addition of (R)-2-imidazol-1-yl-1-phenylethanol in the presence of PPh₃ and di-Et azodicarboxylate in THF (31%), gave II. The latter inhibited farnesyl protein transferase (FPT) with IC₅₀ of 0.3 nM. I are useful for treating and preventing uncontrolled or abnormal proliferation of tissues, such as cancer, atherosclerosis, restenosis, and psoriasis (no data).

IT 368883-02-7P 368883-03-8P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(2-pyridylsulfonyl)methyl]-2,3,4-trihydronaphthalen-1-one
 368883-11-8P 368883-37-8P 368883-39-0P
 368884-12-2P 368884-13-3P 368884-15-5P
 368884-16-6P 368884-31-5P, 6-((1S)-2-Imidazolyl-1-

phenylethoxy)-5-(bromomethyl)-2,3,4-trihydronaphthalen-1-one hydrobromide
368884-36-0P, Methyl 3-[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzoate


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 5-substituted tetralones as Ras farnesyl transferase inhibitors for treatment of proliferative diseases, such as cancer, atherosclerosis, restenosis, and psoriasis)

RN 368883-02-7 HCPLUS

CN 1(2H)-Naphthalenone, 6-[(1S)-2-(2,5-dihydro-1H-imidazol-1-yl)-1-phenylethoxy]-3,4-dihydro-5-[(2-pyridinylthio)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368883-03-8 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(2-pyridinylsulfonyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368883-11-8 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(1-methylethoxy)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368883-37-8 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-nitro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368883-39-0 HCPLUS

CN 1(2H)-Naphthalenone, 5-(aminomethyl)-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 368884-12-2 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-(3-pyridinyl)ethoxy]-5-nitro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368884-13-3 HCPLUS

CN 1(2H)-Naphthalenone, 5-amino-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-(3-pyridinyl)ethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368884-15-5 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-1-(1H-imidazol-1-ylmethyl)-2-methylpropoxy]-5-nitro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368884-16-6 HCPLUS

CN 1(2H)-Naphthalenone, 5-amino-3,4-dihydro-6-[(1S)-1-(1H-imidazol-1-ylmethyl)-2-methylpropoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368884-31-5 HCAPLUS

CN 1(2H)-Naphthalenone, 5-(bromomethyl)-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-, monohydrobromide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HBr

RN 368884-36-0 HCAPLUS

CN Benzoic acid, 3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 368883-98-1P, (\pm)-6-[2-Imidazolyl-1-(3-pyridyl)ethoxy]-5-(2-phenylethyl)-2,3,4-trihydronaphthalen-1-one

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(preparation of 5-substituted tetralones as Ras farnesyl transferase inhibitors for treatment of proliferative diseases, such as cancer, atherosclerosis, restenosis, and psoriasis)

RN 368883-98-1 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)-1-(3-pyridinyl)ethoxy]-5-(2-phenylethyl)- (9CI) (CA INDEX NAME)




IT 369639-18-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 5-substituted tetralones as Ras farnesyl transferase inhibitors for treatment of proliferative diseases, such as cancer, atherosclerosis, restenosis, and psoriasis)

RN 369639-18-9 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-(3-pyridinyl)ethoxy]-5-(2-phenylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 368879-97-4P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-(2-

phenylethyl)-2,3,4-trihydronaphthalen-1-one 368880-02-8P,
 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[2-(4-pyridyl)ethyl]-2,3,4-
 trihydronaphthalen-1-one 368881-42-9P 368881-96-3P
 368881-97-4P 368882-00-2P 368882-01-3P


368883-89-0P 368884-05-3P, (\pm)-6-[2-Imidazolyl-1-(2-
 thienyl)ethoxy]-5-prop-2-enyl-2,3,4-trihydronaphthalen-1-one

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 5-substituted tetralones as Ras farnesyl transferase inhibitors for treatment of proliferative diseases, such as cancer, atherosclerosis, restenosis, and psoriasis)

RN 368879-97-4 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-(2-phenylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-02-8 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-42-9 HCPLUS

CN 1(2H)-Naphthalenone, 6-[(1S)-1-(2,4-difluorophenyl)-2-(1H-imidazol-1-yl)ethoxy]-3,4-dihydro-5-[(2-pyridinylsulfonyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 368881-96-3 HCPLUS

CN β -Alanine, N-[3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]benzoyl]-, ethyl ester

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-97-4 HCPLUS

CN β -Alanine, N-[4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]benzoyl]-, ethyl ester
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-00-2 HCPLUS

CN β -Alanine, N-[3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]benzoyl]-, ethyl ester
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-01-3 HCPLUS

CN β -Alanine, N-[4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]benzoyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368883-89-0 HCPLUS


CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-(2-propenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 368884-05-3 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)-1-(2-thienyl)ethoxy]-5-(2-propenyl)- (9CI) (CA INDEX NAME)



IT **367928-46-9P** **368879-80-5P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-(phenylthiomethyl)-2,3,4-trihydronaphthalen-1-one
368879-81-6P, Methyl 2-[[2-((1S)-2-imidazolyl-1-phenylethoxy)-5-oxo-6,7,8-trihydronaphthyl]methylthio]benzoate **368879-82-7P**,
2-[[2-((1S)-2-Imidazolyl-1-phenylethoxy)-5-oxo-6,7,8-trihydronaphthyl]methylthio]benzoic acid **368879-83-8P**
368879-84-9P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(phenylamino)methyl]-2,3,4-trihydronaphthalen-1-one **368879-85-0P**
, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(methylphenylamino)methyl]-2,3,4-trihydronaphthalen-1-one **368879-86-1P**, Methyl
4-[[2-((1S)-2-imidazolyl-1-phenylethoxy)-5-oxo-6,7,8-trihydronaphthyl]methyl]methylamino]benzoate **368879-88-3P**
368879-89-4P **368879-90-7P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(phenylmethoxy)methyl]-2,3,4-trihydronaphthalen-1-one
368879-91-8P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-(cyclopentyloxymethyl)-2,3,4-trihydronaphthalen-1-one **368879-92-9P**
, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-(prop-2-enyloxymethyl)-2,3,4-trihydronaphthalen-1-one **368879-93-0P** **368879-94-1P**
368879-95-2P **368879-96-3P** **368879-98-5P**,
5-(2H-Benzo[d]-1,3-dioxolan-5-yl)-6-((1S)-2-imidazolyl-1-phenylethoxy)-2,3,4-trihydronaphthalen-1-one **368879-99-6P**,
6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-(3-chlorophenyl)-2,3,4-trihydronaphthalen-1-one **368880-00-6P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-(2-naphthyl)-2,3,4-trihydronaphthalen-1-one
368880-01-7P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[2-(2-pyridyl)ethyl]-2,3,4-trihydronaphthalen-1-one **368880-03-9P**,
(S)-6-(-2-Imidazol-1-yl-1-phenylethoxy)-5-(2-pyridin-3-ylethyl)-3,4-dihydro-2H-naphthalen-1-one **368880-04-0P**, Methyl
4-[2-[(1S)-2-imidazolyl-1-phenylethoxy)-5-oxo-6,7,8-trihydronaphthyl]ethyl]benzoate **368880-05-1P**,
6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[2-(4-fluorophenyl)ethyl]-2,3,4-trihydronaphthalen-1-one **368880-06-2P**, Methyl
3-[2-((1S)-2-imidazolyl-1-phenylethoxy)-5-oxo-6,7,8-trihydronaphthyl]propanoate **368880-07-3P**, 3-[2-((1S)-2-Imidazolyl-1-phenylethoxy)-5-oxo-6,7,8-trihydronaphthyl]propanoic acid
368880-08-4P, 4-[[2-((1S)-2-Imidazolyl-1-phenylethoxy)-5-oxo-6,7,8-trihydronaphthyl]methyl]benzenecarbonitrile **368880-09-5P**,
6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-bromo-2,3,4-trihydronaphthalen-1-one **368880-10-8P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-(3-thienyl)-2,3,4-trihydronaphthalen-1-one **368880-12-0P**
368880-13-1P, 5-Amino-6-((S)-2-imidazol-1-yl-1-phenylethoxy)-3,4-dihydro-2H-naphthalen-1-one **368880-14-2P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-(2-phenylpropyl)-2,3,4-trihydronaphthalen-1-one
368880-15-3P **368880-16-4P**, 6-((S)-2-Imidazol-1-yl-1-phenylethoxy)-5-(3-phenylpropyl)-3,4-dihydro-2H-naphthalen-1-one
368880-17-5P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-benzyl-2,3,4-

trihydronaphthalen-1-one **368880-18-6P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-propyl-2,3,4-trihydronaphthalen-1-one **368880-19-7P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-(2-methylprop-2-enyl)-2,3,4-trihydronaphthalen-1-one **368880-21-1P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-(2-methylpropyl)-2,3,4-trihydronaphthalen-1-one **368880-23-3P**, 6-[2-(1H-Imidazol-1-yl)-1,1-dimethylethoxy]-5-(2-phenylethyl)-3,4-dihydro-1(2H)-naphthalenone **368880-26-6P**, (S)-6-(1-Imidazol-1-ylmethyl-2-methylpropoxy)-5-(2-pyridin-4-ylethyl)-3,4-dihydro-2H-naphthalen-1-one **368880-27-7P** **368880-28-8P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-(methoxymethyl)-2,3,4-trihydronaphthalen-1-one **368880-30-2P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-(phenoxy methyl)-2,3,4-trihydronaphthalen-1-one **368880-32-4P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[[3-(tert-butyl)phenoxy]methyl]-2,3,4-trihydronaphthalen-1-one **368880-34-6P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(3-chlorophenoxy)methyl]-2,3,4-trihydronaphthalen-1-one **368880-36-8P** **368880-38-0P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(3,5-dimethoxyphenoxy)methyl]-2,3,4-trihydronaphthalen-1-one **368880-40-4P** **368880-41-5P** **368880-42-6P** **368880-43-7P** **368880-45-9P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(2-ethoxyphenoxy)methyl]-2,3,4-trihydronaphthalen-1-one **368880-47-1P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(4-ethoxyphenoxy)methyl]-2,3,4-trihydronaphthalen-1-one **368880-49-3P** **368880-50-6P** **368880-51-7P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(4-ethylphenoxy)methyl]-2,3,4-trihydronaphthalen-1-one **368880-52-8P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-(2-naphthyloxymethyl)-2,3,4-trihydronaphthalen-1-one **368880-53-9P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(2-chloro-5-methylphenoxy)methyl]-2,3,4-trihydronaphthalen-1-one **368880-54-0P** **368880-55-1P** **368880-56-2P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(2,4,6-trimethylphenoxy)methyl]-2,3,4-trihydronaphthalen-1-one **368880-57-3P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(4-methylpropyl)phenoxy)methyl]-2,3,4-trihydronaphthalen-1-one **368880-58-4P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(4-(trifluoromethyl)phenoxy)methyl]-2,3,4-trihydronaphthalen-1-one **368880-59-5P** **368880-60-8P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-(8-quinolyloxy methyl)-2,3,4-trihydronaphthalen-1-one **368880-61-9P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(4-chlorophenoxy)methyl]-2,3,4-trihydronaphthalen-1-one **368880-62-0P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(3-methylphenoxy)methyl]-2,3,4-trihydronaphthalen-1-one **368880-63-1P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(4-methylphenoxy)methyl]-2,3,4-trihydronaphthalen-1-one **368880-64-2P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(2-fluorophenoxy)methyl]-2,3,4-trihydronaphthalen-1-one **368880-65-3P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(3-fluorophenoxy)methyl]-2,3,4-trihydronaphthalen-1-one **368880-66-4P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(4-fluorophenoxy)methyl]-2,3,4-trihydronaphthalen-1-one **368880-67-5P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-(naphthyloxymethyl)-2,3,4-trihydronaphthalen-1-one **368880-68-6P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(3-methoxyphenoxy)methyl]-2,3,4-trihydronaphthalen-1-one **368880-69-7P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(2-chlorophenoxy)methyl]-2,3,4-trihydronaphthalen-1-one **368880-70-0P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-(6-quinolyloxy methyl)-2,3,4-trihydronaphthalen-1-one **368880-71-1P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(4-bromophenylthio)methyl]-2,3,4-trihydronaphthalen-1-one **368880-72-2P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(4-fluorophenylthio)methyl]-2,3,4-trihydronaphthalen-1-one **368880-73-3P**, N-[4-[[2-((1S)-2-Imidazolyl-1-phenylethoxy)-5-oxo-6,7,8-trihydronaphthyl]methylthio]phenyl]acetamide **368880-74-4P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(4-hydroxyphenylthio)methyl]-2,3,4-trihydronaphthalen-1-one

368880-75-5P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(4-methylphenylthio)methyl]-2,3,4-trihydronaphthalen-1-one
 368880-76-6P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(2-methylpropylthio)methyl]-2,3,4-trihydronaphthalen-1-one
 368880-77-7P 368880-78-8P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(2-bromophenylthio)methyl]-2,3,4-trihydronaphthalen-1-one
 368880-79-9P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(2-chlorophenylthio)methyl]-2,3,4-trihydronaphthalen-1-one
 368880-80-2P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(2,6-dichlorophenylthio)methyl]-2,3,4-trihydronaphthalen-1-one
 368880-81-3P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(2-methoxyphenylthio)methyl]-2,3,4-trihydronaphthalen-1-one
 368880-82-4P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(2-methylphenylthio)methyl]-2,3,4-trihydronaphthalen-1-one
 368880-83-5P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(4-methoxyphenylthio)methyl]-2,3,4-trihydronaphthalen-1-one
 368880-84-6P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(4-nitrophenylthio)methyl]-2,3,4-trihydronaphthalen-1-one
 368880-85-7P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(3-methoxyphenylthio)methyl]-2,3,4-trihydronaphthalen-1-one
 368880-86-8P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(4-chlorophenylthio)methyl]-2,3,4-trihydronaphthalen-1-one
 368880-87-9P 368880-88-0P 368880-89-1P
 368880-90-4P 368880-91-5P 368880-92-6P, Methyl
 3-[[2-[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzoate 368880-93-7P,
 4-[[2-[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzoic Acid 368880-94-8P,
 3-[[2-[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzoic Acid 368880-95-9P
 368880-96-0P 368880-97-1P 368880-98-2P,
 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-(4-pyridylthiomethyl)-2,3,4-trihydronaphthalen-1-one 368880-99-3P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-(2-pyridylthiomethyl)-2,3,4-trihydronaphthalen-1-one
 368881-00-9P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(2-pyridylsulfonyl)methyl]-2,3,4-trihydronaphthalen-1-one hydrochloride
 368881-01-0P, 6-((S)-2-Imidazol-1-yl-1-phenylethoxy)-5-(naphthalen-1-ylthiomethyl)-3,4-dihydro-2H-naphthalen-1-one 368881-02-1P
 368881-03-2P, 5-(3,4-Dichlorobenzylthiomethyl)-6-((1S)-2-imidazol-1-yl-1-phenylethoxy)-3,4-dihydro-2H-naphthalen-1-one 368881-04-3P
 , (S)-6-[2-[2-(Hydroxymethyl)-1H-imidazol-1-yl]-1-phenylethoxy]-5-[(phenylsulfonyl)methyl]-3,4-dihydro-1(2H)-naphthalenone
 368881-05-4P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(2-methoxyethoxy)methyl]-2,3,4-trihydronaphthalen-1-one 368881-06-5P
 368881-07-6P 368881-08-7P 368881-09-8P,
 N-[2-((S)-2-Imidazol-1-yl-1-phenylethoxy)-5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl]benzenesulfonamide 368881-10-1P,
 N-[2-((S)-2-Imidazol-1-yl-1-phenylethoxy)-5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl]-1-phenylmethanesulfonamide 368881-11-2P
 , N-[2-((S)-2-Imidazol-1-yl-1-phenylethoxy)-5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl]-2-pyridin-2-ylacetamide 368881-12-3P,
 Pyridine-2-carboxylic acid N-[2-((S)-2-imidazol-1-yl-1-phenylethoxy)-5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl]amide 368881-13-4P
 368881-14-5P 368881-15-6P 368881-16-7P
 368881-17-8P 368881-18-9P 368881-19-0P
 368881-20-3P 368881-21-4P 368881-22-5P
 368881-24-7P 368881-26-9P 368881-28-1P
 368881-30-5P 368881-32-7P 368881-33-8P
 368881-34-9P 368881-35-0P 368881-36-1P
 368881-37-2P 368881-38-3P 368881-39-4P,

6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-phenoxy-2,3,4-trihydronaphthalen-1-one **368881-40-7P** **368881-41-8P** **368881-43-0P**,
 6-[[1-(1H-Imidazol-1-ylmethyl)pentyl]oxy]-5-[(phenylsulfonyl)methyl]-3,4-dihydro-1(2H)-naphthalenone **368881-44-1P** **368881-45-2P**
368881-46-3P **368881-47-4P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[[4-(trifluoromethoxy)phenoxy]methyl]-2,3,4-trihydronaphthalen-1-one **368881-48-5P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[[4-(phenoxy)phenoxy]methyl]-2,3,4-trihydronaphthalen-1-one **368881-49-6P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(2-hydroxyethylthio)methyl]-2,3,4-trihydronaphthalen-1-one **368881-50-9P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(2-phenylethylthio)methyl]-2,3,4-trihydronaphthalen-1-one **368881-51-0P** **368881-52-1P** **368881-53-2P**
368881-54-3P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(1-methylimidazol-2-ylthio)methyl]-2,3,4-trihydronaphthalen-1-one **368881-55-4P** **368881-56-5P** **368881-57-6P**,
 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-(2-furylthiomethyl)-2,3,4-trihydronaphthalen-1-one **368881-58-7P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(5-nitrobenzimidazol-2-ylthio)methyl]-2,3,4-trihydronaphthalen-1-one **368881-59-8P** **368881-60-1P**
368881-61-2P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(2,2,2-trifluoroethylthio)methyl]-2,3,4-trihydronaphthalen-1-one **368881-62-3P**, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-(2-naphthylthiomethyl)-2,3,4-trihydronaphthalen-1-one **368881-63-4P**
368881-64-5P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-(2-quinolylthiomethyl)-2,3,4-trihydronaphthalen-1-one **368881-65-6P**
368881-66-7P **368881-67-8P** **368881-68-9P**
368881-69-0P **368881-70-3P** **368881-71-4P**
368881-72-5P **368881-73-6P**, Methyl 2-[[[2-[[1S]-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzoate **368881-74-7P**,
 2-[[[2-[[1S]-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzoic Acid
368881-75-8P, 4-[[[2-[[1S]-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzoic Acid **368881-76-9P**, 3-[[[2-[[1S]-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzoic Acid **368881-77-0P**, 2-[[[2-[[1S]-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]-N-methylbenzamide **368881-78-1P**, N-(2-Hydroxyethyl)-2-[[[2-[[1S]-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide **368881-79-2P**
368881-80-5P **368881-81-6P** **368881-82-7P**
368881-83-8P **368881-84-9P** **368881-85-0P**,
 N-(2-Hydroxyethyl)-3-[[[2-[[1S]-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide
368881-86-1P, N-(2-Hydroxyethyl)-2-[[[2-[[1S]-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide **368881-87-2P**,
 N-(2-Hydroxyethyl)-4-[[[2-[[1S]-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide
368881-88-3P, N-(2-Hydroxyethyl)-4-[[[2-[[1S]-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide **368881-89-4P**,
 N-(2-Hydroxyethyl)-3-[[[2-[[1S]-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide
368881-90-7P, N-[2-(Dimethylamino)ethyl]-4-[[[2-[[1S]-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide **368881-91-8P**,
 N-[2-(Dimethylamino)ethyl]-3-[[[2-[[1S]-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-

phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide **368881-92-9P**, N-[2-(Dimethylamino)ethyl]-2-[[[2-[[[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide **368881-93-0P**,

N-[2-(Dimethylamino)ethyl]-2-[[[2-[[[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide **368881-94-1P**, N-[2-(Dimethylamino)ethyl]-4-[[[2-[[[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide **368881-95-2P**,

N-[2-(Dimethylamino)ethyl]-3-[[[2-[[[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide **368881-98-5P** **368881-99-6P**

368882-02-4P, 4-[[[2-[[[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]-N-methylbenzamide **368882-03-5P**, 3-[[[2-[[[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]-N-methylbenzamide **368882-04-6P**,

4-[[[2-[[[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]-N-methylbenzamide **368882-05-7P**, 3-[[[2-[[[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]-N-methylbenzamide **368882-06-8P**, 2-[[[2-[[[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]-N-methylbenzamide **368882-07-9P**, N-((2R)-2-Hydroxypropyl)-2-[[[2-[[[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide **368882-08-0P**,

N-((2R)-2-Hydroxypropyl)-4-[[[2-[[[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide **368882-09-1P**, N-((2S)-2-Hydroxypropyl)-4-[[[2-[[[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide **368882-10-4P**,

N-((2S)-2-Hydroxypropyl)-3-[[[2-[[[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide **368882-11-5P**, N-((2S)-2-Hydroxypropyl)-2-[[[2-[[[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide **368882-12-6P**,

N-((2S)-2-Hydroxypropyl)-4-[[[2-[[[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide **368882-13-7P**, N-((2S)-2-Hydroxypropyl)-3-[[[2-[[[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide **368882-14-8P**,

N-((2S)-2-Hydroxypropyl)-2-[[[2-[[[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide **368882-15-9P**, N-((2R)-2-Hydroxypropyl)-2-[[[2-[[[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide **368882-16-0P**,

N-((2R)-2-Hydroxypropyl)-4-[[[2-[[[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide **368882-17-1P**, N-((2R)-2-Hydroxypropyl)-3-[[[2-[[[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide **368882-18-2P**,

N-Allyl-3-[[[2-[[[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide **368882-19-3P**, N-Allyl-4-[[[2-[[[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide **368882-20-6P**, N-Allyl-2-[[[2-[[[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide **368882-21-7P**,

N-Allyl-2-[[[2-[[[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide

368882-22-8P, N-Allyl-4-[[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide **368882-23-9P**, N-Allyl-3-[[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide **368882-24-0P**

, 2-[[[2-[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]-N-(2-propynyl)benzamide

368882-25-1P, 4-[[[2-[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]-N-(2-propynyl)benzamide **368882-26-2P**, 3-[[[2-[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]-N-(2-propynyl)benzamide **368882-27-3P**, 4-[[[2-[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]-N-(2-propynyl)benzamide

368882-28-4P, 3-[[[2-[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]-N-(2-propynyl)benzamide **368882-29-5P**, 2-[[[2-[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]-N-(2-propynyl)benzamide **368882-30-8P**

, N-Cyclopentyl-4-[[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide

368882-31-9P, N-Cyclopentyl-3-[[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide **368882-32-0P**, N-Cyclopentyl-2-[[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide **368882-33-1P**,

N-Cyclopentyl-4-[[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide

368882-34-2P, N-Cyclopentyl-3-[[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide **368882-35-3P**, N-Cyclopentyl-2-[[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide **368882-36-4P**,

N-Cyclopropyl-4-[[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide

368882-37-5P, N-Cyclopropyl-3-[[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide **368882-38-6P**, N-Cyclopropyl-2-[[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 5-substituted tetralones as Ras farnesyl transferase inhibitors for treatment of proliferative diseases, such as cancer, atherosclerosis, restenosis, and psoriasis)

RN 367928-46-9 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(2-(1-methylethyl)phenoxy)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368879-80-5 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368879-81-6 HCAPLUS

CN Benzoic acid, 2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368879-82-7 HCAPLUS

CN Benzoic acid, 2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368879-83-8 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(1-methylethyl)thio]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368879-84-9 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(phenylamino)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368879-85-0 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(methylphenylamino)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368879-86-1 HCPLUS

CN Benzoic acid, 4-[methyl[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 368879-88-3 HCPLUS


CN Benzoic acid, 4-[methyl[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]amino]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 368879-87-2


CMF C30 H29 N3 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 368879-89-4 HCAPLUS

CN 1 (2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(1-methylethoxy)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 368879-90-7 HCAPLUS

CN 1 (2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368879-91-8 HCAPLUS

CN 1(2H)-Naphthalenone, 5-[(cyclopentyloxy)methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368879-92-9 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(2-propenyloxy)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368879-93-0 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(2-methylpropoxy)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368879-94-1 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-(propoxymethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368879-95-2 HCPLUS

CN 1(2H)-Naphthalenone, 5-[(1-ethylpropoxy)methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368879-96-3 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(1-methylpropoxy)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368879-98-5 HCAPLUS

CN 1(2H)-Naphthalenone, 5-(1,3-benzodioxol-5-yl)-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368879-99-6 HCAPLUS

CN 1(2H)-Naphthalenone, 5-(3-chlorophenyl)-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-00-6 HCAPLUS

CN [1,2'-Binaphthalen]-5(6H)-one, 7,8-dihydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-01-7 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-03-9 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-04-0 HCPLUS

CN Benzoic acid, 4-[2-[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-05-1 HCPLUS

CN 1(2H)-Naphthalenone, 5-[2-(4-fluorophenyl)ethyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-06-2 HCPLUS

CN 1-Naphthalenepropanoic acid, 5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-07-3 HCPLUS

CN 1-Naphthalenopropanoic acid, 5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-08-4 HCPLUS

CN Benzonitrile, 4-[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-09-5 HCPLUS

CN 1(2H)-Naphthalenone, 5-bromo-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-10-8 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-(3-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 368880-12-0 HCPLUS


CN 1(2H)-Naphthalenone, 5-(3-furanyl)-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 368880-11-9

CMF C25 H22 N2 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 368880-13-1 HCPLUS

CN 1(2H)-Naphthalenone, 5-amino-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-14-2 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-(2-phenylpropyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-15-3 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[2-(3-thienyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-16-4 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-(3-phenylpropyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-17-5 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-18-6 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-19-7 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-(2-methyl-2-propenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-21-1 HCAPLUS


CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 368880-23-3 HCAPLUS


CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(2R)-2-(1H-imidazol-1-yl)-1-1-dimethylethoxy]-5-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 368880-26-6 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-1-(1H-imidazol-1-ylmethyl)-2-methylpropoxy]-5-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-27-7 HCPLUS

CN 1(2H)-Naphthalenone, 6-[(1S)-1-(4-fluorophenyl)-2-(1H-imidazol-1-yl)ethoxy]-3,4-dihydro-5-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-28-8 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-(methoxymethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-30-2 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-(phenoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-32-4 HCPLUS

CN 1(2H)-Naphthalenone, 5-[(3-(1,1-dimethylethyl)phenoxy)methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-34-6 HCPLUS

CN 1(2H)-Naphthalenone, 5-[(3-chlorophenoxy)methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 368880-36-8 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-

phenylethoxy]-5-[[2-methyl-5-(1-methylethyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-38-0 HCPLUS

CN 1(2H)-Naphthalenone, 5-[(3,5-dimethoxyphenoxy)methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-40-4 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[[4-(1-methylethyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-41-5 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[[5,6,7,8-tetrahydro-1-naphthalenyl]oxy]methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 368880-42-6 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[[3-(1-methylethyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-43-7 HCAPLUS

CN 1 (2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[[2-(1-methylethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-45-9 HCAPLUS

CN 1 (2H)-Naphthalenone, 5-[(2-ethoxyphenoxy)methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-47-1 HCAPLUS

CN 1(2H)-Naphthalenone, 5-[(4-ethoxyphenoxy)methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-49-3 HCPLUS

CN 1(2H)-Naphthalenone, 5-[(3-ethylphenoxy)methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-50-6 HCPLUS

CN Benzoic acid, 2-[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-51-7 HCPLUS

CN 1(2H)-Naphthalenone, 5-[(4-ethylphenoxy)methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-52-8 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(2-naphthalenyloxy)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-53-9 HCPLUS

CN 1(2H)-Naphthalenone, 5-[(2-chloro-5-methylphenoxy)methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-54-0 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[[2-(2-methylpropyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-55-1 HCPLUS

CN Benzoic acid, 3-[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-56-2 HCAPLUS


CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(2,4,6-trimethylphenoxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 368880-57-3 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[[4-(methylpropyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)




D1—Me

RN 368880-58-4 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[[4-(trifluoromethyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-59-5 HCPLUS

CN 1(2H)-Naphthalenone, 5-[(1,3-benzodioxol-5-yloxy)methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-60-8 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(8-quinolinyl)oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-61-9 HCPLUS

CN 1(2H)-Naphthalenone, 5-[(4-chlorophenoxy)methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-62-0 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(3-methylphenoxy)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-63-1 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(4-methylphenoxy)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-64-2 HCPLUS

CN 1(2H)-Naphthalenone, 5-[(2-fluorophenoxy)methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-65-3 HCPLUS

CN 1(2H)-Naphthalenone, 5-[(3-fluorophenoxy)methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-66-4 HCPLUS

CN 1(2H)-Naphthalenone, 5-[(4-fluorophenoxy)methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-67-5 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(1-naphthalenyloxy)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-68-6 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(3-methoxyphenoxy)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-69-7 HCAPLUS

CN 1(2H)-Naphthalenone, 5-[(2-chlorophenoxy)methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-70-0 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(6-quinolinyl)oxymethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-71-1 HCAPLUS

CN 1(2H)-Naphthalenone, 5-[[[4-bromophenyl]thio]methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-72-2 HCAPLUS

CN 1(2H)-Naphthalenone, 5-[[[4-fluorophenyl]thio]methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-73-3 HCAPLUS

CN Acetamide, N-[4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-74-4 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-5-[[(4-hydroxyphenyl)thio]methyl]-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-75-5 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[[(4-methylphenyl)thio]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-76-6 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[[(2-methylpropyl)thio]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-77-7 HCPLUS

CN 1(2H)-Naphthalenone, 5-[(cyclohexylthio)methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-78-8 HCPLUS

CN 1(2H)-Naphthalenone, 5-[[2-bromophenyl]thio]methyl-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-79-9 HCPLUS

CN 1(2H)-Naphthalenone, 5-[[2-chlorophenyl]thio]methyl-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-80-2 HCAPLUS

CN 1(2H)-Naphthalenone, 5-[[[(2,6-dichlorophenyl)thio]methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-81-3 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[[[(2-methoxyphenyl)thio]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-82-4 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[[(2-methylphenyl)thio]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-83-5 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[[(4-methoxyphenyl)thio]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-84-6 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[[(4-nitrophenyl)thio]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-85-7 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(3-methoxyphenyl)thio]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-86-8 HCPLUS

CN 1(2H)-Naphthalenone, 5-[(4-chlorophenyl)thio]methyl-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-87-9 HCAPLUS

CN Benzonitrile, 2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-88-0 HCAPLUS

CN 1(2H)-Naphthalenone, 5-[[[(4-bromophenyl)amino]methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-89-1 HCAPLUS

CN 1(2H)-Naphthalenone, 5-[[[(4-fluorophenyl)amino]methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-90-4 HCPLUS

CN 1(2H)-Naphthalenone, 5-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-91-5 HCPLUS

CN Benzoic acid, 4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-92-6 HCPLUS

CN Benzoic acid, 3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-93-7 HCPLUS

CN Benzoic acid, 4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-94-8 HCPLUS

CN Benzoic acid, 3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-95-9 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(phenylsulfinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-96-0 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(phenylsulfonyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-97-1 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[[1-methylethyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-98-2 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(4-pyridinylthio)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-99-3 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(2-pyridinylthio)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-00-9 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(2-pyridinylsulfonyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 368881-01-0 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(1-naphthylthio)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-02-1 HCAPLUS

CN Acetic acid, [[[(5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-03-2 HCAPLUS

CN 1(2H)-Naphthalenone, 5-[[[(3,4-dichlorophenyl)methyl]thio]methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-04-3 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-[2-(hydroxymethyl)-1H-imidazol-1-yl]-1-phenylethoxy]-5-[(phenylsulfonyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-05-4 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(2-methoxyethoxy)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-06-5 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[2-(1-oxido-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-07-6 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[2-(1-oxido-4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-08-7 HCPLUS

CN Benzamide, N-methyl-4-[2-[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-09-8 HCPLUS

CN Benzenesulfonamide, N-[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-10-1 HCPLUS

CN Benzenemethanesulfonamide, N-[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-11-2 HCPLUS

CN 2-Pyridineacetamide, N-[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-12-3 HCPLUS

CN 2-Pyridinecarboxamide, N-[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-13-4 HCPLUS

CN 1-Isoquinolinecarboxamide, N-[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-14-5 HCPLUS

CN 3-Isoquinolinecarboxamide, N-[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-15-6 HCPLUS

CN Pyrazinecarboxamide, N-[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-16-7 HCPLUS

CN 4-Oxazolecarboxamide, 5-(4-chlorophenyl)-N-[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-17-8 HCPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-18-9 HCAPLUS

CN 3-Pyridinecarboxamide, 2-phenoxy-N-[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-19-0 HCAPLUS

CN 8-Quinolinecarboxamide, N-[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-20-3 HCAPLUS

CN Carbamic acid, [[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-21-4 HCPLUS

CN Benzenesulfonamide, N-[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-22-5 HCPLUS

CN Benzenesulfonamide, 4-methoxy-N-[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 368881-24-7 HCPLUS

CN Benzenesulfonamide, 2,4-difluoro-N-[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 368881-23-6
 CMF C28 H25 F2 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 368881-26-9 HCAPLUS
 CN Benzoic acid, 2-[[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]amino]sulfonyl]-, methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 368881-25-8
 CMF C30 H29 N3 O6 S

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2RN 368881-28-1 HCAPLUS
CN 3-Thiophenesulfonamide, 2,5-dichloro-N-[(5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl)methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 368881-27-0
CMF C26 H23 Cl2 N3 O4 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 368881-30-5 HCPLUS

CN Benzenesulfonamide, 3-chloro-N-[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 368881-29-2
CMF C28 H26 Cl N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 368881-32-7 HCPLUS


CN 2-Naphthalenesulfonamide, N-[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]-, trifluoroacetate (9CI)

(CA INDEX NAME)


CM 1

CRN 368881-31-6
CMF C32 H29 N3 O4 S


Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2RN 368881-33-8 HCAPLUS
CN Benzenemethanesulfonamide, N-[(5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-34-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-35-0 HCPLUS

CN Benzamide, N-[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-36-1 HCPLUS

CN Carbamic acid, [(1S)-3-(methylthio)-1-[[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]amino]carbonyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-37-2 HCPLUS

CN Butanamide, 2-amino-4-(methylthio)-N-[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-38-3 HCPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-39-4 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-phenoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-40-7 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-1-(1H-imidazol-1-ylmethyl)-2-methylpropoxy]-5-[[(-methylethyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-41-8 HCAPLUS

CN 1-Isoquinolinecarboxamide, N-[5,6,7,8-tetrahydro-2-[(1S)-1-(1H-imidazol-1-ylmethyl)-2-methylpropoxy]-5-oxo-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-43-0 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-1-(1H-imidazol-1-ylmethyl)pentyl]oxy]-5-[(phenylsulfonyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-44-1 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[[4-(1H-pyrrol-1-yl)phenoxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-45-2 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(1H-indol-4-yloxy)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-46-3 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(6-methyl-3-pyridinyl)oxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-47-4 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[[4-(trifluoromethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-48-5 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(4-phenoxyphenoxy)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-49-6 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-5-[(2-hydroxyethyl)thio]methyl]-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-50-9 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(2-phenylethyl)thio]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-51-0 HCPLUS

CN Propanoic acid, 3-[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-52-1 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(1H-imidazol-2-ylthio)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-53-2 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(1H-1,2,4-triazol-3-ylthio)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-54-3 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[[[(1-methyl-1H-imidazol-2-yl)thio]methyl] (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-55-4 HCPLUS

CN 1(2H)-Naphthalenone, 5-[(2-benzothiazolylthio)methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-56-5 HCPLUS

CN 1(2H)-Naphthalenone, 5-[[5-chloro-2-benzothiazolyl]thio]methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-57-6 HCPLUS

CN 1(2H)-Naphthalenone, 5-[(2-furanylthio)methyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-58-7 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(5-nitro-1H-benzimidazol-2-yl)thio]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-59-8 HCPLUS

CN 3-Pyridinecarboxylic acid, 2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 368881-60-1 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(1-methyl-1H-tetrazol-5-yl)thio]methyl]- (9CI) (CA INDEX NAME)

(CA INDEX NAME)


Absolute stereochemistry.



RN 368881-61-2 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[[2,2,2-trifluoroethyl]thio)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-62-3 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(2-naphthalenylthio)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-63-4 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[[4-methyl-4H-1,2,4-triazol-3-yl)thio]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-64-5 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(2-quinolinylthio)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-65-6 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[[[(4-methoxyphenyl)methyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-66-7 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(2-pyridinylsulfinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-67-8 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(1-methylethyl)sulfinyl]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-68-9 HCAPLUS

CN Acetamide, N-(4-methylphenyl)-N-[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-69-0 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(1H-indazol-5-ylamino)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-70-3 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(4-phenyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-71-4 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[[4-(2-pyridinyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-72-5 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(8-quinolinylamino)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-73-6 HCPLUS

CN Benzoic acid, 2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-74-7 HCPLUS

CN Benzoic acid, 2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-75-8 HCPLUS

CN Benzoic acid, 4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-76-9 HCPLUS

CN Benzoic acid, 3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-77-0 HCAPLUS

CN Benzamide, N-methyl-2-[[[5,6,7,8-tetrahydro-2-[(1*S*)-2-(1*H*-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-78-1 HCAPLUS

CN Benzamide, N-(2-hydroxyethyl)-2-[[[5,6,7,8-tetrahydro-2-[(1*S*)-2-(1*H*-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-79-2 HCPLUS

CN β -Alanine, N-[4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-80-5 HCPLUS

CN β -Alanine, N-[2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-81-6 HCPLUS

CN β -Alanine, N-[3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-82-7 HCAPLUS

CN β -Alanine, N-[2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]benzoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-83-8 HCAPLUS

CN β -Alanine, N-[4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]benzoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-84-9 HCPLUS

CN β -Alanine, N-[3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]benzoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-85-0 HCPLUS

CN Benzamide, N-(2-hydroxyethyl)-3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-86-1 HCAPLUS

CN Benzamide, N-(2-hydroxyethyl)-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 368881-87-2 HCAPLUS

CN Benzamide, N-(2-hydroxyethyl)-4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 368881-88-3 HCPLUS

CN Benzamide, N-(2-hydroxyethyl)-4-[[[5,6,7,8-tetrahydro-2-[(1*S*)-2-(1*H*-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-89-4 HCPLUS

CN Benzamide, N-(2-hydroxyethyl)-3-[[[5,6,7,8-tetrahydro-2-[(1*S*)-2-(1*H*-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-90-7 HCPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-91-8 HCPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-92-9 HCAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-93-0 HCAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-94-1 HCPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-95-2 HCPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-98-5 HCPLUS

CN β -Alanine, N-[2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]benzoyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368881-99-6 HCAPLUS

CN β -Alanine, N-[2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]benzoyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-02-4 HCAPLUS

CN Benzamide, N-methyl-4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-03-5 HCPLUS

CN Benzamide, N-methyl-3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-04-6 HCPLUS

CN Benzamide, N-methyl-4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-05-7 HCPLUS

CN Benzamide, N-methyl-3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-06-8 HCPLUS

CN Benzamide, N-methyl-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI). (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-07-9 HCAPLUS

CN Benzamide, N-[(2R)-2-hydroxypropyl]-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 368882-08-0 HCAPLUS

CN Benzamide, N-[(2R)-2-hydroxypropyl]-4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 368882-09-1 HCAPLUS

CN Benzamide, N-[(2S)-2-hydroxypropyl]-4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 368882-10-4 HCPLUS

CN Benzamide, N-[(2S)-2-hydroxypropyl]-3-[[[5,6,7,8-tetrahydro-2-[(1*H*-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 368882-11-5 HCPLUS

CN Benzamide, N-[(2S)-2-hydroxypropyl]-2-[[[5,6,7,8-tetrahydro-2-[(1*S*)-2-(1*H*-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 368882-12-6 HCAPLUS

CN Benzamide, N-[(2S)-2-hydroxypropyl]-4-[[[5,6,7,8-tetrahydro-2-[(1*S*)-2-(1*H*-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-13-7 HCAPLUS

CN Benzamide, N-[(2*S*)-2-hydroxypropyl]-3-[[[5,6,7,8-tetrahydro-2-[(1*S*)-2-(1*H*-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-14-8 HCAPLUS

CN Benzamide, N-[(2S)-2-hydroxypropyl]-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-15-9 HCAPLUS

CN Benzamide, N-[(2R)-2-hydroxypropyl]-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-16-0 HCAPLUS

CN Benzamide, N-[(2R)-2-hydroxypropyl]-4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-17-1 HCAPLUS

CN Benzamide, N-[(2R)-2-hydroxypropyl]-3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-18-2 HCAPLUS

CN Benzamide, N-2-propenyl-3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-19-3 HCAPLUS

CN Benzamide, N-2-propenyl-4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-20-6 HCAPLUS

CN Benzamide, N-2-propenyl-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-21-7 HCAPLUS

CN Benzamide, N-2-propenyl-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-22-8 HCAPLUS

CN Benzamide, N-2-propenyl-4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-23-9 HCPLUS

CN Benzamide, N-2-propenyl-3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-24-0 HCPLUS

CN Benzamide, N-2-propynyl-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-25-1 HCAPLUS

CN Benzamide, N-2-propynyl-4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-26-2 HCAPLUS

CN Benzamide, N-2-propynyl-3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-27-3 HCPLUS

CN Benzamide, N-2-propynyl-4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-28-4 HCPLUS

CN Benzamide, N-2-propynyl-3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-29-5 HCAPLUS

CN Benzamide, N-2-propynyl-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-30-8 HCAPLUS

CN Benzamide, N-cyclopentyl-4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-31-9 HCPLUS

CN Benzamide, N-cyclopentyl-3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-32-0 HCPLUS

CN Benzamide, N-cyclopentyl-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-33-1 HCAPLUS

CN Benzamide, N-cyclopentyl-4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-34-2 HCAPLUS

CN Benzamide, N-cyclopentyl-3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-35-3 HCPLUS

CN Benzamide, N-cyclopentyl-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-36-4 HCPLUS

CN Benzamide, N-cyclopropyl-4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-37-5 HCPLUS

CN Benzamide, N-cyclopropyl-3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-38-6 HCPLUS

CN Benzamide, N-cyclopropyl-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



- IT 368882-39-7P, N-Cyclopropyl-4-[[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide 368882-40-0P, N-Cyclopropyl-3-[[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide 368882-41-1P, N-Cyclopropyl-2-[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide 368882-42-2P, N-(2-Furylmethyl)-4-[[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide 368882-43-3P, N-(2-Furylmethyl)-3-[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide 368882-44-4P, N-(2-Furylmethyl)-2-[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide 368882-45-5P, N-[2-Hydroxy-1-(hydroxymethyl)ethyl]-2-[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide 368882-46-6P, N-[2-Hydroxy-1-(hydroxymethyl)ethyl]-4-[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide 368882-47-7P, N-[2-Hydroxy-1-(hydroxymethyl)ethyl]-3-[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide 368882-48-8P, N-[2-Hydroxy-1-(hydroxymethyl)ethyl]-4-[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide 368882-49-9P, N-[2-Hydroxy-1-(hydroxymethyl)ethyl]-3-[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide 368882-50-2P, N-[2-Hydroxy-1-(hydroxymethyl)ethyl]-2-[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide 368882-51-3P, N-(2-Furylmethyl)-4-[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide 368882-52-4P, N-(2-Furylmethyl)-3-[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide 368882-53-5P, N-(2-Furylmethyl)-2-[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide 368882-54-6P, N-[(1R)-1-(Hydroxymethyl)propyl]-4-[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide 368882-55-7P, N-[(1R)-1-(Hydroxymethyl)propyl]-3-[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]benzamide 368882-56-8P, N-[(1R)-1-(Hydroxymethyl)propyl]-2-[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-


naphthalenyl]methyl]sulfonyl]benzamide **368882-57-9P**,
 N-[(1R)-1-(Hydroxymethyl)propyl]-2-[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide **368882-58-0P**, N-[(1R)-1-(Hydroxymethyl)propyl]-4-[[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide **368882-59-1P**,
 N-[(1R)-1-(Hydroxymethyl)propyl]-3-[[2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]benzamide **368882-60-4P**, 4-[[2-[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]-N-((2S)-2-methylbutyl)benzamide **368882-61-5P**,
 3-[[2-[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]-N-((2S)-2-methylbutyl)benzamide **368882-62-6P**, 2-[[2-[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]-N-((2S)-2-methylbutyl)benzamide **368882-63-7P**,
 2-[[2-[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]-N-((2S)-2-methylbutyl)benzamide **368882-64-8P**, 4-[[2-[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]-N-((2S)-2-methylbutyl)benzamide **368882-65-9P**, 3-[[2-[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]-N-((2S)-2-methylbutyl)benzamide **368882-66-0P** **368882-67-1P** **368882-68-2P**
368882-69-3P **368882-70-6P** **368882-71-7P**
368882-72-8P, 3-[[2-[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]-N-(2-methoxyethyl)benzamide **368882-73-9P**,
 2-[[2-[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]-N-(2-methoxyethyl)benzamide **368882-74-0P**, 4-[[2-[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]thio]-N-(2-methoxyethyl)benzamide **368882-75-1P**, 4-[[2-[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]-N-(2-methoxyethyl)benzamide **368882-76-2P**, 3-[[2-[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]-N-(2-methoxyethyl)benzamide **368882-77-3P**, 2-[[2-[(1S)-2-(1H-Imidazol-1-yl)-1-phenylethyl]oxy]-5-oxo-5,6,7,8-tetrahydro-1-naphthalenyl]methyl]sulfonyl]-N-(2-methoxyethyl)benzamide **368882-78-4P**, (+)-6-[2-Imidazolyl-1-(2-pyridyl)ethoxy]-5-(2-phenylethyl)-2,3,4-trihydronaphthalen-1-one **368882-79-5P**,
 (+)-6-[2-Imidazolyl-1-(3-pyridyl)ethoxy]-5-(2-phenylethyl)-2,3,4-trihydronaphthalen-1-one **368882-80-8P** **368882-81-9P**
368882-82-0P **368882-83-1P** **368882-84-2P**
368882-85-3P **368882-86-4P** **368882-87-5P**
368882-89-7P **368882-90-0P**, (+)-6-[2-Imidazolyl-1-(2-thienyl)ethoxy]-5-prop-2-enyl-2,3,4-trihydronaphthalen-1-one
368882-91-1P, 6-[1-(1H-Imidazol-1-ylmethyl)-2-methylpropoxy]-5-[(phenylsulfonyl)methyl]-3,4-dihydro-1(2H)-naphthalenone
368882-92-2P, 6-[1-(1H-Imidazol-1-ylmethyl)propoxy]-5-[(phenylsulfonyl)methyl]-3,4-dihydro-1(2H)-naphthalenone
368882-93-3P, (+)-6-[2-(2-Methylimidazol-1-yl)-1-phenylethoxy]-5-phenethyl-3,4-dihydro-2H-naphthalen-1-one **368882-94-4P**
368882-95-5P **368882-96-6P**, 6-[2-(2-Aminoimidazol-1-yl)-1-phenylethoxy]-5-phenethyl-3,4-dihydro-2H-naphthalen-1-one
368882-98-8P **368883-12-9P** **368883-18-5P**
368883-22-1P **368883-31-2P**, (S)-6-(-2-Imidazol-1-yl-1-phenylethoxy)-5-(2-isoquinolin-4-ylethyl)-3,4-dihydro-2H-naphthalen-1-one hydrochloride **368883-51-6P** **368883-77-6P**,

(\pm) -6-(2-Imidazolyl-1-phenylethoxy)-4-phenyl-2,3,4-trihydronaphthalen-1-one 368883-86-7P, (\pm) -6-(2-Imidazolyl-1-phenylethoxy)-5-prop-2-enyl-2,3,4-trihydronaphthalen-1-one 368883-88-9P, 6-(2-Imidazolyl-1-phenylethoxy)-5-propyl-2,3,4-trihydronaphthalen-1-one 368883-90-3P, (\pm) -6-(2-Imidazolyl-1-phenylethoxy)-5-(2-methylprop-2-enyl)-2,3,4-trihydronaphthalen-1-one 368883-93-6P, (\pm) -6-[2-Imidazolyl-1-(2-pyridyl)ethoxy]-5-(2-phenylethyl)-2,3,4-trihydronaphthalen-1-one 368884-03-1P, (\pm) -6-[1-(2-Chlorophenyl)-2-imidazolylethoxy]-5-prop-2-enyl-2,3,4-trihydronaphthalen-1-one 368884-04-2P, (\pm) -6-[1-(2,6-Dichlorophenyl)-2-imidazolylethoxy]-5-prop-2-enyl-2,3,4-trihydronaphthalen-1-one 368884-19-9P 368884-20-2P 368884-21-3P
 368884-24-6P, 6-[(1-(1H-Imidazol-1-ylmethyl)pentyl]oxy]-5-[(phenylsulfonyl)methyl]-3,4-dihydro-1(2H)-naphthalen-1-one 368884-26-8P, (\pm) -6-[2-(2-Methylimidazol-1-yl)-1-phenylethoxy]-5-phenethyl-3,4-dihydro-2H-naphthalen-1-one 368884-29-1P, 6-[2-(2-Nitroimidazol-1-yl)-1-phenylethoxy]-5-phenethyl-3,4-dihydro-2H-naphthalen-1-one 368884-30-4P, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-[(4-methoxyphenoxy)methyl]-2,3,4-trihydronaphthalen-1-one
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (préparation of 5-substituted tetralones as Ras farnesyl transferase inhibitors for treatment of proliferative diseases, such as cancer, atherosclerosis, restenosis, and psoriasis)

RN 368882-39-7 HCPLUS

CN Benzamide, N-cyclopropyl-4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-40-0 HCPLUS

CN Benzamide, N-cyclopropyl-3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-41-1 HCAPLUS

CN Benzamide, N-cyclopropyl-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-42-2 HCAPLUS

CN Benzamide, N-(2-furanyl methyl)-4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-43-3 HCPLUS

CN Benzamide, N-(2-furanyl methyl)-3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-44-4 HCPLUS

CN Benzamide, N-(2-furanyl methyl)-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-45-5 HCAPLUS

CN Benzamide, N-[2-hydroxy-1-(hydroxymethyl)ethyl]-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-46-6 HCAPLUS

CN Benzamide, N-[2-hydroxy-1-(hydroxymethyl)ethyl]-4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-47-7 HCAPLUS

CN Benzamide, N-[2-hydroxy-1-(hydroxymethyl)ethyl]-3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-48-8 HCAPLUS

CN Benzamide, N-[2-hydroxy-1-(hydroxymethyl)ethyl]-4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-49-9 HCPLUS

CN Benzamide, N-[2-hydroxy-1-(hydroxymethyl)ethyl]-3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-50-2 HCPLUS

CN Benzamide, N-[2-hydroxy-1-(hydroxymethyl)ethyl]-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-51-3 HCPLUS

CN Benzamide, N-(2-furanyl methyl)-4-[[[5,6,7,8-tetrahydro-2-[(1*S*)-2-(1*H*-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 368882-52-4 HCPLUS

CN Benzamide, N-(2-furanyl methyl)-3-[[[5,6,7,8-tetrahydro-2-[(1*S*)-2-(1*H*-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 368882-53-5 HCAPLUS

CN Benzamide, N-(2-furanylmethyl)-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-54-6 HCAPLUS

CN Benzamide, N-[(1R)-1-(hydroxymethyl)propyl]-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-55-7 HCAPLUS

CN Benzamide, N-[(1R)-1-(hydroxymethyl)propyl]-3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-56-8 HCAPLUS

CN Benzamide, N-[(1R)-1-(hydroxymethyl)propyl]-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-57-9 HCAPLUS

CN Benzamide, N-[(1R)-1-(hydroxymethyl)propyl]-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-58-0 HCAPLUS

CN Benzamide, N-[(1R)-1-(hydroxymethyl)propyl]-4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-59-1 HCAPLUS

CN Benzamide, N-[(1R)-1-(hydroxymethyl)propyl]-3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-60-4 HCAPLUS

CN Benzamide, N-[(2S)-2-methylbutyl]-4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-61-5 HCAPLUS

CN Benzamide, N-[(2S)-2-methylbutyl]-3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-62-6 HCAPLUS

CN Benzamide, N-[(2S)-2-methylbutyl]-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-63-7 HCAPLUS

CN Benzamide, N-[(2S)-2-methylbutyl]-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 368882-64-8 HCAPLUS

CN Benzamide, N-[(2S)-2-methylbutyl]-4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 368882-65-9 HCPLUS

CN Benzamide, N-[(2S)-2-methylbutyl]-3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 368882-66-0 HCPLUS

CN Benzamide, N-(2-hydroxypropyl)-4-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-67-1 HCAPLUS

CN Benzamide, N-(2-hydroxypropyl)-3-[[[5,6,7,8-tetrahydro-2-[(1*S*)-2-(1*H*-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-68-2 HCAPLUS

CN Benzamide, N-(2-hydroxypropyl)-2-[[[5,6,7,8-tetrahydro-2-[(1*S*)-2-(1*H*-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-69-3 HCAPLUS

CN Benzamide, N-(2-hydroxypropyl)-4-[[[5,6,7,8-tetrahydro-2-[(1*S*)-2-(1*H*-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 368882-70-6 HCAPLUS

CN Benzamide, N-(2-hydroxypropyl)-2-[[[5,6,7,8-tetrahydro-2-[(1*S*)-2-(1*H*-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 368882-71-7 HCAPLUS

CN Benzamide, N-(2-hydroxypropyl)-3-[[[5,6,7,8-tetrahydro-2-[(1*S*)-2-(1*H*-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 368882-72-8 HCAPLUS

CN Benzamide, N-(2-methoxyethyl)-3-[[[5,6,7,8-tetrahydro-2-[(1*S*)-2-(1*H*-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 368882-73-9 HCAPLUS

CN Benzamide, N-(2-methoxyethyl)-2-[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-74-0 HCAPLUS

CN Benzamide, N-(2-methoxyethyl)-4-[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-75-1 HCAPLUS

CN Benzamide, N-(2-methoxyethyl)-4-[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-76-2 HCPLUS

CN Benzamide, N-(2-methoxyethyl)-3-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-77-3 HCPLUS

CN Benzamide, N-(2-methoxyethyl)-2-[[[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]methyl]sulfonyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-78-4 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)-1-(2-pyridinyl)ethoxy]-5-(2-phenylethyl)-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 368882-79-5 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)-1-(3-pyridinyl)ethoxy]-5-(2-phenylethyl)-, (+)- (9CI) (CA INDEX NAME)


Rotation (+').



RN 368882-80-8 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-(3-pyridinyl)ethoxy]-5-[(1-methylethyl)sulfonyl]methyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-81-9 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-(3-pyridinyl)ethoxy]-5-[(2-pyridinylsulfonyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-82-0 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-(3-pyridinyl)ethoxy]-5-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-83-1 HCPLUS

CN 1-Isoquinolinecarboxamide, N-[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-(3-pyridinyl)ethoxy]-5-oxo-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-84-2 HCPLUS

CN Pyrazinecarboxamide, N-[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-(3-pyridinyl)ethoxy]-5-oxo-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-85-3 HCPLUS

CN 4-Cinnolinecarboxamide, N-[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-(3-pyridinyl)ethoxy]-5-oxo-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368882-86-4 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-phenyl-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 368882-87-5 HCPLUS

CN 1(2H)-Naphthalenone, 6-[1-(2-chlorophenyl)-2-(1H-imidazol-1-yl)ethoxy]-3,4-dihydro-5-(2-propenyl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 368882-89-7 HCPLUS


CN 1(2H)-Naphthalenone, 6-[1-(2,6-dichlorophenyl)-2-(1H-imidazol-1-yl)ethoxy]-3,4-dihydro-5-(2-propenyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 368882-88-6

CMF C24 H22 Cl2 N2 O2

Rotation (+).




CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 368882-90-0 HCAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)-1-(2-thienyl)ethoxy]-5-(2-propenyl)-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 368882-91-1 HCAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[1-(1H-imidazol-1-ylmethyl)-2-methylpropoxy]-5-[(phenylsulfonyl)methyl]- (9CI) (CA INDEX NAME)




RN 368882-92-2 HCAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[1-(1H-imidazol-1-ylmethyl)propoxy]-5-[(phenylsulfonyl)methyl]- (9CI) (CA INDEX NAME)



RN 368882-93-3 HCPLUS


CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(2-methyl-1H-imidazol-1-yl)-1-phenylethoxy]-5-(2-phenylethyl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 368882-94-4 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)-1-(2-thienyl)ethoxy]-5-[(2-pyridinylsulfonyl)methyl]- (9CI) (CA INDEX NAME)




RN 368882-95-5 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)-1-(2-thiazolyl)ethoxy]-5-[(2-pyridinylsulfonyl)methyl]- (9CI) (CA INDEX NAME)



RN 368882-96-6 HCPLUS

CN 1(2H)-Naphthalenone, 6-[2-(2-amino-1H-imidazol-1-yl)-1-phenylethoxy]-3,4-dihydro-5-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 368882-98-8 HCPLUS


CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(phenylsulfinyl)methyl]-, trifluoroacetate (20:29) (9CI) (CA INDEX NAME)

CM 1

CRN 368880-95-9

CMF C28 H26 N2 O3 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 368883-12-9 HCAPLUS


CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(phenylmethoxy)methyl]-, trifluoroacetate (4:5) (9CI) (CA INDEX NAME)

CM 1

CRN 368879-90-7

CMF C29 H28 N2 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 368883-18-5 HCAPLUS


CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-(2-propoxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 368883-22-1 HCPLUS


CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[[[2-(4-pyridinyloxy)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 368883-31-2 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[2-(4-isquinolinyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 368883-51-6 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[2-(3-thienyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 368883-77-6 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)-1-phenylethoxy]-4-phenyl- (9CI) (CA INDEX NAME)




RN 368883-86-7 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-(2-propenyl)- (9CI) (CA INDEX NAME)




RN 368883-88-9 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-propyl- (9CI) (CA INDEX NAME)




RN 368883-90-3 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-(2-methyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 368883-93-6 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)-1-(2-pyridinyl)ethoxy]-5-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 368884-03-1 HCPLUS

CN 1(2H)-Naphthalenone, 6-[1-(2-chlorophenyl)-2-(1H-imidazol-1-yl)ethoxy]-3,4-dihydro-5-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 368884-04-2 HCPLUS


CN 1(2H)-Naphthalenone, 6-[1-(2,6-dichlorophenyl)-2-(1H-imidazol-1-yl)ethoxy]-3,4-dihydro-5-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 368884-19-9 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-1-(1H-imidazol-1-ylmethyl)-2-methylpropoxymethyl]-5-[2-(2-pyridinyl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 368884-20-2 HCPLUS

CN 1(2H)-Naphthalenone, 6-[(1S)-1-(2,4-difluorophenyl)-2-(1H-imidazol-1-yl)ethoxy]-3,4-dihydro-5-[(2-pyridinylsulfonyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 368884-21-3 HCPLUS


CN 1(2H)-Naphthalenone, 6-[(1S)-1-(4-fluorophenyl)-2-(1H-imidazol-1-yl)ethoxy]-3,4-dihydro-5-[2-(2-pyridinyl)ethyl]-, dihydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 368884-24-6 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[[1-(1H-imidazol-1-ylmethyl)pentyl]oxy]-5-[(phenylsulfonyl)methyl]- (9CI) (CA INDEX NAME)




RN 368884-26-8 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(2-methyl-1H-imidazol-1-yl)-1-phenylethoxy]-5-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 368884-29-1 HCPLUS


CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(2-nitro-1H-imidazol-1-yl)-1-phenylethoxy]-5-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 368884-30-4 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(4-methoxyphenoxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 368883-23-2, 6-((1S)-2-Imidazolyl-1-phenylethoxy)-5-(bromomethyl)-2,3,4-trihydronaphthalen-1-one 368884-32-6


RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of 5-substituted tetralones as Ras farnesyl transferase inhibitors for treatment of proliferative diseases, such as cancer, atherosclerosis, restenosis, and psoriasis)

RN 368883-23-2 HCPLUS


CN 1(2H)-Naphthalenone, 5-(bromomethyl)-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 368884-32-6 HCPLUS

CN 1(2H)-Naphthalenone, 5-(bromomethyl)-3,4-dihydro-6-[2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)



L40 ANSWER 3 OF 30 HCPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2001:780861 HCPLUS Full-text

DOCUMENT NUMBER: 135:303895

TITLE: Preparation of imidazolyl-substituted
3,4-dihydro-2H-naphthalen-1-ones as Ras farnesyl
transferase inhibitorsINVENTOR(S): Leonard, Daniele Marie; Repine, Joseph Thomas;
Newcastle, Gordon William

PATENT ASSIGNEE(S): Warner-Lambert Co., USA

SOURCE: PCT Int. Appl., 81 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001079179	A2	20011025	WO 2001-US12433	20010417
WO 2001079179	A3	20020523		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,			

BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 CA 2406032 A1 20011025 CA 2001-2406032 20010417
 AU 2001051649 A5 20011030 AU 2001-51649 20010417
 BR 2001010074 A 20021231 BR 2001-10074 20010417
 EP 1276724 A2 20030122 EP 2001-925049 20010417
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2003531142 T 20031021 JP 2001-576780 20010417
 US 2003232790 A1 20031218 US 2002-257128 20021008
 US 2004171844 A1 20040902 US 2004-782015 20040219
 PRIORITY APPLN. INFO.: US 2000-197483P P 20000417
 WO 2001-US12433 W 20010417
 US 2002-257128 B1 20021008

OTHER SOURCE(S): MARPAT 135:303895

GI



AB The title compds. I [wherein Ra, Rb, and Rc = independently H, alkyl, alkenyl, or (un)substituted (hetero)aryl or (hetero)arylalkyl; R1 and R2 = independently H, alkyl, alkenyl, or (un)substituted (hetero)aryl or (hetero)arylalkyl; and R1 and R2 may be attached through a linker or through an alkyl optionally interrupted by a linker, wherein said linker = NHCO, CONH, CO2, S, SO, SO2, O, or NRc; Y = NRc, O, CHRc, or S; n = 0, 2, or 3 with provisos; R3 = (un)substituted aryl, heteroarylalkyl, or arylalkyl; and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof] were prepared and formulated as farnesyl transferase enzyme inhibitors. For example, 4-cyanomethyl-1H-imidazole was N-protected with di-tert-Bu dicarbonate (27%) and coupled with 4-methoxy-3-methylbenzyl alc. to give [3-(4-methoxy-3-methylbenzyl)-3H-imidazol-4-yl]acetonitrile (41%). Oxidation with 2N NaOH (97%), followed by esterification with EtOH (93%), reduction using LiAlH4 (80%), and condensation with 6-hydroxytetralone and TFA workup (43%), afforded II (6% overall yield). The latter inhibited Ras farnesyl transferase in a HEPES/K3PO4 buffer with IC50 of 0.022 μM. I are useful for treating and preventing uncontrolled or abnormal proliferation of tissues, such as cancer, atherosclerosis, restenosis, and psoriasis (no data).

IT 367267-10-5P, 4-[(5-[2-(5-Oxo-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl]imidazol-1-yl)methyl]benzonitrile 367267-11-6P,
 4-[(5-[2-(5-Oxo-1-phenethyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl]imidazol-1-yl)methyl]benzonitrile 367267-13-8P

367267-15-0P 367267-16-1P, 5-Benzyl-6-[2-(3-benzyl-3H-imidazol-4-yl)ethoxy]-3,4-dihydro-2H-naphthalene-1-one
 367267-17-2P, 6-[2-(3-Benzyl-3H-imidazol-4-yl)ethoxy]-5-phenylamino-3,4-dihydro-2H-naphthalene-1-one 367267-19-4P
 367267-20-7P, 6-[2-(3-Benzyl-3H-imidazol-4-yl)ethoxy]-5-isopropoxymethyl-3,4-dihydro-2H-naphthalene-1-one 367267-23-0P
 367267-24-1P, 6-[2-(3-Benzyl-3H-imidazol-4-yl)-1-phenylethoxy]-3,4-dihydro-2H-naphthalene-1-one 367267-25-2P, 4-[[3-[2-(5-Oxo-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl]-3H-imidazol-4-yl]methyl]benzonitrile 367267-26-3P, 6-[2-(5-Benzylimidazol-1-yl)ethoxy]-5-propyl-3,4-dihydro-2H-naphthalene-1-one 367267-27-4P
 , 6-[2-(5-Benzylimidazol-1-yl)ethoxy]-5-phenethyl-3,4-dihydro-2H-naphthalene-1-one 367267-28-5P, 4-[[3-[2-(5-Oxo-1-phenethyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl]-3H-imidazol-4-yl]methyl]benzonitrile 367267-30-9P 367267-31-0P,
 6-[2-(5-Benzylimidazol-1-yl)ethoxy]-5-phenylaminomethyl-3,4-dihydro-2H-naphthalene-1-one 367267-32-1P, 5-Benzyl-6-[2-(5-Benzylimidazol-1-yl)ethoxy]-3,4-dihydro-2H-naphthalene-1-one 367267-33-2P,
 6-[2-(5-Benzylimidazol-1-yl)ethoxy]-5-phenylamino-3,4-dihydro-2H-naphthalene-1-one 367267-35-4P, N-[2-[2-(5-Benzylimidazol-1-yl)ethoxy]-5-oxo-5,6,7,8-tetrahydronaphthalene-1-yl]benzamide
 367267-36-5P, 6-[2-[3-(4-Methoxy-3-methylbenzyl)-3H-imidazol-4-yl]ethoxy]-5-phenethyl-3,4-dihydro-2H-naphthalene-1-one
 367267-37-6P, 6-[2-[3-(4-Methoxy-3-methylbenzyl)-3H-imidazol-4-yl]ethoxy]-3,4-dihydro-2H-naphthalen-1-one 367267-38-7P,
 6-[2-(3-Benzyl-3H-imidazol-4-yl)ethoxy]-5-propyl-3,4-dihydro-2H-naphthalen-1-one 367267-39-8P, 6-[2-(3-Benzyl-3H-imidazol-4-yl)ethoxy]-5-phenethyl-3,4-dihydro-2H-naphthalen-1-one 367267-40-1P,
 6-[2-(5-Benzyl-3H-imidazol-1-yl)ethoxy]-5-(2-pyridin-2-ylethyl)-3,4-dihydro-2H-naphthalene-1-one 367267-41-2P, 6-[2-[3-(4-Methoxy-3-methylbenzyl)-3H-imidazol-4-yl]ethoxy]-5-(2-pyridin-2-ylethyl)-3,4-dihydro-2H-naphthalene-1-one 367267-42-3P 367267-43-4P
 367267-44-5P 367267-45-6P 367267-60-5P
 367267-62-7P 374603-06-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses).

(preparation and formulation of imidazolyl-substituted dihydronaphthalenones

as Ras farnesyl transferase inhibitors for treatment of proliferative diseases)


RN 367267-10-5 HCPLUS

CN Benzonitrile, 4-[[5-[2-[(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)oxy]ethyl]-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)




RN 367267-11-6 HCAPLUS

CN Benzonitrile, 4-[5-[2-[[5,6,7,8-tetrahydro-5-oxo-1-(2-phenylethyl)-2-naphthalenyl]oxy]ethyl]-1H-imidazol-1-yl]methyl- (9CI) (CA INDEX NAME)




RN 367267-13-8 HCAPLUS

CN Benzoic acid, 4-[2-[5,6,7,8-tetrahydro-5-oxo-2-[2-[1-(phenylmethyl)-1H-imidazol-5-yl]ethoxy]-1-naphthalenyl]ethyl- (9CI) (CA INDEX NAME)




RN 367267-15-0 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-5-[(phenylamino)methyl]-6-[2-[1-(phenylmethyl)-1H-imidazol-5-yl]ethoxy]- (9CI) (CA INDEX NAME)




RN 367267-16-1 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-5-(phenylmethyl)-6-[2-[1-(phenylmethyl)-1H-imidazol-5-yl]ethoxy]- (9CI) (CA INDEX NAME)




RN 367267-17-2 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-5-(phenylamino)-6-[2-[1-(phenylmethyl)-1H-imidazol-5-yl]ethoxy]- (9CI) (CA INDEX NAME)




RN 367267-19-4 HCAPLUS

CN Benzamide, N-[5,6,7,8-tetrahydro-5-oxo-2-[2-[1-(phenylmethyl)-1H-imidazol-5-yl]ethoxy]-1-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 367267-20-7 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-5-[(1-methylethoxy)methyl]-6-[2-[1-(phenylmethyl)-1H-imidazol-5-yl]ethoxy]- (9CI) (CA INDEX NAME)




RN 367267-23-0 HCAPLUS

CN 1-Naphthalenepropanoic acid, 5,6,7,8-tetrahydro-5-oxo-2-[2-[1-(phenylmethyl)-1H-imidazol-5-yl]ethoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 367267-24-1 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[1-phenyl-2-[1-(phenylmethyl)-1H-imidazol-5-yl]ethoxy]- (9CI) (CA INDEX NAME)




RN 367267-25-2 HCAPLUS

CN Benzonitrile, 4-[[1-[2-[(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)oxy]ethyl]-1H-imidazol-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 367267-26-3 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-[5-(phenylmethyl)-1H-imidazol-1-yl]ethoxy]-5-propyl- (9CI) (CA INDEX NAME)




RN 367267-27-4 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-5-(2-phenylethyl)-6-[2-[5-(phenylmethyl)-1H-imidazol-1-yl]ethoxy]- (9CI) (CA INDEX NAME)




RN 367267-28-5 HCAPLUS

CN Benzonitrile, 4-[[1-[2-[[5,6,7,8-tetrahydro-5-oxo-1-(2-phenylethyl)-2-naphthalenyl]oxy]ethyl]-1H-imidazol-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 367267-30-9 HCAPLUS

CN Benzoic acid, 4-[2-[[5,6,7,8-tetrahydro-5-oxo-2-[2-[5-(phenylmethyl)-1H-imidazol-1-yl]ethoxy]-1-naphthalenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 367267-31-0 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-5-[(phenylamino)methyl]-6-[2-[5-(phenylmethyl)-1H-imidazol-1-yl]ethoxy]- (9CI) (CA INDEX NAME)




RN 367267-32-1 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-5-(phenylmethyl)-6-[2-[5-(phenylmethyl)-1H-imidazol-1-yl]ethoxy]- (9CI) (CA INDEX NAME)




RN 367267-33-2 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-5-(phenylamino)-6-[2-[5-(phenylmethyl)-1H-imidazol-1-yl]ethoxy]- (9CI) (CA INDEX NAME)




RN 367267-35-4 HCAPLUS

CN Benzamide, N-[5,6,7,8-tetrahydro-5-oxo-2-[2-[5-(phenylmethyl)-1H-imidazol-1-yl]ethoxy]-1-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 367267-36-5 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-[1-[(4-methoxy-3-methylphenyl)methyl]-1H-imidazol-5-yl]ethoxy]-5-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 367267-37-6 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-[1-[(4-methoxy-3-methylphenyl)methyl]-1H-imidazol-5-yl]ethoxy]- (9CI) (CA INDEX NAME)



RN 367267-38-7 HCAPLUS


CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-[1-(phenylmethyl)-1H-imidazol-5-yl]ethoxy]-5-propyl- (9CI) (CA INDEX NAME)



RN 367267-39-8 HCAPLUS


CN 1(2H)-Naphthalenone, 3,4-dihydro-5-(2-phenylethyl)-6-[2-[1-(phenylmethyl)-

1H-imidazol-5-yl]ethoxy]- (9CI) (CA INDEX NAME)




RN 367267-40-1 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-[5-(phenylmethyl)-1H-imidazol-1-yl]ethoxy]-5-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 367267-41-2 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-[1-[(4-methoxy-3-methylphenyl)methyl]-1H-imidazol-5-yl]ethoxy]-5-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 367267-42-3 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-[5-[(4-methoxy-3-methylphenyl)methyl]-1H-imidazol-1-yl]ethoxy]-5-[(phenylmethyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 367267-43-4 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-[1-[(4-methoxy-3-methylphenyl)methyl]-1H-imidazol-5-yl]ethoxy]-5-[(phenylmethyl)sulfonylmethyl]- (9CI) (CA INDEX NAME)



RN 367267-44-5 HCAPLUS


CN Benzonitrile, 4-[[5-[2-[[5,6,7,8-tetrahydro-5-oxo-1-[(2-pyridinylsulfonyl)methyl]-2-naphthalenyl]oxy]ethyl]-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 367267-45-6 HCAPLUS

CN Benzonitrile, 4-[[5-[2-[[5,6,7,8-tetrahydro-1-[(1-methylethyl)sulfonyl]methyl]-5-oxo-2-naphthalenyl]oxy]ethyl]-1H-imidazol-1-

yl]methyl]- (9CI) (CA INDEX NAME)




RN 367267-60-5 HCPLUS

CN 1 (2H)-Naphthalenone, 3,4-dihydro-6-[2-[1-[(4-methoxy-3-methylphenyl)methyl]-1H-imidazol-5-yl]ethoxy]-, trifluoroacetate (4:5) (9CI) (CA INDEX NAME)

CM 1

CRN 367267-37-6


CMF C24 H26 N2 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 367267-62-7 HCPLUS

CN 1 (2H)-Naphthalenone, 3,4-dihydro-5-(2-phenylethyl)-6-[2-[1-(phenylmethyl)-

1H-imidazol-5-yl]ethoxy]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 367267-39-8
CMF C30 H30 N2 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 374603-06-2 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-[1-(phenylmethyl)-1H-imidazol-5-yl]ethoxy]-5-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 367267-38-7
CMF C25 H28 N2 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L40 ANSWER 4 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2001:906214 HCAPLUS Full-text

DOCUMENT NUMBER: 136:31714

TITLE: Method for treating Alzheimer's disease

INVENTOR(S): Ahn, Kyunghye; Emmerling, Mark Richard; Haske, Taraneh; Hupe, Donald J.; Sebolt-Leopold, Judith; Levine, Harry; Scholten, Jeffrey David

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 14 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001051642	A1	20011213	US 2001-771529	20010129
US 2004063770	A1	20040401	US 2003-671385	20030926
PRIORITY APPLN. INFO.:			US 2000-197484P	P 20000417
			US 2001-771529	B1 20010129

GI



AB The present invention provides methods and compns. for inhibiting $\text{A}\beta$ (β -amyloid peptide) synthesis and for treating Alzheimer's disease by administering a farnesyl transferase inhibitor of the formula I: wherein R is hydrogen, alkyl, and substituted alkyl; R1 is hydrogen, Ph, or substituted phenyl; and R2 is hydrogen or benzyl.


IT 367267-37-6P 368879-97-4P

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(method for treating Alzheimer's disease by inhibiting β -amyloid peptide synthesis using farnesyl transferase inhibitors such as dihydronaphthalenones)

RN 367267-37-6 HCAPLUS


CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-[1-[(4-methoxy-3-methylphenyl)methyl]-1H-imidazol-5-yl]ethoxy]- (9CI) (CA INDEX NAME)



RN 368879-97-4 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-(2-phenylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 368879-84-9 368880-01-7 368880-02-8

368880-05-1 368880-96-0 368883-11-8

368883-77-6 379683-37-1 379683-38-2

379683-39-3 379683-40-6 379683-44-0


RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method for treating Alzheimer's disease by inhibiting β -amyloid peptide synthesis using farnesyl transferase inhibitors such as dihydronaphthalenones)

RN 368879-84-9 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(phenylamino)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-01-7 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-02-8 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-05-1 HCAPLUS

CN 1(2H)-Naphthalenone, 5-[2-(4-fluorophenyl)ethyl]-3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368880-96-0 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(phenylsulfonyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 368883-11-8 HCPLUS


CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-[(1-methylethoxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 368883-77-6 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)-1-phenylethoxy]-4-phenyl- (9CI) (CA INDEX NAME)



RN 379683-37-1 HCPLUS


CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-4-yl)ethoxy]- (9CI)
(CA INDEX NAME)



RN 379683-38-2 HCPLUS


CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)-1-phenylethoxy]-2-(2-thienylmethylene)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 379683-39-3 HCPLUS


CN 1(2H)-Naphthalenone, 6-[1-(4-chlorophenyl)-2-(1H-imidazol-1-yl)ethoxy]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 379683-40-6 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1R)-2-(1H-imidazol-1-yl)-1-phenylethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 379683-44-0 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-5-(2-phenylethyl)-6-[2-[1-(phenylmethyl)-1H-imidazol-5-yl]ethoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 367267-39-8


CMF C30 H30 N2 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L40 ANSWER 5 OF 30 HCPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 5

ACCESSION NUMBER: 1998:550412 HCPLUS Full-text

DOCUMENT NUMBER: 129:175640

TITLE: Preparation of 6-(2-imidazol-1-ylethoxy)naphthalen-1-ones as inhibitors of protein farnesyl transferase


Dobrusin, Ellen M.; Doherty, Annette Marian; McNamara, Dennis Joseph; Bikker, Jack; Drowns, Matthew; Stasiak, Marcin; Kaltenbronn, James Stanley; Quin, John, III; Repine, Joseph Thomas
Warner-Lambert Company, USA

ENT ASSIGNEE(S):

SOURCE: PCT Int. Appl., 128 pp.
 CODEN: PIIXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9834921	A1	19980813	WO 1998-US3025	19980211
W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9801080	A	19980812	ZA 1998-1080	19980210
CA 2273895	A1	19980813	CA 1998-2273895	19980211
AU 9861704	A	19980826	AU 1998-61704	19980211
AU 725696	B2	20001019		
EP 966446	A1	19991229	EP 1998-906491	19980211
EP 966446	B1	20051019		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9807674	A	20000215	BR 1998-7674	19980211
NZ 336134	A	20010831	NZ 1998-336134	19980211
JP 2001518076	T	20011009	JP 1998-535105	19980211
AT 307119	T	20051115	AT 1998-906491	19980211
ES 2252827	T3	20060516	ES 1998-906491	19980211
US 6133303	A	20001017	US 1999-355662	19990802
US 6265422	B1	20010724	US 2000-560606	20000428
US 2002006936	A1	20020117	US 2001-910967	20010723
US 6528535	B2	20030304		
PRIORITY APPLN. INFO.:				
		US 1997-37504P	P	19970211
		WO 1998-US3025	W	19980211
		US 1999-355662	A3	19990802
		US 2000-560606	A3	20000428

OTHER SOURCE(S): MARPAT 129:175640
 GI



AB The title compds. [I; Q = O, NOH, NNH₂, etc.; L = H, A1CH:CHCH:CH, A1(CH₂)_nCH(Z), A1(CH₂)_nC(Z);; A1 = (un)substituted aryl, heteroaryl, etc.; n = 0-5; Z = H, NH₂, OH, etc.; X = CH₂, CH₂O, CH₂S, etc.; P = N, CH, etc.; Y = CH₂, NH, O, etc.; Ra, Rb = H, C₁₋₆ alkyl, C₂₋₆ alkenyl, etc.; CRaRb = C₃₋₆ cycloalkyl; m = 0, 2-5; B = (un)substituted pyrrolyl, imidazolyl, oxazolyl, etc.; E1 = H, halo, NO₂, etc.], useful for treating cancer and treating or preventing restenosis or atherosclerosis, were prepared. Thus, treatment of


imidazole with NaH in DMF followed by the addition of 6-(β -chloroethoxy)-1-tetralone in DMF afforded 67% II which showed IC50 of 2.0 μ M against FTase.

IT 211502-23-7P 211502-26-0P 211502-27-1P
 211502-50-0P 211502-74-8P 211503-23-0P
 211503-24-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 6-(2-imidazol-1-ylethoxy)naphthalen-1-ones as inhibitors of protein farnesyl transferase)


RN 211502-23-7 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]- (9CI)
 (CA INDEX NAME)




RN 211502-26-0 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-2-[(4-(methylthio)phenyl)methylene]- (9CI) (CA INDEX NAME)




RN 211502-27-1 HCPLUS

CN 1(2H)-Naphthalenone, 2-[(4-bromophenyl)methylene]-3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 211502-50-0 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-4-yl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 211502-74-8 HCPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-5-methyl-
 (9CI) (CA INDEX NAME)




RN 211503-23-0 HCPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)propoxy]-2-(2-thienylmethylene)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 211503-24-1 HCPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)-1-phenylethoxy]-
 (9CI) (CA INDEX NAME)

✗



IT 211502-24-8P 211502-25-9P 211502-28-2P
 211502-29-3P 211502-30-6P 211502-31-7P
 211502-32-8P 211502-33-9P 211502-34-0P


211502-35-1P 211502-36-2P 211502-38-4P
 211502-39-5P 211502-40-8P 211502-41-9P
 211502-42-0P 211502-43-1P 211502-44-2P
 211502-45-3P 211502-46-4P 211502-47-5P
 211502-48-6P 211502-49-7P 211502-51-1P
 211502-52-2P 211502-53-3P 211502-54-4P
 211502-55-5P 211502-56-6P 211502-57-7P
 211502-60-2P 211502-61-3P 211502-62-4P
 211502-65-7P 211502-66-8P 211502-67-9P
 211502-68-0P 211502-69-1P 211502-70-4P
 211502-71-5P 211502-72-6P 211502-73-7P
 211502-75-9P 211502-86-2P 211502-89-5P
 211502-91-9P 211502-93-1P 211502-95-3P
 211502-97-5P 211502-99-7P 211503-01-4P
 211503-03-6P 211503-05-8P 211503-07-0P
 211503-09-2P 211503-11-6P 211503-12-7P
 211503-13-8P 211503-14-9P 211503-16-1P
 211503-17-2P 211503-18-3P 211503-20-7P
 211503-22-9P 211503-25-2P 211503-30-9P
 211503-33-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 6-(2-imidazol-1-ylethoxy)naphthalen-1-ones as inhibitors of protein farnesyl transferase)


RN 211502-24-8 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(2-methyl-1H-imidazol-1-yl)ethoxy]-(9CI) (CA INDEX NAME)




RN 211502-25-9 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-2-(2-pyridinylmethylene)- (9CI) (CA INDEX NAME)




RN 211502-28-2 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-2-(4-pyridinylmethylene)- (9CI) (CA INDEX NAME)




RN 211502-29-3 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-2-[(4-nitrophenyl)methylene]-(9CI). (CA INDEX NAME)




RN 211502-30-6 HCPLUS

CN 1(2H)-Naphthalenone, 2-[[4-[2-(diethylamino)ethoxy]phenyl]methylene]-3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-(9CI) (CA INDEX NAME)




RN 211502-31-7 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-2-(phenylmethylene)-(9CI) (CA INDEX NAME)




RN 211502-32-8 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-2-[(4-methylthio)phenyl]methyl)-(9CI) (CA INDEX NAME)




RN 211502-33-9 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-2-(3-thienylmethylene)- (9CI) (CA INDEX NAME)




RN 211502-34-0 HCAPLUS

CN Benzoic acid, 4-[(3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-1-oxo-2(1H)-naphthalenylidene)methyl]- (9CI) (CA INDEX NAME)




RN 211502-35-1 HCAPLUS

CN 1(2H)-Naphthalenone, 2-[(4-bromophenyl)methyl]-3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 211502-36-2 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-2-(2-thienylmethylene)- (9CI) (CA INDEX NAME)




RN 211502-38-4 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-2-(1-naphthalenylmethylene)- (9CI) (CA INDEX NAME)




RN 211502-39-5 HCPLUS

CN 1(2H)-Naphthalenone, 2-(2-furanyl methylene)-3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 211502-40-8 HCPLUS

CN 1(2H)-Naphthalenone, 2-[{(4-bromo-2-thienyl)methylene]-3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 211502-41-9 HCPLUS

CN 1(2H)-Naphthalenone, 2-[{(5-chloro-2-thienyl)methylene]-3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 211502-42-0 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-2-[{[5-(methylthio)-2-thienyl]methylene}- (9CI) (CA INDEX NAME)




RN 211502-43-1 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-2-[(3-phenoxy-2-thienyl)methylene]- (9CI) (CA INDEX NAME)




RN 211502-44-2 HCAPLUS

CN 1(2H)-Naphthalenone, 2-([2,2'-bithiophen]-5-ylmethylene)-3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 211502-45-3 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-2-[(5-nitro-2-thienyl)methylene]- (9CI) (CA INDEX NAME)




RN 211502-46-4 HCAPLUS

CN 1(2H)-Naphthalenone, 2-(3-furanylmethylen)-3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 211502-47-5 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-2-[(4-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 211502-48-6 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-2-[(2-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 211502-49-7 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(hydroxy-2-thiazolylmethyl)-6-[2-(1H-imidazol-1-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 211502-51-1 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-4-yl)ethoxy]-2-(3-thienylmethylene)- (9CI) (CA INDEX NAME)




RN 211502-52-2 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-4-yl)ethoxy]-2-(2-thienylmethylene)- (9CI) (CA INDEX NAME)




RN 211502-53-3 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-4-yl)ethoxy]-2-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 211502-54-4 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-4-yl)ethoxy]-2-[4-(methylthio)phenyl]methylenene (9CI) (CA INDEX NAME)



RN 211502-55-5 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-4-yl)ethoxy]-2-[5-(methylthio)-2-thienyl]methylenene, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 211502-56-6 HCAPLUS

CN Benzamide, 4-[[3,4-dihydro-6-[2-(1H-imidazol-4-yl)ethoxy]-1-oxo-2(1H)-


naphthalenylidene]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 211502-57-7 HCAPLUS

CN Benzamide, 4-[[3,4-dihydro-6-[2-(1H-imidazol-4-yl)ethoxy]-1-oxo-2(1H)-naphthalenylidene]methyl]-N,N-diethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 211502-60-2 HCAPLUS

CN Benzoic acid, 4-[[3,4-dihydro-6-[2-(1H-imidazol-4-yl)ethoxy]-1-oxo-2(1H)-naphthalenylidene]methyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 211502-59-9


CMF C23 H20 N2 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 211502-61-3 HCPLUS


CN 1(2H)-Naphthalenone, 2-[(5-chloro-2-thienyl)methylene]-3,4-dihydro-6-[2-(1H-imidazol-4-yl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 211502-62-4 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-4-yl)ethoxy]-2-[(5-methyl-2-thienyl)methylene]- (9CI) (CA INDEX NAME)




RN 211502-65-7 HCPLUS

CN 2-Thiophenecarboxylic acid, 5-[[3,4-dihydro-6-[2-(1H-imidazol-4-yl)ethoxy]-1-oxo-2(1H)-naphthalenylidene]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 211502-64-6

CMF C21 H18 N2 O4 S




CM 2


CRN 76-05-1
 CMF C2 H F3 O2




RN 211502-66-8 HCAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-4-yl)ethoxy]-2-[(3-methyl-2-thienyl)methylene]- (9CI) (CA INDEX NAME)



RN 211502-67-9 HCAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-4-yl)ethoxy]-2-(1-phenylethylidene)- (9CI) (CA INDEX NAME)




RN 211502-68-0 HCAPLUS
 CN 1(2H)-Naphthalenone, 2-(2-furanylmethylen)-3,4-dihydro-6-[2-(1H-imidazol-4-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 211502-69-1 HCAPLUS

CN 1(2H)-Naphthalenone, 2-[(4-bromophenyl)methylene]-3,4-dihydro-6-[2-(1H-imidazol-4-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 211502-70-4 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[3-(1H-imidazol-4-yl)propoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 211502-71-5 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-2-[(2E)-3-phenyl-2-propenylidene]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 211502-72-6 HCAPLUS

CN 1(2H)-Naphthalenone, 2-(cyclohexylmethylene)-3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-, monohydrochloride, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 211502-73-7 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-7-methyl-2-(2-thienylmethylene)-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 211502-75-9 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-5-methyl-2-(2-thienylmethylene)-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 211502-86-2 HCPLUS

CN 1(2H)-Naphthalenone, 2-[(2-chlorophenyl)methylene]-3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 211502-89-5 HCPLUS

CN 1(2H)-Naphthalenone, 2-[(3-chlorophenyl)methylene]-3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 211502-91-9 HCPLUS

CN 1(2H)-Naphthalenone, 2-[(4-chlorophenyl)methylene]-3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 211502-93-1 HCPLUS

CN 1(2H)-Naphthalenone, 2-[(1,3-benzodioxol-5-ylmethylene)-]3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 211502-95-3 HCPLUS

CN 1(2H)-Naphthalenone, 2-[(4-fluorophenyl)methylene]-3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 211502-97-5 HCAPLUS

CN 1(2H)-Naphthalenone, 2-[(2,3-dichlorophenyl)methylene]-3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 211502-99-7 HCAPLUS

CN 1(2H)-Naphthalenone, 2-[(2,6-dichlorophenyl)methylene]-3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 211503-01-4 HCAPLUS

CN 1(2H)-Naphthalenone, 2-[(3,4-dichlorophenyl)methylene]-3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-, (2E)- (9CI). (CA INDEX NAME)


Double bond geometry as shown.



RN 211503-03-6 HCAPLUS

CN 1(2H)-Naphthalenone, 2-[(3,5-dichlorophenyl)methylene]-3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 211503-05-8 HCPLUS

CN 1(2H)-Naphthalenone, 2-[{(2,5-dimethoxyphenyl)methylene]-3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 211503-07-0 HCPLUS

CN 1(2H)-Naphthalenone, 2-[{(2,3-dimethoxyphenyl)methylene]-3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 211503-09-2 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-2-[{[2-(trifluoromethyl)phenyl]methylene}-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 211503-11-6 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-2-[{(2,4,6-

trimethoxyphenyl)methylene]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 211503-12-7 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-2-[(3,4,5-trimethoxyphenyl)methylene]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 211503-13-8 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-2-[(4-iodophenyl)methylene]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 211503-14-9 HCPLUS

CN 1(2H)-Naphthalenone, 2-[(4-(dimethylamino)phenyl)methylene]-3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 211503-16-1 HCAPLUS

CN 1(2H)-Naphthalenone, 2-[(4-(1,1-dimethylethyl)phenyl)methylene]-3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 211503-17-2 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-2-[(3-methoxyphenyl)methylene]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 211503-18-3 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-2-[(3-methylphenyl)methylene]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 211503-20-7 HCAPLUS


CN 1(2H)-Naphthalenone, 2-[(4-(diethylamino)phenyl)methylene]-3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-, (2E)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1




CRN 211503-19-4


CMF C26 H29 N3 O2

Double bond geometry as shown.



CM 2


CRN 76-05-1
CMF C2 H F3 O2RN 211503-22-9 HCAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)propoxy]- (9CI)
(CA INDEX NAME)RN 211503-25-2 HCAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)-1-phenylethoxy]-2-(2-thienylmethylene)- (9CI) (CA INDEX NAME)RN 211503-30-9 HCAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-4-yl)ethoxy]-2-[(5-methyl-2-thienyl)methylene]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 211503-33-2 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-4-yl)ethoxy]-2-(1-phenylethyldene)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 211503-29-6P 211503-34-3P 211503-39-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 6-(2-imidazol-1-yloxy)naphthalen-1-ones as inhibitors of protein farnesyl transferase)


RN 211503-29-6 HCAPLUS

CN 1H-Imidazole-1-carboxylic acid, 4-[2-[(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 211503-34-3 HCAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[3-[1-(triphenylmethyl)-1H-imidazol-4-yl]propoxy]- (9CI) (CA INDEX NAME)



RN 211503-39-8 HCAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[2-(1H-imidazol-1-yl)ethoxy]-7-methyl-
 (9CI) (CA INDEX NAME)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 6 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:409528 HCAPLUS Full-text
 DOCUMENT NUMBER: 142:463728
 TITLE: Preparation of 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles for the treatment of tuberculosis
 INVENTOR(S): Tsubouchi, Hidetsugu; Sasaki, Hirofumi; Itotani, Motohiro; Haraguchi, Yoshikazu; Miyamura, Shin; Matsumoto, Makoto; Hashizume, Hiroyuki; Tomishige, Tatsuo; Kawasaki, Masanori; Ohguro, Kinue; Sumida, Takumi; Hasegawa, Takeshi; Tanaka, Kazuho; Takemura, Isao
 PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 941 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042542	A1	20050512	WO 2004-JP16492	20041029
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004285811	A1	20050512	AU 2004-285811	20041029
CA 2539335	A1	20050512	CA 2004-2539335	20041029
EP 1678185	A1	20060712	EP 2004-793412	20041029
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004014909	A	20061107	BR 2004-14909	20041029
CN 1878777	A	20061213	CN 2004-80032244	20041029
JP 2005320316	A	20051117	JP 2004-318005	20041101
PRIORITY APPLN. INFO.:			JP 2003-373206	A 20031031

OTHER SOURCE(S):
GI

MARPAT 142:463728



AB The title compds. I [R1 = H, alkyl; n = 0-6; R1 and (CH2)nR2, together with the adjacent carbon atom, may form a spiro ring represented by II (wherein R = substituted piperidyl); R2 = benzothiazolyloxy, quinolyloxy, pyridyloxy, etc.] which have an excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria, were prepared and formulated. Thus, reacting (R)-2-chloro-1-(2-methyl-2-oxiranylmethyl)-4-nitro-1H-imidazole with 6-hydroxy-2-[4-(4-trifluoromethoxybenzyl)piperazin-1-yl]benzothiazole in the presence of NaH in DMF afforded 33% (R)-2-methyl-6-nitro-2-{2-[4-(4-trifluoromethoxybenzyl)piperazin-1-yl]benzothiazol-6-yloxy}-2,3-dihydroimidazo[2,1-b]oxazole which showed MIC of 0.2 µg/mL in antibacterial test against M. tuberculosis Kurono in 7H11 medium.

IT 851694-21-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles for the treatment of tuberculosis)

RN 851694-21-8 HCPLUS

CN 1(2H)-Naphthalenone, 6-[[{(2R)-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazol-2-yl}methoxy]-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 7 OF 30 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1262333 HCPLUS Full-text

DOCUMENT NUMBER: 144:22949

TITLE: Preparation of 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles as antibacterial agents

INVENTOR(S): Tsubochi, Hidetsugu; Sasaki, Hirofumi; Kuroda,

Hideaki; Itotani, Motohiro; Hasegawa, Takeshi;
 Haraguchi, Yoshikazu; Kuroda, Takeshi; Matsuzaki,
 Takayuki; Tai, Kuninori; Komatsu, Makoto; Matsumoto,
 Makoto; Hashizume, Hiroyuki; Tomishige, Tatsuo; Seike,
 Yuji; Kawasaki, Masanori; Sumida, Takumi; Miyamura,
 Shin; Oguro, Kinue; Tanaka, Kazuho; Takemura, Isao
 Ohtsuka Pharmaceutical Co., Ltd., Japan

PATENT ASSIGNEE(S):

SOURCE: Jpn. Kokai Tokkyo Koho, 1050 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese




FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005330266	A	20051202	JP 2005-113726	20050411
PRIORITY APPLN. INFO.:			JP 2004-114975	A 20040409
			JP 2004-125055	A 20040421

OTHER SOURCE(S): MARPAT 144:22949

GI



AB The title compds. [I; wherein R1 = H, C1-6 alkyl; n = an integer of 0-6; R2 = OR3, SR5, CO2R6, O2CNR7R8, Q, NR19R20, Q1; wherein R3 = H, C1-6 alkoxy, C1-6 alkoxy-C1-6 alkyl, (un)substituted phenyl-C1-6 alkoxy, biphenyl-C1-6 alkoxy, phenyl-C2-6 alkaryl, C1-6 alkylsulfonyl, etc.; R5 = tetrazolyl or phenyltetrazolyl optionally substituted by halo or C1-6 alkyl on phenyl; R6 = C1-6 alkyl; R7, R8 = H, C1-8 alkyl, halo-C1-6 alkyl, C1-6 alkoxy carbonyl-C1-6 alkyl, C3-8 cycloalkyl, phenyl-C1-6 alkyl, Ph, naphthyl, pyridyl, etc.; X = halo, amino-C1-6 alkyl, C1-6 alkylamino-C1-6 alkyl; R11 = H, C1-6 alkyl, halo-C1-6 alkyl, C1-6 alkoxy, halo-C1-6 alkoxy, etc.; m = an integer of 0-3; R40 = C1-6 alkyl, Ph, halophenyl; or R1 and -(CH2)nR2 may be united via a nitrogen atom to form together with the adjacent carbon atom a spiro ring represented by the general formula Q2; wherein R41 = H, C1-6 alkyl, phenyl-C1-6 alkyl, biphenyl-C1-6 alkyl, (un)substituted Ph, etc.] or optical isomers thereof or pharmacol. acceptable salts thereof are prepared. These compds. exhibit

excellent bactericidal activity against *Tubercle bacillus*, multiple drug resistant *T. bacillus*, and atypical acid-fast bacteria, and are useful as antitubercular agents. Thus, 0.43 g (S)-1-(2-chloro-4-nitroimidazol-1-yl)-2-methyl-3-[4-(4-trifluoromethoxyphenyl)piperazin-1-yl]propan-2-ol and 0.22 g 2-chloro-4-nitro-1H-imidazole were suspended in 4 mL MeCN, treated with 0.17 g NaHCO₃, and refluxed for 9 h to give 31% (S)-1-(2-chloro-4-nitroimidazol-1-yl)-2-methyl-3-[4-(4-trifluoromethoxyphenyl)piperazin-1-yl]propan-1-ol which (5.85 g) was dissolved in 150 mL THF, treated with 0.66 g NaH under ice-cooling and refluxed for 6 h to give 48% (S)-2-[(4-(4-trifluoromethoxyphenyl)piperazin-1-yl)methyl]-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole (II). II and compound (III) showed min. inhibitory concentration of 0.024 and 0.0015 µg/mL, resp., against *Mycobacterium tuberculosis* H37Rv.

IT

851694-21-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles as antibacterial agents and antitubercular agents)


RN

851694-21-8 HCPLUS

CN

1(2H)-Naphthalenone, 6-[[[(2R)-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L40 ANSWER 8 OF 30 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:768186 HCPLUS [Full-text](#)
 DOCUMENT NUMBER: 142:32431
 TITLE: Unexpected partial H1-receptor agonism of imidazole-type histamine H3-receptor antagonists lacking a basic side chain
 AUTHOR(S): Sadek, B.; Elz, S.; Pertz, H. H.; Stark, H.; Schunack, W.
 CORPORATE SOURCE: Faculty of Pharmacy & Health Sciences, Ajman University of Science and Technology, Al-Ain, United Arab Emirates
 SOURCE: Inflammation Research (2004), 53(Suppl. 2), S109-S115
 CODEN: INREFB; ISSN: 1023-3830
 PUBLISHER: Birkhaeuser Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Objective and design: The putative partial H1-receptor agonism of some H3-receptor antagonists belonging to the proxifan series was characterized in a functional in-vitro assay using guinea-pig ileum. Methods: Whole segments of guinea-pig ileum were mounted in Tyrode's solution under isotonic conditions in the presence of atropine (10⁻⁷ M) and were cumulatively treated with histamine as an internal reference. After washout, the putative H1-receptor agonists were added cumulatively to determine agonist potency (pEC50) and

intrinsic activity (Emax) relative to histamine. Maximal or supramaximal concns. of partial agonists, or sufficient concns. of H1-receptor antagonists were incubated for 3-15 min prior to construction of a second concentration-effect curve to histamine in order to calculate partial agonist or antagonist affinity for the H1 receptor (pK_p or pA₂ value, resp.). Results: Several analogs of FUB 372 displayed low H1-receptor affinities (pA₂ or pK_p 4.2-5.5) except for a Me benzoate derivative (pA₂ = 6.81, Schild plot slope unity). FUB 372, four ortho-substituted derivs. (R = F, CH₃, OCH₃, CF₃), and ciproxifan were weak contractile agents (Emax 9-38%, pEC₅₀ 4.73-5.68, histamine: 6.70) susceptible to antagonism by the H1-antihistaminergic drug mepyramine (2·10⁻⁹-10⁻⁷ M). Agonist potency and H1-receptor affinity of these compds. did not correlate with the data of a set of H1-histaminergic 2-phenylhistamines bearing the same substituents. Conclusions: A specific subset of proxifans related to FUB 372 and ciproxifan represent a unique type of H1-receptor agonists lacking a basic side chain.


IT 184027-56-3

RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)

(unexpected partial H1-receptor agonism of imidazole-type histamine H3-receptor antagonists lacking basic side chain)

RN 184027-56-3 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[3-(1H-imidazol-4-yl)propoxy]- (9CI)
(CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 9 OF 30 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:660243 HCPLUS Full-text

DOCUMENT NUMBER: 133:358880

TITLE: Novel Histamine H3-Receptor Antagonists with Carbonyl-Substituted 4-(3-(Phenoxy)propyl)-1H-imidazole Structures like Ciproxifan and Related Compounds


AUTHOR(S): Stark, Holger; Sadek, Bassem; Krause, Michael; Huels, Annette; Ligneau, Xavier; Ganellin, C. Robin; Arrang, Jean-Michel; Schwartz, Jean-Charles; Schunack, Walter
CORPORATE SOURCE: Institut fuer Pharmazie, Freie Universitaet Berlin, Berlin, 14195, USA

SOURCE: Journal of Medicinal Chemistry (2000), 43(21), 3987-3994

PUBLISHER: CODEN: JMCMAR; ISSN: 0022-2623
American Chemical Society

DOCUMENT TYPE: Journal
LANGUAGE: English

GI



AB Novel histamine H₃-receptor antagonist phenoxypropylimidazoles such as I [R = H, HO, MeO, OHC, HOCH₂; MeCO, EtCO, Me(CH₂)₃, Bu, Me(CH₂)₄CO, Me(CH₂)₅CO, Me₂CHCO, Me₃CCH₂CO, cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, PhCH₂CO, piperidinopropylcarbonyl, EtO₂C(CH₂)₃, HO₂C(CH₂)₃, MeCOCH₂, MeCO(CH₂)₂, MeCOCH:CH, HOCCH:CH, MeSO₂, cyclopentyl; R₁ = H, F, Me, F₃C, MeO; R₂ = H, Me; R₃ = H, Me, O₂N; RR₁ = COCH₂CH₂, CO(CH₂)₃, (CH₂)₃, (CH₂)₄] have been synthesized according to Mitsunobu or SNAr reactions. With in vitro and in vivo screening for H₃-receptor antagonist potency, the carbonyl-substituted derivs. proved to be highly active compds. A number of compds. showed in vitro affinities in the subnanomolar concentration range, and I [R = Me(CH₂)₄CO; R₁ = R₂ = R₃ = H] and I (R = MeCO; R₁ = Me; R₂ = R₃ = H) showed in vivo antagonist potencies of about 0.1 mg/kg after po administration. Many proxifans were also tested for their affinities at other histamine receptor subtypes thereby demonstrating their pronounced H₃-receptor subtype selectivity. Since the cyclopropyl ketone derivative I (R = cyclopropylcarbonyl; R₁ = R₂ = R₃ = H) (ciproxifan) had high affinity in vitro as well as high potency in vivo, it was selected for further studies in monkeys. It showed good oral absorption and long-lasting, dose-dependent plasma levels making it a promising compound for drug development.

IT 184027-57-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of phenoxypropylimidazole derivs. as histamine H₃ receptor antagonists)


RN 184027-57-4 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[3-(1H-imidazol-4-yl)propoxy]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 184027-56-3


CMF C16 H18 N2 O2



CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 10 OF 30 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1998:603193 HCPLUS Full-text
 DOCUMENT NUMBER: 129:216420
 TITLE: Preparation of tetralone derivatives as antiarrhythmic agents
 INVENTOR(S): Ahmad, Saleem; Stein, Philip D.; Ferrara, Francis N.; Atwal, Karnail S.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
 SOURCE: PCT Int. Appl., 204 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9836749	A1	19980827	WO 1998-US2338	19980207
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6048877	A	20000411	US 1998-9812	19980120
AU 9861486	A	19980909	AU 1998-61486	19980207
PRIORITY APPLN. INFO.:			US 1997-38917P	P 19970221
			WO 1998-US2338	W 19980207
OTHER SOURCE(S): GI	MARPAT	129:216420		




AB The title compds. [I; R₁ = halo, alkyl, alkenyl, etc.; R₂ = H, alkyl, halo, etc.; R₃ = O, OH, alkoxy, etc.; R₄ = H, alkyl, alkyl(COalkyl), alkyl(COOalkyl); R₃R₄ taken together with the atoms to which they are attached form a 5-7 membered ring containing up to three heteroatoms selected from O, N and S; R₅ = H, alkyl, alkenyl, etc.; n = 0-2], useful in the treatment of arrhythmia, were prepared. Thus, treatment of 6-methoxytetralone with paraformaldehyde and N-methylanilinium trifluoroacetate in THF followed by reaction of the resulting 2-methylene-6-methoxy-1-tetralone with 4-phenylpiperidine over alumina in PhMe afforded the title compound II. Compds. I are effective at 0.001-10 mg/kg/day.

IT 212257-47-1P 212257-66-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetralones as antiarrhythmic agents)


RN 212257-47-1 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[(1-phenyl-1H-imidazol-2-yl)methoxy]-2-[2-(4-phenyl-1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 212257-66-4 HCPLUS

CN 1(2H)-Naphthalenone, 6-(1H-benzimidazol-2-ylmethoxy)-3,4-dihydro-2-[2-(4-phenyl-1-piperidinyl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 11 OF 30 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996:738181 HCPLUS Full-text


DOCUMENT NUMBER: 126:18872

TITLE: Preparation of imidazole derivatives as histamine H₃ receptor ligands

INVENTOR(S): Schwartz, Jean-Charles; Arrang, Jean-Michel; Garbarg, Monique; Quemener, Agnes; Lecomte, Jeanne-Marie; Ligneau, Xavier; Schunack, Walter G.; Stark, Holger; Purand, Katja; et al.

PATENT ASSIGNEE(S): Institut National de la Sante et de la Recherche Medicale, Fr.; Societe Civile Bioprojet
 SOURCE: PCT Int. Appl., 144 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9629315	A2	19960926	WO 1996-FR432	19960321
WO 9629315	A3	19961024		
W: CA, JP, MX, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2732017	A1	19960927	FR 1995-3267	19950321
FR 2732017	B1	20000922		
CA 2190865	A1	19960926	CA 1996-2190865	19960321
EP 760811	A1	19970312	EP 1996-908172	19960321
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10501001	T	19980127	JP 1996-528146	19960321
US 6248765	B1	20010619	US 1997-750163	19970109
PRIORITY APPLN. INFO.:			FR 1995-3267	A 19950321
			WO 1996-FR432	W 19960321
OTHER SOURCE(S):	MARPAT 126:18872			
GI				




AB Title compds. [I; RZ1Z2Z3R1; R1 = alkyl, aryl, etc.; Z1 = alk(en)ylene, alkynylene; Z2 = O2CNH, O2C, CH2, O, NH, CO, etc.; Z3 = bond, alk(en)ylene(oxy) or -(thio)] were prepared. Thus, I [R = (CH2)3OH] was treated with Me3CNC to give I [R = (CH2)3O2CNHCMe3]. Data for biol. activity of I were given.

IT 184027-56-3P 184027-57-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of imidazole derivs. as histamine H3 receptor ligands)

RN 184027-56-3 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[3-(1H-imidazol-4-yl)propoxy]- (9CI)
 (CA INDEX NAME)




RN 184027-57-4 HCPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-6-[3-(1H-imidazol-4-yl)propoxy]-,
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 184027-56-3

CMF C16 H18 N2 O2




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



L40 ANSWER 12 OF 30 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1992:255341 HCPLUS Full-text

DOCUMENT NUMBER: 116:255341

TITLE: Preparation of N-substituted tetrahydronaphthyl-N-hydroxyureas and analogs as 5-lipoxygenase inhibitors

INVENTOR(S): Adams, Jerry Leroy; Garigipati, Ravi Shanker;
Griswold, Don Edgar; Schmidt, Stanley James

PATENT ASSIGNEE(S): SmithKline Beecham Corp., USA

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9114674	A2	19911003	WO 1991-US2010	19910325
WO 9114674	A3	19920109		
W: AU, CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				

CA 2078126	A1	19910928	CA 1991-2078126	19910325
AU 9175875	A	19911021	AU 1991-75875	19910325
AU 660277	B2	19950622		
EP 522000	A1	19930113	EP 1991-907085	19910325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05505610	T	19930819	JP 1991-506661	19910325
ZA 9102264	A	19920429	ZA 1991-2264	19910326
RITY APPLN. INFO.:			US 1990-500153	A 19900327
			US 1990-500179	A 19900327
			WO 1991-US2010	A 19910325

OTHER SOURCE(S) : MARPAT 116:255341

GI



AB Title compds. I (R1 = H, C1-10 alkyl, C1-10 alkoxy, etc.; R2, R3 = R4C:BN(ORa), R4 = (halo)(hydroxy) C1-6 alkyl, C2-6 alkenyl, (halo)heteroaryl, C1-6 alkoxy, R5R6N wherein R5 = H, alkyl, R6 = C1-6 alkyl, aryl, PhCH₂, etc.; B = O, S, Ra = H, cation, aroyl, C1-12 alkoyl; W = CH₂(CH₂)_s, O(CH₂)_s, S(CH₂)_s, NR₇(CH₂)_s, s = 0-3, R7 = H, C1-4 alkyl, Ph, C1-6 alkoyl, aroyl; l = q = 0, 1) or a salt thereof, are prepared I are also analgesics. To 6-hydroxy-1-tetralone was added NaH, followed by 4-(MeO)C₆H₄CH₂C1 and the mixture was heated to 90° for 1 h to give the tetralone derivs. To this in pyridine was added HONH₂.HCl to give the oxime, which was treated with BH₃-pyridine and converted to the N-hydroxyamine derivative to which was added Me₃SiNCO to give after work up the title compound II. II inhibited 5-lipoxygenase with IC₅₀ of 0.5 μM and an analgesic activity ED₅₀ of 10 mg/kg.


IT 139149-45-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of lipoxygenase inhibitors)

RN 139149-45-4 HCAPLUS

CN 1 (2H)-Naphthalenone, 6-(1H-benzimidazol-2-ylmethoxy)-3,4-dihydro- (9CI)
(CA INDEX NAME)




December 20, 2006

ACCESSION NUMBER: 143:97264 MARPAT Full-text
 TITLE: Preparation of benzopyrans and other compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity
 INVENTOR(S): Vasudevan, Jayasree; Wang, Liming; Liu, Xiaoxia; Tsang, Kwok Yin; Li, Ling; Takeuchi, Janet A.; Vu, Thong; Beard, Richard L.; Bhat, Smita; Vuligonda, Vidyasagar; Chandraratna, Roshantha A.
 PATENT ASSIGNEE(S): Allergan, Inc., USA
 SOURCE: PCT Int. Appl., 239 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058798	A2	20050630	WO 2004-US42897	20041217
WO 2005058798	A8	20051013		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005176689	A1	20050811	US 2004-14460	20041216
CA 2550123	A1	20050630	CA 2004-2550123	20041217
EP 1699775	A2	20060913	EP 2004-815022	20041217
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU			
PRIORITY APPLN. INFO.:			US 2003-530462P	20031217
			WO 2004-US42897	20041217

GI



AB Compds. (shown as I and 16 addnl. Markush formulas defined in the claims; variables defined below; e.g. 2-[4-[(8-cyclopropyl-3,4-dihydro-4,4-dimethylspiro[2H-1-benzopyran-2,1'-cyclopropane]-6-yl)ethynyl]phenyl]propionic acid (shown as II)) specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme. Although the methods of preparation are not claimed, example preps. for 63 claimed compds. and many intermediates are included. For example, II was prepared in 2 steps (56 and 57 %) by 1st coupling 8-cyclopropyl-6-ethynyl-3,4-dihydro-4,4-dimethylspiro[2H-1-benzopyran-2,1'-cyclopropane] with Me 2-(4-iodophenyl)propionate and then saponifying the ester intermediate. For I: A is Ph, naphthyl, pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrazolyl, said Ph and heteroaryl groups being (un)substituted with 1-2 R2 groups; X is O, S or NR where R is H, C1-6 alkyl or benzyl; Y is H, C1-10 alkyl, benzyl, C1-6 alkyl- or halogen-substituted benzyl, fluoro-substituted C1-10 alkyl, C3-6 cycloalkyl, C1-6 alkyl or substituted C3-6 cycloalkyl, C2-6 alkenyl having 1 or 2 double bonds, C2-6 alkynyl, C4-6 alkenylalkynyl, C4-6 alkynylalkenyl, Cl, Br, or I or C1-6 alkoxy; Z = -C.tplbond.C-, -(CR1:CR1)n', where n' is 1-5, -CONR1-, NR1CO-, -CO-O-, -O-CO-, -CSNR1-, NR1CS-, -CO-S-, -S-CO-, -N:N-, -NR1-CO-NR1-; R1 = H or C1-6 alkyl; p = 0-4; R2 = H, C1-6 alkyl, F, Cl, Br, I, CF3, fluoro-substituted C1-6 alkyl, C1-6 alkoxy, or C1-6 alkylthio; R3 = C1-6 alkyl, F, Cl, Br, I, fluoro-substituted C1-6 alkyl, OH, SH, C1-6 alkoxy, C1-6 alkylthio or benzyl; m = 0 to 2; R4 = H, C1-6 alkyl, or F; fluoro-substituted C1-6 alkyl, or halogen; o = 0-2; W is -C(R5)2- or -CR5:CR5-; R5 = H, halogen, or C1-3 alkyl with the proviso that when W is -C(R5)2- then at least one R5 is C1-3 alkyl, and R8 is H, C1-6 alkyl, -CH2O(C1-6-alkyl), CH2OCO(C1-6-alkyl) or a cation of a pharmaceutically acceptable base.

MSTR 1



G14—G1—G4—G7—G(0)—O—G11

G1 = 16-1 17-3

December 20, 2006

18-19(0)

G4 = 395-2 394-4

G7 = bond
G14 = 845

G50 = C(O)
 Patent location: claim 1
 Note: substitution is restricted
 Note: also incorporates claim 7, claim 14, claim 20,
 claim 27, claim 33, claim 40, claim 44, claim 48,
 claim 52, claim 56, claim 60, claim 64, claim 68,
 claim 72, claim 76, and claim 80
 Note: or pharmaceutically acceptable salts

L40 ANSWER 14 OF 30 MARPAT COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 143:97263 MARPAT Full-text
 TITLE: Preparation of benzopyran and related analogs for
 treating retinoid responsive disorders using selective
 inhibitors of CYP26A and CYP26B
 INVENTOR(S): Vasudevan, Jayasree; Yang, Rong; Wang, Liming; Liu,
 Xiaoxia; Tsang, Kwok Yin; Li, Ling; Takeuchi, Janet
 A.; Vu, Thong; Beard, Richard L.; Bhat, Smita;
 Chandraratna, Roshantha A.
 PATENT ASSIGNEE(S): Allergan, Inc., USA
 SOURCE: PCT Int. Appl., 286 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058301	A1	20050630	WO 2004-US41889	20041213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

CA 2550010 A1 20050630 CA 2004-2550010 20041213


US 2005187298 A1 20050825 US 2004-10953 20041213

EP 1696899 A1 20060906 EP 2004-814113 20041213

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
 BA, HR, IS, YU

PRIORITY APPLN. INFO.: US 2003-530601P 20031217
 WO 2004-US41889 20041213

GI



AB Title compds. for retinoid responsive disorder are prepared that possess a 10-fold selectivity for inhibition of cytochromes CYP26B relative to CYP26A. For instance, 2-[4-[(8-cyclopropyl-3,4-dihydro-4,4-dimethylspiro[benzopyran-2,1'-cyclopropane]-6-yl)ethynyl]phenyl]propionic acid (I) is prepared in several steps from prior art 8-cyclopropyl-4,4-dimethylspiro[benzopyran-2,1'-cyclopropane] and Me 2-(4-iodophenyl)propionate (preparation given). Selected examples show this selectivity as well as weak binding to RAR receptors. I are useful in the treatment of, e.g., autoimmune disorders.


MSTR 16

G14—G1—G4—G7—G(0)—O—G11


G1 = 16-1 17-3

I8—I9(0)

G4 = 395-2 394-4



G7 = bond
G14 = 845



G50 = C(O)
Patent location: disclosure
Note: substitution is restricted
Note: or pharmaceutically acceptable salts

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 15 OF 30 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 136:216646 MARPAT Full-text
TITLE: Preparation of tetrahydronaphthalenes,
tetrahydroisoquinolines, chromans,
spirobenzopyrancyclopropanes and related compounds as
cytochrome P 450 RAI inhibitors
INVENTOR(S): Vasudevan, Jayasree; Johnson, Alan T.; Huang, Dehua;
Wang, Liming; Chandraratna, Roshantha A.
PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
SOURCE: PCT Int. Appl., 269 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
WO 2002018361	A2	20020307	WO 2001-US25443	20010814
WO 2002018361	A3	20030731		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 6252090	B1	20010626	US 2000-651235	20000829
US 6291677	B1	20010918	US 2000-651001	20000829
US 6303785	B1	20011016	US 2000-651003	20000829
US 6369261	B1	20020409	US 2000-651004	20000829
US 6369225	B1	20020409	US 2000-651566	20000829
US 6380256	B1	20020430	US 2000-651564	20000829
US 6387951	B1	20020514	US 2000-651234	20000829
CA 2420869	A1	20020307	CA 2001-2420869	20010814
AU 2001086471	A5	20020313	AU 2001-86471	20010814
EP 1366036	A2	20031203	EP 2001-965920	20010814
EP 1366036	B1	20060111		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004507531	T	20040311	JP 2002-523479	20010814
US 2002156082	A1	20021024	US 2002-79993	20020221
US 6603019	B2	20030805		
US 2002160986	A1	20021031	US 2002-97368	20020314
US 2002183285	A1	20021205	US 2002-97315	20020314
US 2003186947	A1	20031002	US 2003-364225	20030211
US 6713647	B2	20040330		
HK 1059439	A1	20060707	HK 2004-102361	20040331
PRIORITY APPLN. INFO.:				
			US 2000-651001	20000829
			US 2000-651003	20000829
			US 2000-651004	20000829
			US 2000-651234	20000829
			US 2000-651235	20000829
			US 2000-651564	20000829
			US 2000-651566	20000829
			WO 2001-US25443	20010814
			US 2002-79993	20020221

GI




AB Title compds., e.g., [I; A = (substituted) Ph, naphthyl, thieryl, furyl; X = O, S; Y1 = H, alkyl, PhCH2, fluoroalkyl, cycloalkyl, cycloalkylalkyl, Cl, Br, iodo; Z = C.tpbond.C, (CR1:CR1)n, CONR1, CO2, N:N, SCO, etc.; R1 = H, alkyl; n = 1-5; R2 = H, alkyl, F, Cl, Br, iodo, CF3, fluoroalkyl, alkoxy, alkylthio; R3 = alkyl, F, Cl, Br, iodo, fluoroalkyl, OH, SH, alkoxy, alkylthio, PhCH2; R4 = H, alkyl, F, fluoroalkyl, halo; R8 = H, alkyl, CH2OA; A = alkyl, cation; m, q = 0-2; n = 0-4], were prepared. Thus, 8-cyclopropyl-6-ethynyl-3,4-dihydro-4,4-dimethylspiro[2H-1-benzopyran-2,1'-cyclopropane] (preparation given), Me 2-fluoro-4-iodophenylacetate (preparation given), Et3N, CuI, and (PPh3)2PdCl2 were stirred in THF to give 46% Me 4-[[8-cyclopropyl-3,4-dihydro-4,4-dimethylspiro[2H-1-benzopyran-2,1'-cyclopropane]-6-yl]ethynyl]-2-fluorobenzeneacetate. This ester was stirred with NaOH in H2O/MeOH to give 100% 4-[[8-cyclopropyl-3,4-dihydro-4,4-dimethylspiro[2H-1-benzopyran-2,1'-


December 20, 2006

cyclopropane]-6-yl]ethynyl]-2- fluorobenzeneacetic acid. The acid inhibited cytochrome P 450 RAI with IC₅₀ = 0.014 μM.


MSTR 8




G1 = 558



G2 = 437-18 436-20



G5 = 48-17 47-19



G6 = C(O)
 G10 = (0-4) CH₂
 G17 = O
 G20 = NH


Patent location: claim 130
 Note: substitution is restricted

L40 ANSWER 16 OF 30 MARPAT COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 135:344377 MARPAT Full-text
 TITLE: Preparation of tetrahydronaphthalenes,
 tetrahydroisoquinolines, chromans,
 spirobenzopyrancyclopropanes and related compounds as
 cytochrome P450RAI inhibitors.
 INVENTOR(S): Vasudevan, Jayasree; Johnson, Alan T.; Wang, Liming;
 Huang, Dehua; Chandraratna, Roshantha A.
 PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
 SOURCE: U.S., 79 pp., Cont.-in-part of U.S. Ser. No. 651,235.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6313107	B1	20011106	US 2000-672751	20000928
US 6252090	B1	20010626	US 2000-651235	20000829
US 6387892	B1	20020514	US 2001-875967	20010607
US 2002132796	A1	20020919	US 2001-963318	20010607
US 6495552	B2	20021217		
CA 2423919	A1	20020404	CA 2001-2423919	20010814
WO 2002026727	A2	20020404	WO 2001-US25465	20010814
WO 2002026727	A3	20020516		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001086478	A5	20020408	AU 2001-86478	20010814
EP 1322631	A2	20030702	EP 2001-965927	20010814
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004509955	T	20040402	JP 2002-531111	20010814
US 2003078270	A1	20030424	US 2002-212533	20020805
US 6855512	B2	20050215		
PRIORITY APPLN. INFO.:			US 2000-651235	20000829
			US 2000-672751	20000928
			US 2001-963318	20010607
			WO 2001-US25465	20010814


GI




AB Title compds., e.g., [I; A = (substituted) Ph, naphthyl, thieryl, furyl; X = O, S; Y1 = H, alkyl, PhCH2, fluoroalkyl, cycloalkyl, cycloalkylalkyl, Cl, Br, iodo; Z = C.tplbond.C, (CR1:CR1)n, CONR1, CO2, N:N, SCO, etc.; R1 = H, alkyl; n = 1-5; R2 = H, alkyl, F, Cl, Br, iodo, CF3, fluoroalkyl, alkoxy, alkylthio; R3 = alkyl, F, Cl, Br, iodo, fluoroalkyl, OH, SH, alkoxy, alkylthio, PhCH2; R4 = H, alkyl, F, fluoroalkyl, halo; R8 = H, alkyl, CH2OA; A = alkyl, cation; m, q = 0-2; n = 0-4], were prepared. Thus, 8-cyclopropyl-6-ethynyl-3,4-dihydro-4,4-dimethylspiro[2H-1-benzopyran-2,1'-cyclopropane] (preparation given), Me 2-fluoro-4-iodophenylacetate (preparation given), Et3N, CuI, and (PPh3)2PdCl2 were stirred in THF to give 46% Me 4-[[8-cyclopropyl-3,4-dihydro-4,4-dimethylspiro[2H-1-benzopyran-2,1'-cyclopropane]-6-yl]ethynyl]-2-

fluorobenzeneacetate. This was stirred with NaOH in H₂O/MeOH to give 100% 4-[[8-cyclopropyl-3,4-dihydro-4,4-dimethylspiro[2H-1-benzopyran-2,1'-cyclopropane]-6-yl]ethynyl]-2-fluorobenzeneacetic acid. The latter inhibited cytochrome P450RAI with IC₅₀ = 0.014 μM.


MSTR 8




G1 = 558



G2 = 437-18 436-20



G5 = 48-17 47-19



G6 = C(O)

G10 = (0-4) CH₂

G17 = O

G20 = NH

Patent location:

claim 7

Note: substitution is restricted

Note: also incorporates broader disclosure

REFERENCE COUNT:

107 THERE ARE 107 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 17 OF 30 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 135:303682 MARPAT Full-text

TITLE: Preparation of arylethyynylphenylalkanoates and -benzoates and analogs as cytochrome P450RAI inhibitors

INVENTOR(S): Vasudevan, Jayasree; Johnson, Alan T.; Chandraratna,

Roshantha A.
 PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
 SOURCE: U.S., 71 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6303785	B1	20011016	US 2000-651003	20000829
CA 2420869	A1	20020307	CA 2001-2420869	20010814
WO 2002018361	A2	20020307	WO 2001-US25443	20010814
WO 2002018361	A3	20030731		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2001086471	A5	20020313	AU 2001-86471	20010814
EP 1366036	A2	20031203	EP 2001-965920	20010814
EP 1366036	B1	20060111		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004507531	T	20040311	JP 2002-523479	20010814
AT 315558	T	20060215	AT 2001-965920	20010814
ES 2256288	T3	20060716	ES 2001-1965920	20010814
HK 1059439	A1	20060707	HK 2004-102361	20040331
PRIORITY APPLN. INFO.:			US 2000-651001	20000829
			US 2000-651003	20000829
			US 2000-651004	20000829
			US 2000-651234	20000829
			US 2000-651235	20000829
			US 2000-651564	20000829
			US 2000-651566	20000829
			WO 2001-US25443	20010814

AB Title compds., e.g., 4-(PhCH₂Z)C₆H₄C.tplbond.CC₆H₄(CO₂H)-4 (Z = cyclopropylidene), were prepared Data for biol. activity of title compds. were given.


MSTR 8

191—T85—192—2810—C(0)—G11


G1 = 558



G2 = 437-18 436-20



G5 = 48-17 47-19



G6 = C(O)
G10 = (O-4) CH2
G17 = O
G20 = NH

Patent location: disclosure
Note: substitution is restricted

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 18 OF 30 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 135:242148 MARPAT Full-text

TITLE: Synthesis of (hetero)arylacetic acids and derivatives thereof as inhibitors of cytochrome p450RAI-1

INVENTOR(S): Vasudevan, Jayasree; Johnson, Alan T.; Huang, Dehua; Chandraratna, Roshantha A.

PATENT ASSIGNEE(S): Allergan Sales, Inc., USA

SOURCE: U.S., 67 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6291677	B1	20010918	US 2000-651001	20000829
CA 2420869	A1	20020307	CA 2001-2420869	20010814
WO 2002018361	A2	20020307	WO 2001-US25443	20010814
WO 2002018361	A3	20030731		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,

RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG

AU 2001086471 A5 20020313 AU 2001-86471 20010814

EP 1366036 A2 20031203 EP 2001-965920 20010814

EP 1366036 B1 20060111

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004507531 T 20040311 JP 2002-523479 20010814



AT 315558 T 20060215 AT 2001-965920 20010814

ES 2256288 T3 20060716 ES 2001-1965920 20010814

HK 1059439 A1 20060707 HK 2004-102361 20040331

PRIORITY APPLN. INFO.: US 2000-651001 20000829
US 2000-651003 20000829
US 2000-651004 20000829
US 2000-651234 20000829
US 2000-651235 20000829
US 2000-651564 20000829
US 2000-651566 20000829
WO 2001-US25443 20010814


GI




AB Title compds. I [A = (hetero)aryl; Y = H, alkyl, benzyl, etc.; Z = C.tplbond.C, CONR1, NR1CO, COO, OCO, etc.; R1 = H, alkyl; p = 0 - 5; R2 = H, alkyl, F, Cl, Br, I, CF3, alkoxy; R3 = alkyl, F, Cl, Br, I, CF3, etc.; m = 0 - 2; R4 = H, alkyl, halo; q, n = 0 - 4; R8 = H, alkyl, CH2Oalkyl or a cation of a pharmaceutically acceptable base] were prepared Over 140 compds. were synthesized. For instance, 6-ethynyl-4,4-dimethyl-1,2,3,4-tetrahydronaphthalene-1-one [preparation given] was coupled to Et 4-iodobenzoate (CuI, (Ph3P)2Cl2Pd, Et3N, THF, room temperature) to give the corresponding acetylene. This acetylene was used to alkylate cyclopropyl amine (DCM, HOAc, NaCNBH3, room temperature) and the resulting amine methylated (acetone, MeI, K2CO3, room temperature). Saponification of the intermediate provided II (EtOHaq, THF, NaOH, 80°C, 1 h.). II had Kd for

retinoic receptors RAR α = 280 nM, RAR β = 4.8 nM and RAR γ 9.8 nM and IC50 = 3 μ M for cytochrome P450RAI-1. They are used for treating diseases responsive to treatment by retinoids.


MSTR 8




G1 = 558



G2 = 437-18 436-20



G5 = 48-17 47-19



G6 = C(O)
G10 = (0-4) CH₂
G17 = O
G20 = NH

Patent location: disclosure
Note: substitution is restricted



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 19 OF 30 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 128:102268 MARPAT Full-text
TITLE: Preparation of substituted tetrahydronaphthalene and dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
INVENTOR(S): Vuligonda, Vidyasagar; Teng, Min; Beard, Richard L.; Johnson, Alan T.; Lin, Yuan; Chandraratna, Roshantha A.; Song, Tae K.; Wong, Harold N.; Duong, Tien T.; Gillett, Samuel J.

PATENT ASSIGNEE(S): Allergan, USA
 SOURCE: PCT Int. Appl., 236 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9748672	A2	19971224	WO 1997-US10725	19970619
WO 9748672	A3	19980716		
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5723666	A	19980303	US 1996-667215	19960621
US 5741896	A	19980421	US 1996-667664	19960621
US 5747542	A	19980505	US 1996-667666	19960621
US 5763635	A	19980609	US 1996-667665	19960621
US 5773594	A	19980630	US 1996-667663	19960621
US 5808124	A	19980915	US 1996-667216	19960621
CA 2258313	A1	19971224	CA 1997-2258313	19970619
AU 9737162	A	19980107	AU 1997-37162	19970619
AU 724541	B2	20000921		
EP 915825	A2	19990519	EP 1997-933997	19970619
EP 915825	B1	20040506		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000511558	T	20000905	JP 1998-503375	19970619
AT 265997	T	20040515	AT 1997-933997	19970619
US 6051731	A	20000418	US 1997-923897	19970904
US 5998655	A	19991207	US 1998-30353	19980225
US 6117987	A	20000912	US 1998-57386	19980408
US 6187933	B1	20010213	US 2000-492495	20000127
US 6653483	B1	20031125	US 2000-550952	20000417
US 2001000511	A1	20010426	US 2000-735172	20001211
US 6344561	B2	20020205		
US 2002099038	A1	20020725	US 2001-900593	20010706
US 6465663	B2	20021015		
US 2002173631	A1	20021121	US 2002-141655	20020508
US 6555690	B2	20030429		
US 2003078440	A1	20030424	US 2002-269270	20021011
US 6855832	B2	20050215		
US 2003187235	A1	20031002	US 2002-314758	20021209
US 6720425	B2	20040413		
US 2004127469	A1	20040701	US 2003-731448	20031209
US 6818775	B2	20041116		
PRIORITY APPLN. INFO.:			US 1996-667215	19960621
			US 1996-667216	19960621
			US 1996-667663	19960621
			US 1996-667664	19960621
			US 1996-667665	19960621
			US 1996-667666	19960621
			WO 1997-US10725	19970619
			US 1997-923897	19970904
			US 1998-57386	19980408
			US 2000-492495	20000127
			US 2000-550952	20000417
			US 2000-735172	20001211
			US 2001-900593	20010706
			US 2002-141655	20020508

GI




AB Compds. of formula I [Z = N=N, ethenyl, (substituted) CONH, CO₂, etc.; Y = Ph, naphthyl, heteroaryl, etc.; A = alkyl, cycloalkyl, alkenyl, alkynyl, etc.; B = H, CO₂H, CHO, , etc.; X = (substituted) (CH₂)_p; p = 0-2; R = H, alkyl, halo, CF₃, etc.; R¹ = H, (fluoro-substituted) alkyl; n = 0-4; R², R³ = H, alkyl, alkoxy, alkylthio, arylthio, heteroaryl, etc.; R²R³ = oxo, acetal, thioacetal, alkylidene, (substituted) NH, etc.] are prepared, and have retinoid and/or retinoid antagonist-like biol. activity. Thus, II was prepared from 2-bromo-5,6-dihydro-5,5-dimethyl-8-(phenylthio)naphthalene (preparation given) and Et 4-vinylbenzoate. II showed and IC₈₀ of 4.3 nM in the ornithine decarboxylase (ODC) assay.


MSTR 1A

G1—G7—G8—G9


G1 = 1078



G6 = O
 G7 = 905-1 906-3



G8 = 687-2 686-4



G23 = NH

G35 = O

Derivative: and pharmaceutically acceptable salts

Patent location: claim 1

Note: substitution is restricted

Note: also incorporates claims 21, 41, 61, 81, 95, and 101

Note: additional ring formation also claimed

L40 ANSWER 20 OF 30 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 128:23037 MARPAT Full-text

TITLE: Preparation of antiviral phenanthrenecarboxylic acid derivatives

INVENTOR(S): Hornback, Williams J.; Mauldin, Scott C.; Munroe, John E.

PATENT ASSIGNEE(S): Eli Lilly and Company, USA; Hornback, William J.; Mauldin, Scott C.; Munroe, John E.

SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9742156	A1	19971113	WO 1997-US7438	19970502
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
EP 806410	A2	19971112	EP 1997-303043	19970502
EP 806410	A3	19980603		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO			
CA 2253401	A1	19971113	CA 1997-2253401	19970502
AU 9729955	A	19971126	AU 1997-29955	19970502
JP 2000510465	T	20000815	JP 1997-540049	19970502
AT 203007	T	20010715	AT 1997-303043	19970502
ES 2159815	T3	20011016	ES 1997-303043	19970502


US 6156924 A 20001205 PRIORITY APPLN. INFO.:

US 1999-214530 19990106
US 1996-16901P 19960506
WO 1997-US7438 19970502

GI




I



II

AB The terpene phenanthrenecarboxylic acid derivs. I (R, R1 = H, OH, alkyl, alkoxy, hydroxalkyl, sulfhydryl, sulfamyl, SO₂Cl, SC(:O)NMe₂, amino, alkylamino dialkylamino, alkylsulfonylamino, di(alkylsulfonyl)amino, etc.; R2 = H, OH, amino, alkylamino, dialkylamino, alkoxy, =O, alkanoyloxy, alkanoylamino, hydroxyimino, R2-R3 may be a bond; R3 = H, halo, alkyl, =O; R4 = H or alkyl, R5 = HO, halo, alkoxy, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, amino) were prepared as drugs which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. Thus, abietic acid was treated with MeI and the ester underwent acetoxylation with AcO₂ in presence of SeO₂ followed by hydrogenolysis to give the phenanthrenecarboxylic acid derivative II. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal. Thus, using in vitro CPE/XTT assay I had an IC₅₀ of 1-2.4 µg/mL for influenza A/Kawasaki/89.

MSTR 1



G1 = 79

79—G11

G11 = 81

H₃C—G12

G12 = imidazolyl

G24+G25= O

Derivative:

or pharmaceutically acceptable salts

Patent location:

claim 1

Note:

substitution is restricted

L40 ANSWER 21 OF 30 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 128:13354 MARPAT Full-text

TITLE: Preparation of antiviral compounds

INVENTOR(S): Mauldin, Scott C.; Munroe, John E.

PATENT ASSIGNEE(S): Eli Lilly and Company, USA; Mauldin, Scott C.; Munroe, John E.

SOURCE: PCT Int. Appl., 49 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9742155	A1	19971113	WO 1997-US7531	19970502
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2253857	A1	19971113	CA 1997-2253857	19970502
AU 9727525	A	19971126	AU 1997-27525	19970502
EP 811600	A2	19971210	EP 1997-303042	19970502
EP 811600	A3	19980603		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2000511514	T	20000905	JP 1997-540100	19970502
US 6100426	A	20000808	US 1999-214524	19990106
US 6180815	B1	20010130	US 2000-546135	20000410
PRIORITY APPLN. INFO.:			US 1996-16964P	19960506
			WO 1997-US7531	19970502

GI



AB Compds. of formula I [R₁, R₂ = H, OH, alkyl, alkoxy, etc.; R₃ = H, OH, amino, oxo, oxime, alkylamino, etc.; R₄ = H, halo, alkyl, oxo; R₅ = H, alkyl; R₆ = H, halo, alkoxy, etc.] are prepared. These compds. inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof. Thus, II is prepared from abietic acid in 7 steps.

MSTR 1

$$G1 = 79$$

$$79 \text{---} G11$$

$$G11 = 81$$

$$H_2C \text{---} G12$$

G12 = imidazolyl

G24+G25= O

Derivative:

or pharmaceutically acceptable salts

Patent location:

claim 1

Note:

substitution is restricted

L40 ANSWER 22 OF 30 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

128:23036 MARPAT Full-text

TITLE:

Preparation of antiviral phenanthrenecarboxylic acid derivatives

INVENTOR(S):

Hornback, William J.; Mauldin, Scott C.; Munroe, John E.

PATENT ASSIGNEE(S):

Eli Lilly and Company, USA; Hornback, William J.; Mauldin, Scott C.; Munroe, John E.

SOURCE:

PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:


English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9742154	A1	19971113	WO 1997-US7403	19970502
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 806411	A2	19971112	EP 1997-303046	19970502
EP 806411	A3	19980603		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
CA 2253739	A1	19971113	CA 1997-2253739	19970502
AU 9727505	A	19971126	AU 1997-27505	19970502
JP 2000510464	T	20000815	JP 1997-540037	19970502
AT 203008	T	20010715	AT 1997-303046	19970502
ES 2159816	T3	20011016	ES 1997-303046	19970502
US 6096917	A	20000801	US 1999-214534	19990106
GR 3036821	T3	20020131	GR 2001-401682	20011008
PRIORITY APPLN. INFO.:			US 1996-16925P	19960506
			WO 1997-US7403	19970502

GI



AB The terpene phenanthrenecarboxylic acid derivs. I (R, R1 = H, OH, alkyl, alkoxy, hydroxyalkyl, sulfhydryl, sulfamyl, SO₂Cl, SC(:O)NMe₂, amino, alkylamino dialkylamino, alkylsulfonylamino, di(alkylsulfonyl)amino, etc.; R2 = H, OH, amino, alkylamino, dialkylamino alkoxy, =O, alkanoyloxy, alkanoylamino, hydroxyimino, R2-R3 may be a bond; R3 = H, halo, alkyl, =O; R4 = H or alkyl; R5 = HO, halo, alkoxy, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, amino) were prepared as drugs which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. Thus, Me O-methylpodocarpate, was treated with iodotrimethylsilane followed by alkylation with allyl bromide to give the phenanthrenecarboxylate deriv II. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof. Thus, using the *vitro* CPE/XTT assay I had an IC₅₀ of 0.005-100 µg/mL for influenza A.



G1 = 79

~~79~~—G11

G11 = 81

~~H₂C~~—G12

G12 = imidazolyl

G24+G25= O

Derivative:

or pharmaceutically acceptable salts

Patent location:

claim 1

Note:

substitution is restricted

L40 ANSWER 23 OF 30 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

128:23035 MARPAT Full-text

TITLE:

Preparation of abietic acid analogs for use as
antiviral agents

INVENTOR(S):

Mauldin, Scott C.; Munroe, John E.

PATENT ASSIGNEE(S):

Eli Lilly and Company, USA; Mauldin, Scott C.; Munroe,
John E.

SOURCE:

PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9741861	A1	19971113	WO 1997-US7527	19970502
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
EP 806409	A1	19971112	EP 1997-303047	19970502
EP 806409	B1	20010314		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
SI, LT, LV, FI, RO


CA 2253742	A1	19971113	CA 1997-2253742	19970502
AU 9728266	A	19971126	AU 1997-28266	19970502
JP 2000510469	T	20000815	JP 1997-540098	19970502
AT 199707	T	20010315	AT 1997-303047	19970502
ES 2155239	T3	20010501	ES 1997-303047	19970502
US 6103923	A	20000815	US 1999-214535	19990106
US 6175034	B1	20010116	US 2000-545852	20000410
GR 3035980	T3	20010831	GR 2001-400831	20010531
PRIORITY APPLN. INFO.:			US 1996-16902P	19960506
			WO 1997-US7527	19970502

GI



AB Abietic acid analogs I [R0 = R1 = H, OH, alkyl, alkoxy, hydroxyalkyl, sulfhydryl, sulfamoyl, SO2Cl, SCONMe2, NH2, alkylamino, alkylsulfonylamino; R4 = H, OH, alkoxy, acyloxy, acylamino, alkylamino, silyloxy, hydroxyimino, alkoxyimino, oxo; R7 = H, alkyl; R8 = OH, halogen, alkoxy, pyrrolidinyl, piperidinyl, piperazinyl, morpholino, alkylamino], which inhibit an envelope influenza-type virus by inhibiting the fusion of the virus with the host cell, were prepared. Thus, ester II was prepared starting from abietic acid via a synthetic sequence which included aromatization/acetylation with SeO2 and acetic anhydride, side chain oxidation with CrO3, bromination, and dehydrobromination. The prepared compds. were tested in vitro using the plaque reduction assay and gave IC50 values in the range of 0.54 - 6.4 µg/mL for influenza A/Kawasaki virus.

MSTR 1



G1 = 79

78—G11

G11 = 81

H₂C—G12

G12 = imidazolyl



G24+G25= O

Derivative: or pharmaceutically acceptable salts
 Patent location: claim 1
 Note: substitution is restricted

L40 ANSWER 24 OF 30 MARPAT COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 128:23034 MARPAT Full-text
 TITLE: Preparation of podocarpic and abietic acid analogs for
 use as antiviral agents
 INVENTOR(S): Mauldin, Scott C.; Munroe, John E.
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA; Mauldin, Scott C.; Munroe,
 John E.
 SOURCE: PCT Int. Appl., 54 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9741860	A1	19971113	WO 1997-US7526	19970502
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2253398	A1	19971113	CA 1997-2253398	19970502
AU 9728265	A	19971126	AU 1997-28265	19970502
EP 811599	A2	19971210	EP 1997-303023	19970502
EP 811599	A3	19980701		
EP 811599	B1	20010307		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2000510834	T	20000822	JP 1997-540097	19970502
AT 199538	T	20010315	AT 1997-303023	19970502
ES 2154879	T3	20010416	ES 1997-303023	19970502
HK 1006087	A1	20020222	HK 1998-105152	19980610
US 6124494	A	20000926	US 1999-214532	19990106
US 6180816	B1	20010130	US 2000-546551	20000410
GR 3035870	T3	20010831	GR 2001-400723	20010515
PRIORITY APPLN. INFO.:			US 1996-16926P	19960506
			WO 1997-US7526	19970502

GI



AB Podocarpic and abietic acid analogs I [R0 = R1 = H, OH, alkyl, alkoxy, hydroxalkyl, sulfhydryl, sulfamoyl, SO2Cl, SCONMe2, NH2, alkylamino, alkylsulfonylamino; R4 = H, OH, alkoxy, acyloxy, acylamino, alkylamino, silyloxy, hydroxyimino, alkoxyimino, oxo; R = H; R6 = H, halogen, alkyl, oxo; R7 = H, alkyl; RR6 = bond; R8 = OH, halogen, alkoxy, pyrrolidinyl, piperidinyl, piperazinyl, morpholino, alkylamino], which inhibit an envelope influenza-type virus by inhibiting the fusion of the virus with the host cell, were prepared. Thus, ester II was prepared starting from abietic acid via a synthetic sequence which included aromatization/acetylation with SeO2 and acetic anhydride, side chain removal with AlCl3, and oxidation with CrO3. The prepared compds. were tested in vitro using the CPE/XTT assay and gave IC50 values < 0.1 µg/mL for influenza A/Kawasaki/89 and >100 µg/mL for influenza B/Lee virus.


MSTR 1



$$G1 = 79$$



$$G11 = 81$$



G12 = imidazolyl

G24+G25= O

Derivative:

or pharmaceutically acceptable salts

Patent location:

claim 1

Note:

substitution is restricted

L40 ANSWER 25 OF 30 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 128:23033 MARPAT Full-text

TITLE:

Preparation of podocarpic and abietic acid analogs for
use as antiviral agents

INVENTOR(S):

Colacino, Joseph M.; Hornback, William J.; Mauldin,
Scott C.; Munroe, John E.; Tang, Joseph Chiou-Chung

PATENT ASSIGNEE(S):

Eli Lilly and Company, USA; Colacino, Joseph M.;
Hornback, William J.; Mauldin, Scott C.; Munroe, John
E.; Tang, Joseph Chiou-Chung

SOURCE:

PCT Int. Appl., 127 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:



English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9741849	A1	19971113	WO 1997-US7525	19970502
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 806203	A2	19971112	EP 1997-303022	19970502
EP 806203	A3	19980429		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
CA 2253743	A1	19971113	CA 1997-2253743	19970502
AU 9730586	A	19971126	AU 1997-30586	19970502
JP 2000511886	T	20000912	JP 1997-540096	19970502
US 6127422	A	20001003	US 1999-214536	19990106
PRIORITY APPLN. INFO.:			US 1996-16906P	19960506
			WO 1997-US7525	19970502

GI



AB Podocarpic and abietic acid analogs I [R0 = R1 = H, OH, alkyl, alkoxy, hydroxyalkyl, sulfhydryl, sulfamoyl, SO2Cl, SCONMe2, NH2, alkylamino, alkylsulfonylamino; R4 = H, OH, alkoxy, acyloxy, acylamino, alkylamino, silyloxy, hydroxyimino, alkoxyimino, piperazinylimino, hydrazinylideny, oxo; R = H; R6 = H, halogen, alkyl, oxo; R7 = H, alkyl; RR6 = bond; R8 = OH, halogen, alkoxy, pyrrolidinyl, piperidinyl, piperazinyl, morpholino, alkylamino], which inhibit an envelope influenza-type virus by inhibiting the fusion of the virus with the host cell, were prepared for use in treating viral infections such as influenza, hepatitis C, bovine diarrhea, and tick borne encephalitis. Thus, ester II was prepared starting from podocarpic acid via esterification and O-alkylation. The prepared compds. were tested in vitro using CPE/XTT assay and gave IC50 values in the range of 0.01 - 32.0 $\mu\text{g}/\text{mL}$ for influenza A/Kawasaki/89 and 0.7 - 97.0 $\mu\text{g}/\text{mL}$ for influenza B/Great Lakes virus.

MSTR 1



$$\text{G1} = 79$$

$$79 \text{---} \text{G11}$$

$$\text{G11} = 81$$

$$\text{H}_2\text{C} \text{---} \text{G12}$$

$$\text{G12} = \text{imidazolyl}$$

$$\text{G24+G25} = 0$$

Derivative: or pharmaceutically acceptable salts
Patent location: claim 1

L40 ANSWER 26 OF 30 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 128:23032 MARPAT

Full-text

TITLE:

Preparation of podocarpic acid analogs for use as antiviral agents

INVENTOR(S):

Hornback, William J.; Munroe, John E.

PATENT ASSIGNEE(S):

Eli Lilly and Company, USA; Hornback, William J.; Munroe, John E.


SOURCE:

PCT Int. Appl., 40 pp.

CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9741822	A2	19971113	WO 1997-US7522	19970502
WO 9741822	A3	19980514		
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 806408	A1	19971112	EP 1997-303020	19970502
EP 806408	B1	20001213		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
CA 2253405	A1	19971113	CA 1997-2253405	19970502
AU 9727522	A	19971126	AU 1997-27522	19970502
JP 2000510468	T	20000815	JP 1997-540095	19970502
AT 198070	T	20001215	AT 1997-303020	19970502
ES 2152630	T3	20010201	ES 1997-303020	19970502
US 6103922	A	20000815	US 1999-214525	19990106
GR 3035556	T3	20010629	GR 2001-400397	20010309
PRIORITY APPLN. INFO.:			US 1996-16879P	19960506
			WO 1997-US7522	19970502

GI



AB Podocarpic acid analogs I [R0 = R1 = H, OH, alkyl, alkoxy, hydroxyalkyl, sulfhydryl, sulfamoyl, SO2Cl, SCONMe2, NH2, alkylamino, alkylsulfonylamino; R4 = H, OH, alkoxy, acyloxy, acylamino, alkylamino, silyloxy, hydroxyimino, alkoxyimino, oxo; R7 = H, alkyl; R8 = OH, halogen, alkoxy, pyrrolidinyl, piperidinyl, piperazinyl, morpholino, alkylamino], which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell, were prepared. Thus, ester II was prepared starting from Me O-methylpodocarpate via a synthetic sequence which included oxidation with CrO3, silylation with ClSiMe2CMe3, bromination, and dehydrobromination. The prepared compds. were tested in vitro using the CPE/XTT assay and gave IC50 values in the range of 0.039 - 4.6 µg/mL for influenza A/Kawasaki and in the range of 10 - 17.1 µg/mL for influenza B/Great Lakes.

MSTR 1



G1 = 79

79—G11

G11 = 81

H₂C—G12

G12 = imidazolyl

G24+G25= O

Derivative:

or pharmaceutically acceptable salts

Patent location:

claim 1

Note:

substitution is restricted

L40 ANSWER 27 OF 30 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 124:289584 MARPAT Full-text

TITLE: Preparation of 7-[(benzimidazolylmethyl)aminocarbonyl]-1,4-benzodiazepine-2-acetates and analogs as vitronectin receptor antagonists

INVENTOR(S): Ali, Fadia; Bondinell, William; Huffman, William Francis; Lago, M. Amparo; Keenan, Richard McCulloch; Kwon, Chet; Miller, William Henry; Nguyen, Thomas; Takata, Dennis T.

PATENT ASSIGNEE(S): SmithKline Beecham Corp., USA

SOURCE: PCT Int. Appl., 193 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9600730	A1	19960111	WO 1995-US8306	19950629
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, PT,				


RO, RU, SD, SG, SI, SK, TJ, TT, UA, US, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,				
BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9530010 A 19960125 AU 1995-30010 19950629				
AU 702661 B2 19990225				
EP 767792 A1 19970416 EP 1995-926152 19950629				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1156995 A 19970813 CN 1995-194853 19950629				
HU 76344 A2 19970828 HU 1996-3525 19950629				
BR 9508178 A 19971118 BR 1995-8178 19950629				
JP 10504808 T 19980512 JP 1995-503462 19950629				
US 5977101 A 19991102 US 1996-505171 19961220				
NO 9605608 A 19970227 NO 1996-5608 19961227				
NZ 329656 A 20000128 NZ 1998-329656 19980128				
NZ 329822 A 20000228 NZ 1998-329822 19980223				
PRIORITY APPLN. INFO.:				
	US 1994-267695	19940629		
	US 1995-428933	19950425		
	WO 1995-US8306	19950629		

GT

Digitized by srujanika@gmail.com

$\text{C}_6\text{H}_5\text{NH}_2 + \text{CH}_3\text{I} \rightarrow \text{C}_6\text{H}_5\text{N}^+ \text{I}^- + \text{CH}_3\text{NH}_2$

$$\text{R}_3 \text{---} \text{G} \text{---} \text{WA} \quad \text{H} \quad \text{C}$$



AB Title compds. [e.g., I; A = fibrinogen receptor antagonist template (sic); G = NH, O, S, etc.; R₂,R₃ = H, halo, alkyl, etc.; R₂R₃ = atoms to form a ring; W = CHR₁UCHR₁V, VZ; R₁ = H, (un)substituted alkyl; U,V = bond, CO, O, CH:CH, etc.; Z = N-attached pyrrolidine- or piperidine-di-yl] were prepared. Thus, Me 7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate was amidated by 2-aminomethylbenzimidazole to give, after saponification, title compound II. Title compds. inhibit vitronectin binding to SK&F 107260 in the concentration range of about 0.001 to 50μM (sic).

MSTR 1A

G1—G18


G1. = 3

G2—G12


$$G_2 = 7-2 \ 8-4 \quad / \ 14-2 \ 15-4 \quad / \ 29-2 \ 51-4 \quad / \ 17-2 \ 20-4$$

G19-G22 G9-G19 G23-G19-G24 G11-G19-G10-G19


G7 = O
G9 = 58-2 59-15



G12 = 123



G18 = 276



G19 = alkylene (opt. subst.)

G27 = CH

G30 = C(0)

Derivative:

or pharmaceutically acceptable salts

Patent location: claim 1

Note: additional ring formation is claimed.

NOTE: Additional ring formation is allowed.

L40 ANSWER 28 OF 30 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER 106-74612 MARPAT 7-11-06

ACCESSION NUMBER:

126: /4613 MARPAT Full-text

TITLE: Preparation of tetrahydronaphthalene inhibitors of 5-lipoxygenase

INVENTOR(S): Billington, David; Leon, Pascale; Sciberras, Sophie;

Canet, Emmanuel; Lonch

PATENT ASSIGNEE(S): Adir Et Compagnie,

SOURCE: Fr. Demande,

CODEN:

DOCUMENT

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. .

KIND DATE

APPLICATION NO. DATE

December 20, 2006

FR 2731704

A1 19960920

FR 1995-3036

19950316

FR 2731704


B1 19970425

FR 1995-3036

19950316

PRIORITY APPLN. INFO.:

GI




I

AB The title compds. [I; R1 = (CH₂)_n; A = (un)substituted Ph, (un)substituted heterocyclyl, etc.; n = 0-4; R2 = OH, (un)substituted alkoxy; R3 = H, (un)substituted alkyl; R4, R5 = H, alkenyl, (un)substituted aralkyl; R6, R7 = H, (un)substituted alkyl, (un)substituted alkenyl, etc.; R₂R₃ = O₂C, OCH₂, CH₂CH₂, etc.] [e.g., 1-(2-hydroxyethyl)-7-(naphthalen-2-ylmethoxy)-1,2,3,4-tetrahydronaphthalen-1-ol], which are active inhibitors of 5-lipoxygenase (e.g., I demonstrate a 70-100% in-vitro inhibition of LTB₄ at 10⁻⁶ M) and useful for treating a variety of 5-lipoxygenase-mediated diseases (e.g., arthritis, etc.), are prepared and a I-containing formulation presented.

MSTR 2

G14—G4

G1 = imidazolyl (opt. subst.)
 G3 = (0-4) CH₂
 G4 = 141



G14 = 445


445—G3—G1

Patent location: claim 14

MSTR 5

G1—G3—O—G14


G1 = imidazolyl (opt. substd.)
 G3 = (0-4) CH₂
 G14 = 453



Patent location: claim 14

L40 ANSWER 29 OF 30 MARPAT COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 119:28016 MARPAT Full-text
 TITLE: Preparation of N-substituted 3-oximinoquinolin-2,4-(1H)-diones useful for treating viral infections
 INVENTOR(S): Afonso, Adriano; Weinstein, Jay; Gentles, Margaret J.
 PATENT ASSIGNEE(S): Schering Corp., USA
 SOURCE: U.S., 14 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5190956	A	19930302	US 1990-579919	19900907
PRIORITY APPLN. INFO.:			US 1990-579919	19900907
GI				




AB Title compds. I (X = N, O, S, C; m = 0-4; R2 = alkyl, alkoxy, aryloxy, aryl, aralkyloxy, halo, etc.; R3 = alkyl, aralkyl, (substituted) aryl, alkaryl, alkylheteroaryl, alkoxyalkoxyaryl, etc.; n = 0-2) showing in vitro antiherpes simplex virus activity and II (R1 = alkyl, aryl, R4CO wherein R4 = H, aryl, alkaryl, alkenyl, H2N, H, heteroaryl, etc.), are prepared Isatoic anhydride


December 20, 2006

in DMF was added to NaH in DMF followed by Me(CH₂)₅CH₂Br in DMF to give 1-heptylisatoic anhydride. To this was added di-Et malonate in dimethylacetamide to give 1-heptyl-3-carbethoxy-2(1H)-quinolinone which was treated with 2N NaOH to give 1-heptyl-4-hydroxy-2(1H)quinolinone which was treated with NaNO₂ to give I (R_{2m} = 0, X = N, R_{3n} = 1-heptyl) (III). The IC₅₀ of III for antiherpes simplex virus activity in vitro was 2.5 µg/mL. III was inactive when tested in vivo.


MSTR 1




$$G1 = 17$$



$$G2 = 27$$



$$G6 = 169$$



Patent location: disclosure

L40 ANSWER 30 OF 30 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2004-294426 [27] WPIX
 CROSS REFERENCE: 2002-194824
 DOC. NO. CPI: C2004-112625 [27]
 TITLE: Use of imidazole derivatives including dihydronaphthalenone imidazoles for inhibiting amyloid

plaque formation in cell population for treating
Alzheimer's disease
DERWENT CLASS: B03
INVENTOR: AHN K; EMMERLING M R; HASKE T; HUPE D J; LEVINE H;
SCHOLTEN J D; SEBOT-LEOPOLD J
PATENT ASSIGNEE: (WARN-C) WARNER LAMBERT CO
COUNTRY COUNT: 1

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG.	MAIN IPC
US 20040063770	A1	20040401	(200427)*	EN	14[2]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 20040063770	A1 Provisional	US 2000-197484P	20000417
US 20040063770	A1 Cont of	US 2001-771529	20010129
US 20040063770	A1	US 2003-671385	20030926

PRIORITY APPLN. INFO: US 2003-671385 20030926
US 2000-197484P 20000417
US 2001-771529 20010129

AN 2004-294426 [27] WPIX

CR 2002-194824

AB US 20040063770 A1 UPAB: 20050528

NOVELTY - Inhibition of amyloid plaque formation in a cell population involves contacting the cell population with imidazole derivatives including dihydronaphthalenone imidazoles.

DETAILED DESCRIPTION - Inhibition of amyloid plaque formation in a cell population involves contacting the cell population with (S) 6-(2-imidazol-1-yl-1-phenyl-ethoxy)-5-phenethyl-3,4-dihydro-2H-naphthalen-1-one, 6-(2-(1H-imidazol-4-yl)-ethoxy)-3,4-dihydro-2H-naphthalen-1-one, E-(+/-)6-(2-imidazol-1-yl-1-phenyl-ethoxy)-2-thiophen-2-ylmethylen-3,4-dihydro-2H-naphthalen-1-one, 6-(1-(4-chloro-phenyl)-2-imidazol-1-yl-ethoxy)-3,4-dihydro-2H-naphthalen-1-one, (R) 6-(2-imidazol-1-yl-1-phenyl-ethoxy)-3,4-dihydro-2H-naphthalen-1-one, 6-(2-imidazol-1-yl-1-phenyl-ethoxy)-4-phenyl-3,4-dihydro-2H-naphthalen-1-one, 6-(2-imidazol-1-yl-1-phenyl-ethoxy)-5-isopropoxymethyl-3,4-dihydro-2H-naphthalen-1-one, (S) 6-(2-imidazol-1-yl-1-phenyl-ethoxy)-5-phenylaminomethyl-3,4-dihydro-2H-naphthalen-1-one, (S) 6-(2-imidazol-1-yl-1-phenyl-ethoxy)-5-(2-(4-fluorophenyl)ethyl)-3,4-dihydro-2H-naphthalen-1-one, (S) 5-benzenesulfonylmethyl-6-(2-imidazol-1-yl-1-phenyl-ethoxy)-3,4-dihydro-2H-naphthalen-1-one, (S) 6-(2-imidazol-1-yl-1-phenyl-ethylsulfanyl)-5-phenethyl-3,4-dihydro-2H-naphthalen-1-one, (S) 6-(2-imidazol-1-yl-1-phenyl-ethoxy)-5-(2-pyridin-2-yl-ethyl)-3,4-dihydro-2H-naphthalen-1-one, 6-(2-imidazol-1-yl-1-phenyl-ethoxy)-5-(2-pyridin-4-yl-ethyl)-3,4-dihydro-2H-naphthalen-1-one, 4-(5-oxo-1-phenethyl-5,6,7,8-tetrahydro-naphthalen-2-yloxy)-4-phenyl-butrylic acid, 6-(2-(3-benzyl-3H-imidazol-4-yl)-ethoxy)-5-phenethyl-3,4-dihydro-2H-naphthalen-1-one, trifluoro-acetate, (S) (1-((4-benzyloxy-benzyl)-((2-methyl-2-phenyl-propylcarbamoyl)-methyl)-carbamoyl)-2-(3H-imidazol-4-yl)-ethyl)-carbamic acid benzyl ester, (S) (2-(1H-imidazol-4-yl)-1-((4-methyl-benzyl)-(((1-phenyl-cyclobutylmethyl)-carbamoyl)-methyl)-carbamoyl)-ethyl)-carbamic acid benzyl ester, 1-methyl-4-(3-chlorophenyl)-6-((4-chlorophenyl)-(1-methylimidazol-5-yl)aminomethyl)-2,3-dihydroquinolin-2-one, or (S) (1-((4-benzyloxy-benzyl)-((2-benzyloxy-ethylcarbamoyl)-methyl)-carbamoyl)-2-(1H-imidazol-4-yl)ethyl)-carbamic acid benzyl ester.

ACTIVITY - Neuroprotective; Nootropic.

MECHANISM OF ACTION - Amyloid aggregation inhibitor; Farnesyl protein transferase inhibitor.

Efficacy of (S) 6-(2-imidazol-1-yl-1-phenyl-ethoxy)-5-phenethyl-3,4-dihydro-2H-naphthalen-1-one (Ia) to inhibit amyloid aggregation was evaluated in CHO cells transfected with human amyloid precursor protein in Dulbecco's Modified Eagle medium containing (Ia). The grown cells were incubated at 37 degrees C and protein content was determined using BCA protein assay. (Ia) showed IC₅₀ of 0.7 micro M.


USE - For inhibiting amyloid plaque formation in cell (e.g. brain cell, pancreatic cell, kidney cell, cardiac cell, neuronal cell or thyroid cell) in an animal and for treating amyloidosis associated with Alzheimer's disease (claimed) and Down's syndrome.

ADVANTAGE - The compounds are potent farnesyl protein transferase inhibitors.

AN.S DCR-885624

CN.S 6-(2-Imidazol-1-yl-1-phenyl-ethoxy)-5-phenethyl-3,4-dihydro-2H-naphthalen-1-one


SDCN RADX2Z



AN.S DCR-518729

CN.S 6-[2-(1H-Imidazol-4-yl)-ethoxy]-3,4-dihydro-2H-naphthalen-1-one


SDCN RA6LJH



AN.S DCR-518736

CN.S 6-(2-Imidazol-1-yl-1-phenyl-ethoxy)-2-thiophen-2-ylmethyleno-3,4-dihydro-2H-naphthalen-1-one


SDCN RA6LJO



AN.S DCR-518767

CN.S 6-[1-(4-Chloro-phenyl)-2-imidazol-1-yl-ethoxy]-3,4-dihydro-2H-naphthalen-1-one


SDCN RA6LKI



AN.S DCR-518771

CN.S 6-(2-Imidazol-1-yl-1-phenyl-ethoxy)-4-phenyl-3,4-dihydro-2H-naphthalen-1-one


SDCN RA6LKL



AN.S DCR-483087

CN.S 6-(2-Imidazol-1-yl-1-phenyl-ethoxy)-5-isopropoxymethyl-3,4-dihydro-2H-naphthalen-1-one


SDCN RA5URE



AN.S DCR-885626

CN.S 6-(2-Imidazol-1-yl-1-phenyl-ethoxy)-5-phenylaminomethyl-3,4-dihydro-2H-naphthalen-1-one


SDCN RADX33



AN.S DCR-885627

CN.S 5-[2-(4-Fluoro-phenyl)-ethyl]-6-(2-imidazol-1-yl-1-phenyl-ethoxy)-3,4-dihydro-2H-naphthalen-1-one


SDCN RADX34



AN.S DCR-885625

CN.S 5-Benzenesulfonylmethyl-6-(2-imidazol-1-yl-1-phenyl-ethoxy)-3,4-dihydro-2H-naphthalen-1-one


SDCN RADX35



AN.S DCR-885619

CN.S 6-(2-Imidazol-1-yl-1-phenyl-ethoxy)-5-(2-pyridin-2-yl-ethyl)-3,4-dihydro-2H-naphthalen-1-one


SDCN RADX38



AN.S DCR-483099

CN.S 6-(2-Imidazol-1-yl-1-phenyl-ethoxy)-5-(2-pyridin-4-yl-ethyl)-3,4-dihydro-2H-naphthalen-1-one

SDCN RA5URQ




AN.S DCR-885086


CN.S 6-[2-(3-Benzyl-3H-imidazol-4-yl)-ethoxy]-5-phenethyl-3,4-dihydro-2H-naphthalen-1-one trifluoro-acetate

SDCN RADX3A

CM 1



CM 2



=> fil beilst
FILE 'BEILSTEIN' ENTERED AT 16:33:21 ON 20 DEC 2006
COPYRIGHT (c) 2006 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE LAST UPDATED ON JUNE 16, 2006

FILE COVERS 1771 TO 2006.

*** FILE CONTAINS 9,606,495 SUBSTANCES ***

>>> PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For more detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<



* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
* FOR PRICE INFORMATION SEE HELP COST *

NEW

- * PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.
- * NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.

=> d que 119

L15 STR



VPA 14-16/15/19 U

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

L17 2 SEA FILE=BEILSTEIN SSS FUL L15

L19 2 SEA FILE=BEILSTEIN ABB=ON PLU=ON L17 AND BABSAN/FA

=> d 119 ide allref 1-2


L19 ANSWER 1 OF 2 BEILSTEIN COPYRIGHT 2006 BEILSTEIN MDL on STN

Beilstein Records (BRN):	8813504
Chemical Name (CN):	6-<3-(1H-imidazol-4-yl)-propoxy>-3,4-dihydro-2H-naphthalen-1-one; compound with but-2-enedioic acid
Autonom Name (AUN):	6-<3-(1H-imidazol-4-yl)-propoxy>-3,4-dihydro-2H-naphthalen-1-one; compound with but-2-enedioic acid
Fragm. Molec. Formula (FMF):	C16 H18 N2 O2 , C4 H4 O4
Molecular Formula (MF):	C16 H18 N2 O2 . C4 H4 O4
Molecular Weight (MW):	270.33, 116.07

Fragment BRN (FBRN): 8783262, 605762
 Lawson Number (LN): 28336, 8766, 1622
 File Segment (FS): Stereo compound
 Compound Type (CTYPE): heterocyclic
 Constitution ID (CONSID): 7460181
 Tautomer ID (TAUTID): 8294782
 Entry Date (DED): 2001/07/25
 Update Date (DUPD): 2001/07/25

CM 1

FBRN 8783262
 FMF C16 H18 N2 O2



CM 2

FBRN 605762
 FMF C4 H4 O4



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
FMF	Fragment Molecular Formula	2
MF	Molecular Formula	1
FW	Formular Weight	2
FBRN	Fragment BRN	2
LN	Lawson Number	3
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1

TAUTID	Tautomer ID	1
DED	Entry Date	1
DUPD	Update Date	1
MP	Melting Point	1


All References:

ALLREF

1. Stark, Holger; Sadek, Bassem; Krause, Michael; Huels, Anette; Ligneau, Xavier; Ganellin, C. Robin; Arrang, Jean-Michel; Schwartz, Jean-Charles; Schunack, Walter, J.Med.Chem., CODEN: JMCMAR, 43(21), <2000>, 3987 - 3994; BABS-6282075

L19 ANSWER 2 OF 2 BEILSTEIN COPYRIGHT 2006 BEILSTEIN MDL on STN

Beilstein Records (BRN) :	8783262
Chemical Name (CN) :	6-<3-(1H-imidazol-4-yl)-propoxy>-3,4-dihydro-2H-naphthalen-1-one
Autonom Name (AUN) :	6-<3-(1H-imidazol-4-yl)-propoxy>-3,4-dihydro-2H-naphthalen-1-one
Molec. Formula (MF) :	C16 H18 N2 O2
Molecular Weight (MW) :	270.33
Lawson Number (LN) :	28336, 8766
Compound Type (CTYPE) :	heterocyclic
Constitution ID (CONSID) :	7435575
Tautomer ID (TAUTID) :	8275662
Entry Date (DED) :	2001/07/25
Update Date (DUPD) :	2001/07/25



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	2
FS	File Segment	1
CTYPE	Compound Type	1

CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
DED	Entry Date	1
DUPD	Update Date	1
CDER	Chemical Derivative	1
PHARM	Pharmacological Data	2

All References:

ALLREF

1. Stark, Holger; Sadek, Bassem; Krause, Michael; Huels, Anette; Ligneau, Xavier; Ganellin, C. Robin; Arrang, Jean-Michel; Schwartz, Jean-Charles; Schunack, Walter, J.Med.Chem., CODEN: JMCMAR, 43(21), <2000>, 3987 - 3994; BABS-6282075

INVENTOR SEARCH

=> fil hcap medline embase biosis wpix
FILE 'HCAPLUS' ENTERED AT 16:34:25 ON 20 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 16:34:25 ON 20 DEC 2006

FILE 'EMBASE' ENTERED AT 16:34:25 ON 20 DEC 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 16:34:25 ON 20 DEC 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'WPIX' ENTERED AT 16:34:25 ON 20 DEC 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

=> d que 139
L29 2117 SEA ("AHN K"/AU OR "AHN K A"/AU OR "AHN K B"/AU OR "AHN K C"/AU OR "AHN K D"/AU OR "AHN K E"/AU OR "AHN K H"/AU OR "AHN K H K H"/AU OR "AHN K I"/AU OR "AHN K J"/AU OR "AHN K K"/AU OR "AHN K L"/AU OR "AHN K M"/AU OR "AHN K O"/AU OR "AHN K P"/AU OR "AHN K R"/AU OR "AHN K S"/AU OR "AHN K S A 3"/AU OR "AHN K T"/AU OR "AHN K W"/AU OR "AHN K Y"/AU OR "AHN K Z"/AU OR "AHN KYUNGHYE"/AU)
L30 356 SEA ("EMMERLING M"/AU OR "EMMERLING M R"/AU OR "EMMERLING MARK"/AU OR "EMMERLING MARK R"/AU OR "EMMERLING MARK RICHARD"/AU)
L31 51 SEA ("HASKE T"/AU OR "HASKE T L"/AU OR "HASKE T N"/AU OR "HASKE TARANEH"/AU OR "HASKE TARANEH N"/AU)
L32 299 SEA ("HUPE D"/AU OR "HUPE D J"/AU OR "HUPE DONALD"/AU OR "HUPE DONALD J"/AU OR "HUPE DONALD JOHN"/AU)
L33 221 SEA ("SEBOLT J"/AU OR "SEBOLT LEOPOLD"/AU OR "SEBOLT LEOPOLD J"/AU OR "SEBOLT LEOPOLD J S"/AU OR "SEBOLT LEOPOLD JUDITH"/AU OR "SEBOLT LEOPOLD JUDITH S"/AU OR "SEBOLT LEOPOLD JUDY"/AU OR "SEBOLT LEOPOLD J"/AU)
L34 2356 SEA (L*** OR L*** OR L***)
L35 228 SEA ("SCHOLTEN J"/AU OR "SCHOLTEN J D"/AU OR "SCHOLTEN JEFF"/AU OR "SCHOLTEN JEFF D"/AU OR "SCHOLTEN JEFFEREY D"/AU OR "SCHOLTEN JEFFERY D"/AU OR "SCHOLTEN JEFFERY DAVID"/AU OR "SCHOLTEN JEFFREY A"/AU OR "SCHOLTEN JEFFREY DAVID"/AU)
L36 132 SEA (L29 AND (L30 OR L31 OR L32 OR L33 OR L34 OR L35)) OR (L30 AND (L31 OR L32 OR L33 OR L34 OR L35)) OR (L31 AND (L32 OR L33 OR L34 OR L35)) OR (L32 AND (L33 OR L34 OR L35)) OR (L33 AND (L34 OR L35)) OR (L34 AND L35)
L38 33 SEA L36 AND ALZH?
L39 18 DUP REM L38 (15 DUPLICATES REMOVED)

=> d 139 ibib abs tot

L39 ANSWER 1 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2005:260614 HCAPLUS Full-text
DOCUMENT NUMBER: 143:95053
TITLE: Extracellular deposits of A β produced in cultures
of **Alzheimer** disease brain vascular smooth

AUTHOR(S): muscle cells
 Frackowiak, Janusz; Potempaska, Anna; LeVine,
Harry; Haske, Taraneh; Dickson, Dennis;
Mazur-Kolecka, Bozena

CORPORATE SOURCE: New York State Institute for Basic Research in
 Developmental Disabilities, Staten Island, NY, USA
 SOURCE: Journal of Neuropathology & Experimental Neurology
 (2005), 64(1), 82-90
 CODEN: JNENAD; ISSN: 0022-3069

PUBLISHER: Lippincott Williams & Wilkins
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB *Alzheimer* disease (AD) and Down syndrome (DS) brains contain deposits of amyloid- β peptide that are located extracellularly in the neuropil and in blood vessels walls. A small fraction of brain A β is detected intracellularly in neurons, smooth muscle cells, and microglia. The roles of these extracellular and intracellular pools of A β in pathogenesis of AD-type dementia are controversial. Cell culture models of vascular amyloidosis- β revealed intracellular, but not extracellular deposition of A β . Here we demonstrate for the first time, formation of extracellular deposits of A β in primary cultures of vascular smooth muscle cells isolated from AD cases with cerebrovascular amyloid angiopathy. Extracellular A β deposition required the use of cultures that produced high quantities of A β , which contained at least 50% of cells forming intracellular A β deposits, and providing extracellular matrix proteins. During 12 days of culture in this system, we observed accumulation of nonfibrillar, granular deposits in extracellular matrix, similar to early stages of vascular amyloidogenesis in vivo. This is a valuable system to study the effects of various potential amyloidogenic factors on formation of extracellular A β deposits.

REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 2 OF 18 HCPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2001:906214 HCPLUS Full-text

DOCUMENT NUMBER: 136:31714

TITLE: Method for treating *Alzheimer's* disease

INVENTOR(S): Ahn, Kyunghye; Emmerling, Mark
Richard; Haske, Taraneh; Hupe,
Donald J.; Sebolt-Leopold, Judith;
Levine, Harry; Scholten, Jeffrey David

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 14 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001051642	A1	20011213	US 2001-771529	20010129
US 2004063770	A1	20040401	US 2003-671385	20030926
PRIORITY APPLN. INFO.:			US 2000-197484P	P 20000417
			US 2001-771529	B1 20010129

GI



AB The present invention provides methods and compns. for inhibiting A β (β -amyloid peptide) synthesis and for treating **Alzheimer's** disease by administering a farnesyl transferase inhibitor of the formula I: wherein R is hydrogen, alkyl, and substituted alkyl; R1 is hydrogen, Ph, or substituted phenyl; and R2 is hydrogen or benzyl.

L39 ANSWER 3 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2000:65334 HCAPLUS Full-text

DOCUMENT NUMBER: 132:102869

TITLE: Naphthylazo compounds for inhibition of amyloidosis and for diagnostic imaging of amyloid aggregation

INVENTOR(S): Hays, Sheryl Jeanne; *LeVine, Harry, III;*
Scholten, Jeffery David

PATENT ASSIGNEE(S): Warner-Lambert Co., USA

SOURCE: U.S., 5 pp.

CODEN: USXXAM


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
US 6017913	A	20000125	US 1999-304016	19990503
PRIORITY APPLN. INFO.:			US 1999-304016	19990503
OTHER SOURCE(S):	MARPAT	132:102869		
GI				



AB Amyloid aggregation in animals is inhibited by administering a naphthylazo compound I [R1, R2 = H, (substituted) alkyl, or complete heterocyclic ring; R3 = H, alkyl; R4-R7 = substituent group]. The compds. are especially useful in preventing and treating **Alzheimer's** disease. A method for diagnosis of amyloid aggregation is also disclosed.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 4 OF 18 HCPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 4
 ACCESSION NUMBER: 2000:44640 HCPLUS Full-text
 DOCUMENT NUMBER: 132:131626
 TITLE: Screening for pharmacologic inhibitors of amyloid fibril formation
 AUTHOR(S): *LeVine, Harry, III.; Scholten, Jeffrey D.*
 CORPORATE SOURCE: Department of Neuroscience Therapeutics,
 Warner-Lambert Company, Ann Arbor, MI, 48105-1047, USA
 SOURCE: Methods in Enzymology (1999), 309(Amyloid, Prions, and Other Protein Aggregates), 467-476
 CODEN: MENZAU; ISSN: 0076-6879
 PUBLISHER: Academic Press
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review with 22 refs. is given on screening assays for inhibitors of amyloid fibril formation including pathophysiol. of fibril formation, a detailed description of the spontaneous fibril formation assay and the seeded fibril assay, other methods for measuring amyloid fibril formation, and characteristics of amyloid fibril formation inhibitor assays. (c) 1999 Academic Press.
 REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 5 OF 18 HCPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 5
 ACCESSION NUMBER: 1999:222215 HCPLUS Full-text
 DOCUMENT NUMBER: 131:57322
 TITLE: Apolipoprotein E alters metabolism of A β PP in cells engaged in β -amyloidosis
 AUTHOR(S): Mazur-Kolecka, Bozena; Frackowiak, Janusz; Krzeslowska, Jolanta; Ramakrishna, Narayan; Haske, Taraneh; Emmerling, Mark R.; Zhang, Wei; Kim, Kwang S.; Wisniewski, Henryk M.
 CORPORATE SOURCE: Department of Pathological Neurobiology, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY, USA
 SOURCE: Journal of Neuropathology and Experimental Neurology (1999), 58(3), 288-295
 CODEN: JNENAD; ISSN: 0022-3069
 PUBLISHER: American Association of Neuropathologists, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Canine smooth muscle cells (SMCs), cultured from amyloid-affected brain blood vessels accumulate Alzheimer amyloid- β peptide (A β) intracellularly, either spontaneously or after treatment with apolipoprotein E (apoE). ApoE is codeposited with A β , which suggests that apoE participates in A β accumulation. We tested the hypothesis that apoE-induced accumulation of A β in SMCs is caused by an increased production of amyloid- β precursor protein (A β PP) and/or its altered metabolism. We found that 24 h of treatment with apoE3 or apoE4 induced intracellular accumulation of A β -immunoreactive deposits in SMCs but did not influence A β PP production and processing. The treatment with apoE3 or E4 for 3 days resulted in the following: increased A β -accumulation; reduced levels of secreted A β ; increased production and cellular retention of mature A β PP770; and reduced culture growth, cell proliferation, and viability. ApoE4, but not apoE3, increased cellular levels of mRNA A β PP 770 (the main form produced in SMCs) about ninefold. ApoE3 stimulated production and cellular retention of endogenous apoE. We hypothesize that A β accumulation is triggered by apoE, which may bind and immobilize soluble A β produced in SMCs.

The newly formed A β deposits may further accelerate A β accumulation by altering metabolism of A β PP.

REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 6 OF 18 HCPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 6
 ACCESSION NUMBER: 1999:272914 HCPLUS Full-text
 DOCUMENT NUMBER: 131:96769
 TITLE: Emerging strategies for the treatment of Alzheimer's disease at the Millennium
 AUTHOR(S): Emmerling, Mark R.; Spiegel, Katharyn; Hall, Edward D.; Levine, Harry; Walker, Lary C.; Schwarz, Roy D.; Gracon, Stephen
 CORPORATE SOURCE: Neuroscience Therapeutics, Parke-Davis Pharmaceutical Research, A Warner-Lambert Company, Ann Arbor, MI, 48106, USA
 SOURCE: Emerging Drugs (1999), 4, 35-86
 CODEN: EMDRFV; ISSN: 1361-9195
 PUBLISHER: Ashley Publications
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English

AB A review with 303 refs. It is estimated that by the year 2050 the number of cases of Alzheimer's disease (AD) will more than triple in the United States alone. As longevity increases, AD cases are expected to skyrocket from 4 - 14 m. Globally, the nos. may reach 60 - 80 m. Those expected to develop AD in the next century are presently in their 20s, 30s or 40s. Thus, steps must be taken to prevent this imminent epidemic, and the emotional and economic toll that it will exact on both patients and families. Numerous new strategies to treat AD have emerged in the last decade. This is the direct result of an increased understanding of the mol. pathol. associated with the development of AD dementia, as well as the harvesting of results from case-control and cohort epidemiol. studies. AD is no longer viewed solely as a disease of neurotransmitter deficits or amyloid deposition. Rather, it is a combination of events (amyloidosis, neurofibrillary pathol., inflammation, oxidative stress and cerebral vascular insufficiency) that conspire to produce this dementia. This avalanche of information reveals the complexity of the genetic and environmental contributors to AD. At the same time, these advances also delineate new avenues by which AD may be palliated, halted or averted. In the present review, we shall explore the emerging opportunities for the treatment and prevention of AD.

REFERENCE COUNT: 303 THERE ARE 303 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 7 OF 18 HCPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 7
 ACCESSION NUMBER: 1997:405898 HCPLUS Full-text
 DOCUMENT NUMBER: 127:29104
 TITLE: Naphthylazo compounds for inhibition of amyloidosis and diagnostic imaging
 INVENTOR(S): Hays, Sheryl Jeanne; Levine, Harry, III; Scholten, Jeffery David
 PATENT ASSIGNEE(S): Warner-Lambert Company, USA
 SOURCE: PCT Int. Appl., 18 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.

KIND DATE


APPLICATION NO.

DATE

-----	-----	-----	-----
WO 9716194	A1	19970509	WO 1996-US16747
W: AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KE, KR,			19961018
LK, LR, LS, LT, LV, MG, MK, MN, MW, MX, NO, NZ, PL, RO, SD, SG,			
SI, SK, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU,			
TJ, TM			
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
AU 9676642	A	19970522	AU 1996-76642
TW 452491	B	20010901	TW 1996-85113270
ZA 9609189	A	19970529	ZA 1996-9189
US 5955472	A	19990921	US 1998-66397
PRIORITY APPLN. INFO.:			19980429
			US 1995-6230P P 19951102
			WO 1996-US16747 W 19961018

OTHER SOURCE(S): MARPAT 127:29104

GI



AB Amyloid aggregation in animals is inhibited by administering a naphthylazo compound I [R1, R2 = H, C1-4 alkyl, hydroxy-(C1-4)alkyl, C1-4 alkoxy-(C2-4)alkyl, C3-6 cycloalkyl, or R1NR2 = C4-12 heterocyclyl; n = 1-3; R3 = H, C1-4 alkyl; R4, R5 = H, OH, halo, C1-4 alkyl, etc.; R6, R7 = H, OH, halo, etc.] or a pharmaceutically acceptable acid addition salt thereof. The compds. are especially useful and preventing and treating *Alzheimer's* disease.
Radioactive atom-labeled I are also disclosed for diagnosis of amyloid aggregation by imaging of brain tissue.

L39 ANSWER 8 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 8

ACCESSION NUMBER: 1997:405899 HCAPLUS Full-text
 DOCUMENT NUMBER: 127:29105
 TITLE: 9-Acridinones for inhibition of amyloidosis and for diagnostic imaging
 INVENTOR(S): Hays, Sheryl Jeanne; Levine, Harry, III;
Scholten, Jeffrey David
 PATENT ASSIGNEE(S): Warner-Lambert Company, USA
 SOURCE: PCT Int. Appl., 16 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9716191	A1	19970509	WO 1996-US16745	19961018
W: AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KE, KR, LK, LR, LS, LT, LV, MG, MK, MN, MW, MX, NO, NZ, PL, RO, SD, SG, SI, SK, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU,				

TJ, TM

RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

AU 9674563 A 19970522 AU 1996-74563 19961018

TW 470644 B 20020101 TW 1996-85113271 19961030

ZA 9609186 A 19970529 ZA 1996-9186 19961031


US 5972956 A 19991026 US 1998-66376 19980429

PRIORITY APPLN. INFO.: US 1995-6388P P 19951102

WO 1996-US16745 W 19961018

OTHER SOURCE(S): MARPAT 127:29105

GI



I

AB Amyloid aggregation in animals is inhibited by administering a 9-acridinone compound I [R1, R2 = H, halo, nitro, amino, hydroxy, trifluoromethyl, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, (R5)(R6)N-alkylene, (R5)(R6)N-alkyleneoxy, (R5)(R6)N-alkylenethio; R3 = H, C1-4 alkyl; R4 = alkylene-N(R5)(R6); alkylene = (branched) C2-4 hydrocarbyl; R5, R6 = H, C1-4 alkyl, hydroxy-(C1-4)alkyl, or R5NR6 = piperidyl or pyrrolidinyl] or pharmaceutically acceptable salt thereof. The compds. are especially useful in preventing and treating *Alzheimer*'s disease. I which have ≥ 1 radioactive atom are disclosed for diagnosis of amyloid aggregation by imaging of brain tissue.

L39 ANSWER 9 OF 18 HCPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 9

ACCESSION NUMBER: 1995:309359 HCPLUS Full-text

DOCUMENT NUMBER: 122:96250

TITLE: PD 142676 (CI 1002), a novel anticholinesterase and muscarinic antagonist

AUTHOR(S): *Emmerling, Mark R.; Gregor, Vlad E.; Schwarz, Roy D.; Scholten, Jeff D.; Callahan, Michael J.; Lee, Chitase; Moore, Catherine J.; Raby, Charlotte; Lipinski, William J.; Davis, Robert E.*

CORPORATE SOURCE: Parke-Davis, Pharmaceutical Research, Warner-Lambert, Ann Arbor, MI, 48106, USA

SOURCE: Molecular Neurobiology (1994), 9(1-3), 93-106
CODEN: MONBEW; ISSN: 0893-7648

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Inhibition of brain acetylcholinesterase (AChE) can provide relief from the cognitive loss associated with *Alzheimer*'s disease (AD). However, unwanted peripheral side effects often limit the usefulness of the available anticholinesterases. Recently, the authors identified a dihydroquinazoline compound, PD 142676 (CI 1002) that is a potent anticholinesterase and a functional muscarinic antagonist at higher concns. Peripherally, PD 142676, unlike other anticholinesterases, inhibits gastrointestinal motility in rats,

an effect consistent with its muscarinic antagonist properties. Centrally, the compound acts as a cholinomimetic. In rats, PD 142676 decreases core body temperature. It also increases neocortical arousal, as measured by quant. electroencephalog., and cortical acetylcholine levels, measured by in vivo microdialysis. The compound improves the performance of C57/B10j mice in a water maze task and of aged rhesus monkeys in a delayed match-to-sample task involving short-term memory. The combined effect of AChE inhibition and muscarinic antagonism distinguishes PD 142676 from other anticholinesterases, and may be useful in treating the cognitive dysfunction of AD and produce fewer peripheral side effects.

L39 ANSWER 10 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1995:859497 HCAPLUS Full-text
 DOCUMENT NUMBER: 123:305794
 TITLE: CI-1002: A combined acetylcholinesterase inhibitor and muscarinic antagonist
 AUTHOR(S): *Emmerling, Mark R.; Gregor, Vlad E.; Callahan, Michael J.; Schwarz, Roy D.; Scholten, Jeff D.; Orr, Edward L.; Pugsley, Thomas; Moore, Catherine J.; Raby, Charlotte; et al.*
 CORPORATE SOURCE: Parke-Davis Pharmaceutical Research Division, Division Warner Lambert Co., Ann Arbor, MI, 48106, USA
 SOURCE: CNS Drug Reviews (1995), 1(1), 27-49
 CODEN: CDREFB; ISSN: 1080-563X
 PUBLISHER: Neva Press
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review, with 58 refs. CI-1002 represents a distinct advance in the development of acetylcholinesterase inhibitors for the treatment *Alzheimer's* disease. The compound introduces an acetylcholinesterase inhibitor that also possesses muscarinic antagonist activity which is about 1/10 of the acetylcholinesterase inhibitor activity. The pharmacol. actions of CI-1002 are not accompanied by cholinergically mediated side effects that are typically associated with other acetylcholinesterase inhibitors. Thus, CI-1002 provides a precedent for combining its properties into a cognition-enhancing drug. Based on preclin. results, CI-1002 performs as well if not better than tacrine in improving performance on cognitive tasks. Thus CI-1002 is predicted to be useful for treatment of *Alzheimer's* disease.

L39 ANSWER 11 OF 18 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 ACCESSION NUMBER: 2000:290023 BIOSIS Full-text
 DOCUMENT NUMBER: PREV200000290023
 TITLE: Inhibition of amyloidosis by 9-acridinones.
 AUTHOR(S): Hays, Sheryl Jeanne [Inventor, Reprint author]; *LeVine, Harry* [Inventor]; *Scholten, Jeffery David* [Inventor]
 CORPORATE SOURCE: Brighton, MI, USA
 ASSIGNEE: Warner-Lambert Company, Morris Plains, NJ, USA
 PATENT INFORMATION: US 5972956 19991026
 SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Oct. 26, 1999) Vol. 1227, No. 4. e-file.
 CODEN: OGUPE7. ISSN: 0098-1133.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 ENTRY DATE: Entered STN: 6 Jul 2000
 Last Updated on STN: 7 Jan 2002

AB Amyloid aggregation in animals is inhibited by administering a 9-acridinone compound of formula I, defined herein. The compounds are especially useful in preventing and treating **Alzheimer's** disease.

L39 ANSWER 12 OF 18 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2000:10680 BIOSIS Full-text
 DOCUMENT NUMBER: PREV200000010680
 TITLE: Naphthylazo inhibition of amyloidosis.
 AUTHOR(S): Hays, Sheryl Jeanne [Inventor, Reprint author];
LeVine, Harry [Inventor]; *Scholten, Jeffery David* [Inventor]
 CORPORATE SOURCE: Univ. of Michigan, Ann Arbor, MI, USA
 ASSIGNEE: Warner-Lambert Company
 PATENT INFORMATION: US 5955472 19990921
 SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Sep. 21, 1999) Vol. 1226, No. 3. print.
 CODEN: OGUPE7. ISSN: 0098-1133.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 ENTRY DATE: Entered STN: 23 Dec 1999
 Last Updated on STN: 31 Dec 2001

L39 ANSWER 13 OF 18 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 1999:80041 BIOSIS Full-text
 DOCUMENT NUMBER: PREV199900080041
 TITLE: Complement activation by smooth muscle cell associated beta-amyloid peptide.
 AUTHOR(S): Watson, M. D.; Evans, L. M.; *Haske, T.*; Lynch, T.; *Levine, H. X.*; Spiegel, K.; Shivers, B. D.; *Emmerling, M. R.*
 CORPORATE SOURCE: Parke-Davis Pharm. Res. Div., Warner-Lambert Co., Neurosci. Therap., 2800 Plymouth Rd., Ann Arbor, MI 48105, USA
 SOURCE: Society for Neuroscience Abstracts, (1998) Vol. 24, No. 1-2, pp. 1463. print.
 Meeting Info.: 28th Annual Meeting of the Society for Neuroscience, Part 2. Los Angeles, California, USA.
 November 7-12, 1998.
 ISSN: 0190-5295.
 DOCUMENT TYPE: Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 LANGUAGE: English
 ENTRY DATE: Entered STN: 1 Mar 1999
 Last Updated on STN: 1 Mar 1999

L39 ANSWER 14 OF 18 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 1997:369815 BIOSIS Full-text
 DOCUMENT NUMBER: PREV199799669018
 TITLE: Complement activation by A-beta-1-42 bound to cultured smooth muscle cells: A possible mechanism for cell death in AD brains.
 AUTHOR(S): Watson, M. D.; *Haske, T.*; Lynch, T.; Barnes, L. M.; *Levine, H.*; Spiegel, K.; Shivers, B. D.; *Emmerling, M. R.*
 CORPORATE SOURCE: Park-Davis Pharmaceutical Res., Div. Warner-Lambert Co., Ann Arbor, MI, USA
 SOURCE: Experimental and Clinical Immunogenetics, (1997) Vol. 14,

December 20, 2006

No. 1, pp. 86.
 Meeting Info.: 6th European Meeting on Complement in Human Disease. Innsbruck, Austria. March 12-15, 1997.
 CODEN: ECIME4. ISSN: 0254-9670.

DOCUMENT TYPE: Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 4 Sep 1997
 Last Updated on STN: 4 Sep 1997

L39 ANSWER 15 OF 18 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 1996:247251 BIOSIS Full-text
 DOCUMENT NUMBER: PREV199698803380

TITLE: CI-1002, a novel anticholinesterase and muscarinic antagonist.

AUTHOR(S): *Emmerling, Mark R.; Gregor, Vlad E.; Schwarz, Roy D.; Scholten, Jeff D.; Callahan, Michael J.; Lee, Chitase; Moore, Catherine J.; Raby, Charlotte; Lipinski, William J.; Davis, Robert E.*

CORPORATE SOURCE: Parke-Davis Pharm. Res., Div. Warner-Lambert, Ann Arbor, MI 48106, USA

SOURCE: Hanin, I. [Editor]; Yoshida, M. [Editor]; Fisher, A. [Editor]. ADV BEHAV BIOL, (1995) pp. 483-490. Advances in Behavioral Biology; Alzheimer's and Parkinson's diseases: Recent developments.
 Publisher: Plenum Press, 233 Spring Street, New York, New York, USA; Plenum Press, London, England, UK. Series: Advances in Behavioral Biology.

Meeting Info.: Selected Papers from the Third International Conference. Chicago, Illinois, USA. November 1-6, 1993.
 CODEN: ADBBBW. ISSN: 0099-6246. ISBN: 0-306-45004-6.

DOCUMENT TYPE: Book
 Conference; (Meeting)
 Book; (Book Chapter)
 Conference; (Meeting Paper)

LANGUAGE: English

ENTRY DATE: Entered STN: 31 May 1996
 Last Updated on STN: 31 May 1996

L39 ANSWER 16 OF 18 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 1995:278220 BIOSIS Full-text
 DOCUMENT NUMBER: PREV199598292520

TITLE: PD 114542 stains neuritic processes in affected regions of *Alzheimer's* disease brain but not in age-matched control brain.

AUTHOR(S): *Levine, Harry Iii; Scholten, Jeff;*
Shivers, Brenda D.

CORPORATE SOURCE: Dep. Neurodegenerative Neurol. Disorders, Parke-Davis Pharm. Res. Div., Warner-Lambert Co., Ann Arbor, MI 48106, USA

SOURCE: Journal of Cellular Biochemistry Supplement, (1995) Vol. 0, No. 21B, pp. 105.
 Meeting Info.: Keystone Symposium on the Molecular and Cellular Basis of Human Neurodegenerative Disease. Breckenridge, Colorado, USA. April 3-9, 1995.
 ISSN: 0733-1959.

DOCUMENT TYPE: Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)

LANGUAGE: Conference; (Meeting Poster)
 ENTRY DATE: English
 Entered STN: 5 Jul 1995
 Last Updated on STN: 5 Jul 1995

L39 ANSWER 17 OF 18 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 1993:175662 BIOSIS Full-text
 DOCUMENT NUMBER: PREV199344083262
 TITLE: In vitro pharmacology of PD 142676, a novel cholinesterase inhibitor.
 AUTHOR(S): *Emmerling, M. R.; Schwarz, R. D.; Gregor, V. E.; Lee, C.; Raby, C.; Scholten, J. D.; Pugsley, T. A.; Davis, R. E.*
 CORPORATE SOURCE: Parke-Davis Pharm. Res. Div., Warner-Lambert Co., Ann Arbor, MI 48106, USA
 SOURCE: Society for Neuroscience Abstracts, (1992) Vol. 18, No. 1-2, pp. 1246.
 Meeting Info.: 22nd Annual Meeting of the Society for Neuroscience. Anaheim, California, USA. October 25-30, 1992.
 ISSN: 0190-5295.
 DOCUMENT TYPE: Conference; (Meeting)
 LANGUAGE: English
 ENTRY DATE: Entered STN: 2 Apr 1993
 Last Updated on STN: 4 Apr 1993

L39 ANSWER 18 OF 18 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

ACCESSION NUMBER: 2004-294426 [27] WPIX
 CROSS REFERENCE: 2002-194824
 DOC. NO. CPI: C2004-112625 [27]
 TITLE: Use of imidazole derivatives including dihydronaphthalenone imidazoles for inhibiting amyloid plaque formation in cell population for treating *Alzheimer's disease*
 DERWENT CLASS: B03
 INVENTOR: *AHN K; EMMERLING M R; HASKE T; HUPE D J; LEVINE H; SCHOLTEN J D; SEBOT-LEOPOLD J*
 PATENT ASSIGNEE: (WARN-C) WARNER LAMBERT CO
 COUNTRY COUNT: 1

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
US 20040063770	A1	20040401	(200427)*	EN	14[2]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 20040063770	A1 Provisional	US 2000-197484P	20000417
US 20040063770	A1 Cont of	US 2001-771529	20010129
US 20040063770	A1	US 2003-671385	20030926

PRIORITY APPLN. INFO: US 2003-671385 20030926
 US 2000-197484P 20000417
 US 2001-771529 20010129

AN 2004-294426 [27] WPIX

CR 2002-194824

AB US 20040063770 A1 UPAB: 20050528

NOVELTY - Inhibition of amyloid plaque formation in a cell population involves contacting the cell population with imidazole derivatives including dihydronaphthalenone imidazoles.

DETAILED DESCRIPTION - Inhibition of amyloid plaque formation in a cell population involves contacting the cell population with (S) 6-(2-imidazol-1-yl-1-phenyl-ethoxy)-5-phenethyl-3,4-dihydro-2H-naphthalen-1-one, 6-(2-(1H-imidazol-4-yl)-ethoxy)-3,4-dihydro-2H-naphthalen-1-one, E-(+/-)6-(2-imidazol-1-yl-1-phenyl-ethoxy)-2-thiophen-2-ylmethylen-3,4-dihydro-2H-naphthalen-1-one, 6-(1-(4-chloro-phenyl)-2-imidazol-1-yl-ethoxy)-3,4-dihydro-2H-naphthalen-1-one, (R) 6-(2-imidazol-1-yl-1-phenyl-ethoxy)-3,4-dihydro-2H-naphthalen-1-one, 6-(2-imidazol-1-yl-1-phenyl-ethoxy)-4-phenyl-3,4-dihydro-2H-naphthalen-1-one, 6-(2-imidazol-1-yl-1-phenyl-ethoxy)-5-isopropoxymethyl-3,4-dihydro-2H-naphthalen-1-one, (S) 6-(2-imidazol-1-yl-1-phenyl-ethoxy)-5-phenylaminomethyl-3,4-dihydro-2H-naphthalen-1-one, (S) 6-(2-imidazol-1-yl-1-phenyl-ethoxy)-5-(2-(4-fluorophenyl)ethyl)-3,4-dihydro-2H-naphthalen-1-one, (S) 5-benzenesulfonylmethyl-6-(2-imidazol-1-yl-1-phenyl-ethoxy)-3,4-dihydro-2H-naphthalen-1-one, (S) 6-(2-imidazol-1-yl-1-phenyl-ethylsulfanyl)-5-phenethyl-3,4-dihydro-2H-naphthalen-1-one, (S) 6-(2-imidazol-1-yl-1-phenyl-ethoxy)-5-(2-pyridin-2-yl-ethyl)-3,4-dihydro-2H-naphthalen-1-one, 6-(2-imidazol-1-yl-1-phenyl-ethoxy)-5-(2-pyridin-4-yl-ethyl)-3,4-dihydro-2H-naphthalen-1-one, 4-(5-oxo-1-phenethyl-5,6,7,8-tetrahydro-naphthalen-2-yloxy)-4-phenyl-butrylic acid, 6-(2-(3-benzyl-3H-imidazol-4-yl)-ethoxy)-5-phenethyl-3,4-dihydro-2H-naphthalen-1-one, trifluoro-acetate, (S) (1-((4-benzyloxy-benzyl)-((2-methyl-2-phenyl-propylcarbamoyl)-methyl)-carbamoyl)-2-(3H-imidazol-4-yl)-ethyl)-carbamic acid benzyl ester, (S) (2-(1H-imidazol-4-yl)-1-((4-methyl-benzyl)-(((1-phenyl-cyclobutylmethyl)-carbamoyl)-methyl)-carbamoyl)-ethyl)-carbamic acid benzyl ester, 1-methyl-4-(3-chlorophenyl)-6-((4-chlorophenyl)-(1-methylimidazol-5-yl)aminomethyl)-2,3-dihydroquinolin-2-one, or (S) (1-((4-benzyloxy-benzyl)-((2-benzyloxy-ethylcarbamoyl)-methyl)-carbamoyl)-2-(1H-imidazol-4-yl)ethyl)-carbamic acid benzyl ester.

ACTIVITY - Neuroprotective; Nootropic.

MECHANISM OF ACTION - Amyloid aggregation inhibitor; Farnesyl protein transferase inhibitor.

Efficacy of (S) 6-(2-imidazol-1-yl-1-phenyl-ethoxy)-5-phenethyl-3,4-dihydro-2H-naphthalen-1-one (Ia) to inhibit amyloid aggregation was evaluated in CHO cells transfected with human amyloid precursor protein in Dulbecco's Modified Eagle medium containing (Ia). The grown cells were incubated at 37 degrees C and protein content was determined using BCA protein assay. (Ia) showed IC₅₀ of 0.7 micro M.

USE - For inhibiting amyloid plaque formation in cell (e.g. brain cell, pancreatic cell, kidney cell, cardiac cell, neuronal cell or thyroid cell) in an animal and for treating amyloidosis associated with Alzheimer's disease (claimed) and Down's syndrome.

ADVANTAGE - The compounds are potent farnesyl protein transferase inhibitors.

=> D HIS NOFIL

(FILE 'HOME' ENTERED AT 14:48:00 ON 20 DEC 2006)

FILE 'HCAPLUS' ENTERED AT 14:48:28 ON 20 DEC 2006
E US2003-671385/APPS

L1 1 SEA ABB=ON PLU=ON US2003-671385/AP
SEL RN

FILE 'REGISTRY' ENTERED AT 14:48:41 ON 20 DEC 2006

L2 36 SEA ABB=ON PLU=ON (114787-91-6/BI OR 131384-38-8/BI OR
175708-15-3/BI OR 18502-05-1/BI OR 192185-68-5/BI OR 196695-46-
2/BI OR 209906-86-5/BI OR 24424-99-5/BI OR 26231-23-2/BI OR
27656-18-4/BI OR 3470-50-6/BI OR 367267-37-6/BI OR 367267-46-7/
BI OR 367267-47-8/BI OR 367267-48-9/BI OR 367267-49-0/BI OR
367267-50-3/BI OR 367267-53-6/BI OR 367267-54-7/BI OR 367267-55
-8/BI OR 368879-84-9/BI OR 368879-97-4/BI OR 368880-01-7/BI OR
368880-02-8/BI OR 368880-05-1/BI OR 368880-25-5/BI OR 368880-96
-0/BI OR 368883-11-8/BI OR 368883-77-6/BI OR 379683-37-1/BI OR
379683-38-2/BI OR 379683-39-3/BI OR 379683-40-6/BI OR 379683-43
-9/BI OR 379683-44-0/BI OR 536-74-3/BI)

L3 4 SEA ABB=ON PLU=ON "NAPHTHALEN" AND "ONE" AND "IMIDAZOL" AND
"YL" AND "PHENYL" AND "ETHOXY" AND "4-FLUOROPHENYL" AND
"ETHYL"
D SCA L3

FILE 'HCAPLUS' ENTERED AT 14:51:24 ON 20 DEC 2006

L4 2 SEA ABB=ON PLU=ON L3
L5 1 SEA ABB=ON PLU=ON L4 AND L1

FILE 'REGISTRY' ENTERED AT 14:51:34 ON 20 DEC 2006

L6 STR
L7 0 SEA SSS SAM L6
L8 1762424 SEA ABB=ON PLU=ON NCNC2/ESS
L9 15 SEA SUB=L8 SSS SAM L6
L10 479 SEA SUB=L8 SSS FUL L6

FILE 'HCAPLUS' ENTERED AT 14:53:49 ON 20 DEC 2006

L11 12 SEA ABB=ON PLU=ON L10

FILE 'REGISTRY' ENTERED AT 14:54:13 ON 20 DEC 2006

L12 0 SEA ABB=ON PLU=ON L10 AND MEDLINE/LC
L13 0 SEA ABB=ON PLU=ON L10 AND (EMBASE OR BIOSIS)/LC
DIS

FILE 'BEILSTEIN' ENTERED AT 14:54:36 ON 20 DEC 2006

L14 0 SEA SSS SAM L6 .
L15 STR L6
L16 1 SEA SSS SAM L15
L17 2 SEA SSS FUL L15
L18 0 SEA ABB=ON PLU=ON L17 AND RN/FA
L19 2 SEA ABB=ON PLU=ON L17 AND BABSAN/FA
SEL BABSAN L19

FILE 'MARPAT' ENTERED AT 14:56:53 ON 20 DEC 2006

L20 3 SEA SSS SAM L15
L21 21 SEA SSS FUL L15
L22 17 SEA ABB=ON PLU=ON L21 NOT L11

FILE 'WPIX' ENTERED AT 14:58:04 ON 20 DEC 2006

L23 12 SEA SSS SAM L15
 L24 135 SEA SSS FUL L15
 L25 4 SEA ABB=ON PLU=ON L24/DCR
 SEL L24 SDCN
 L26 4 SEA ABB=ON PLU=ON (RADX2Z/DCN OR RADX3A/DCN OR RADX31/DCN OR
 RADX33/DCN OR RADX34/DCN OR RADX35/DCN OR RADX38/DCN OR
 RA5TKN/DCN OR RA5TKQ/DCN OR RA5TKS/DCN OR RA5TKT/DCN OR
 RA5TKU/DCN OR RA5TKV/DCN OR RA5TKW/DCN OR RA5TKX/DCN OR
 RA5TKY/DCN OR RA5TLA/DCN OR RA5TLB/DCN OR RA5TLC/DCN OR
 RA5TLD/DCN OR RA5TLE/DCN OR RA5TLF/DCN OR RA5TLG/DCN OR
 RA5TLH/DCN OR RA5TLI/DCN OR RA5TLJ/DCN OR RA5TL0/DCN OR
 RA5TL1/DCN OR RA5TL2/DCN OR RA5TL3/DCN OR RA5TL4/DCN OR
 RA5TL5/DCN OR RA5TL6/DCN OR RA5TL7/DCN OR RA5TL8/DCN OR
 RA5TL9/DCN OR RA5URA/DCN OR RA5URB/DCN OR RA5URC/DCN OR
 RA5URD/DCN OR RA5URE/DCN OR RA5URG/DCN OR RA5URH/DCN OR
 RA5URI/DCN OR RA5URJ/DCN OR RA5URK/DCN OR RA5URM/DCN OR
 RA5URN/DCN OR RA5URO/DCN OR RA5URP/DCN OR RA5URQ/DCN OR
 RA5URR/DCN OR RA5URS/DCN OR RA5URT/DCN OR RA5URU/DCN OR
 RA5URV/DCN OR RA5URW/DCN OR RA5URX/DCN OR RA5URY/DCN OR
 RA5URZ/DCN OR RA5UR8/DCN OR RA5USA/DCN OR RA5USB/DCN OR
 RA5USD/DCN OR RA5USF/DCN OR RA5USG/DCN OR RA5USK/DCN OR
 RA5USL/DCN OR RA5USN/DCN OR RA5USR/DCN OR RA5UST/DCN OR
 RA5USW/DCN OR RA5USY/DCN OR RA5US0/DCN OR RA5US1/DCN OR
 RA5US4/DCN OR RA5US6/DCN OR RA5US7/DCN OR RA5US8/DCN OR
 RA5US9/DCN OR RA5UTG/DCN OR RA5UTH/DCN OR RA5UTI/DCN OR
 RA5UTR/DCN OR RA5UTT/DCN OR RA5UTU/DCN OR RA5UTV/DCN OR
 RA5UTW/DCN OR RA5UTY/DCN OR RA5UUA/DCN OR RA5UUB/DCN OR
 RA5UUC/DCN OR RA5UUG/DCN OR RA5UUH/DCN OR RA5UII/DCN OR
 RA5UUO/DCN OR RA5UUP/DCN OR RA5UUQ/DCN OR RA5UUS/DCN OR
 RA5UUT/DCN OR RA5UV/DCN OR RA5UY/DCN OR RA5UZ/DCN OR
 RA5UU0/DCN OR RA5UU1/DCN OR RA5UU2/DCN OR RA5UU3/DCN OR
 RA5UU4/DCN OR RA5UU6/DCN OR RA5UU7/DCN OR RA5UU8/DCN OR
 RA5UU9/DCN OR RA5UVB/DCN OR RA5UVM/DCN OR RA5UVN/DCN OR
 RA5UVO/DCN OR RA5UVQ/DCN OR RA5UVR/DCN OR RA5UVS/DCN OR
 RA5UVV/DCN OR RA5UVW/DCN OR RA5UVX/DCN OR RA5UVY/DCN OR
 RA5UV1/DCN OR RA5UV2/DCN OR RA5UV3/DCN OR RA5UV5/DCN OR
 RA5UV9/DCN OR RA5UW0/DCN OR RA5UW1/DCN OR RA6LJH/DCN OR
 RA6LJO/DCN OR RA6LKI/DCN OR RA6LKJ/DCN OR RA6LKL/DCN)
 SEL L24 DCSE
 L27 0 SEA ABB=ON PLU=ON (481429-0-0-0/DCRE OR 481432-0-0-0/DCRE OR
 481434-0-0-0/DCRE OR 481435-0-0-0/DCRE OR 481436-0-0-0/DCRE OR
 481437-0-0-0/DCRE OR 481438-0-0-0/DCRE OR 481439-0-0-0/DCRE OR
 481440-0-0-0/DCRE OR 481441-0-0-0/DCRE OR 481442-0-0-0/DCRE OR
 481443-0-0-0/DCRE OR 481444-0-0-0/DCRE OR 481445-0-0-0/DCRE OR
 481446-0-0-0/DCRE OR 481447-0-0-0/DCRE OR 481448-0-0-0/DCRE OR
 481449-0-0-0/DCRE OR 481450-0-0-0/DCRE OR 481452-0-0-0/DCRE OR
 481453-0-0-0/DCRE OR 481454-0-0-0/DCRE OR 481455-0-0-0/DCRE OR
 481456-0-0-0/DCRE OR 481457-0-0-0/DCRE OR 481458-0-0-0/DCRE OR
 481459-0-0-0/DCRE OR 481460-0-0-0/DCRE OR 481461-0-0-0/DCRE OR
 483080-0-0-0/DCRE OR 483082-0-0-0/DCRE OR 483083-0-0-0/DCRE OR
 483084-0-0-0/DCRE OR 483085-0-0-0/DCRE OR 483085-1-0-0/DCRE OR
 483087-0-0-0/DCRE OR 483087-0-1-0/DCRE OR 483089-0-0-0/DCRE OR
 483090-0-0-0/DCRE OR 483091-0-0-0/DCRE OR 483092-0-0-0/DCRE OR
 483093-0-0-0/DCRE OR 483095-0-0-0/DCRE OR 483095-1-0-0/DCRE OR
 483096-0-0-0/DCRE OR 483097-0-0-0/DCRE OR 483098-0-0-0/DCRE OR
 483098-1-0-0/DCRE OR 483099-0-0-0/DCRE OR 483100-0-0-0/DCRE OR
 483101-0-0-0/DCRE OR 483101-1-0-0/DCRE OR 483102-0-0-0/DCRE OR
 483104-0-0-0/DCRE OR 483105-0-0-0/DCRE OR 483107-0-0-0/DCRE OR
 483108-0-0-0/DCRE OR 483109-0-0-0/DCRE OR 483110-0-0-0/DCRE OR
 483111-0-0-0/DCRE OR 483113-0-0-0/DCRE OR 483116-0-0-0/DCRE OR

483118-0-0-0/DCRE OR 483119-0-0-0/DCRE OR 483120-0-0-0/DCRE OR
 483120-1-0-0/DCRE OR 483121-0-0-0/DCRE OR 483122-0-0-0/DCRE OR
 483123-0-0-0/DCRE OR 483125-0-0-0/DCRE OR 483127-0-0-0/DCRE OR
 483128-0-0-0/DCRE OR 483133-0-0-0/DCRE OR 483134-0-0-0/DCRE OR
 483136-0-0-0/DCRE OR 483140-0-0-0/DCRE OR 483142-0-0-0/DCRE OR
 483145-0-0-0/DCRE OR 483147-0-0-0/DCRE OR 483165-0-0-0/DCRE OR
 483166-0-0-0/DCRE OR 483167-0-0-0/DCRE OR 483176-0-0-0/DCRE OR
 483178-0-0-0/DCRE OR 483179-0-0-0/DCRE OR

L28 4 SEA ABB=ON PLU=ON L25 OR L26

FILE 'HCAPLUS, MEDLINE, EMBASE, BIOSIS, WPIX' ENTERED AT 16:16:45 ON 20
 DEC 2006

L*** DEL 506 S AHN K/AU
 E AHN K/AU

L29 2117 SEA ABB=ON PLU=ON ("AHN K"/AU OR "AHN K A"/AU OR "AHN K
 B"/AU OR "AHN K C"/AU OR "AHN K D"/AU OR "AHN K E"/AU OR "AHN
 K H"/AU OR "AHN K H K H"/AU OR "AHN K I"/AU OR "AHN K J"/AU OR
 "AHN K K"/AU OR "AHN K L"/AU OR "AHN K M"/AU OR "AHN K O"/AU
 OR "AHN K P"/AU OR "AHN K R"/AU OR "AHN K S"/AU OR "AHN K S A
 3"/AU OR "AHN K T"/AU OR "AHN K W"/AU OR "AHN K Y"/AU OR "AHN
 K Z"/AU OR "AHN KYUNGHYE"/AU)
 E EMMERLING M/AU

L30 356 SEA ABB=ON PLU=ON ("EMMERLING M"/AU OR "EMMERLING M R"/AU OR
 "EMMERLING MARK"/AU OR "EMMERLING MARK R"/AU OR "EMMERLING
 MARK RICHARD"/AU)
 E HASKE T/AU

L31 51 SEA ABB=ON PLU=ON ("HASKE T L"/AU OR "HASKE T N"/AU OR "HASKE
 T N"/AU OR "HASKE TARANEH"/AU OR "HASKE TARANEH N"/AU)
 E HUPE D/AU

L32 299 SEA ABB=ON PLU=ON ("HUPE D"/AU OR "HUPE D J"/AU OR "HUPE
 DONALD"/AU OR "HUPE DONALD J"/AU OR "HUPE DONALD JOHN"/AU)
 E SEBOLT-L/AU

L*** DEL 27 S E4
 E SEBOLT/AU

L33 221 SEA ABB=ON PLU=ON ("SEBOLT J"/AU OR "SEBOLT LEOPOLD"/AU OR
 "SEBOLT LEOPOLD J"/AU OR "SEBOLT LEOPOLD J S"/AU OR "SEBOLT
 LEOPOLD JUDITH"/AU OR "SEBOLT LEOPOLD JUDITH S"/AU OR "SEBOLT
 LEOPOLD JUDY"/AU OR "SEBOLT LEOPOLD J"/AU)
 E LEVINE III/AU

L*** DEL 58 S E4-5
 E LEVINE H/AU

L*** DEL 1957 S E3-25

L*** DEL 341 S E30-45

L34 2356 SEA ABB=ON PLU=ON (L*** OR L*** OR L***)
 E SCHOLTEN J/AU

L35 228 SEA ABB=ON PLU=ON ("SCHOLTEN J"/AU OR "SCHOLTEN J D"/AU OR
 "SCHOLTEN JEFF"/AU OR "SCHOLTEN JEFF D"/AU OR "SCHOLTEN
 JEFFEREY D"/AU OR "SCHOLTEN JEFFERY D"/AU OR "SCHOLTEN JEFFERY
 DAVID"/AU OR "SCHOLTEN JEFFREY"/AU OR "SCHOLTEN JEFFREY A"/AU
 OR "SCHOLTEN JEFFREY D"/AU OR "SCHOLTEN JEFFREY DAVID"/AU)

L36 132 SEA ABB=ON PLU=ON (L29 AND (L30 OR L31 OR L32 OR L33 OR L34
 OR L35)) OR (L30 AND (L31 OR L32 OR L33 OR L34 OR L35)) OR
 (L31 AND (L32 OR L33 OR L34 OR L35)) OR (L32 AND (L33 OR L34
 OR L35)) OR (L33 AND (L34 OR L35)) OR (L34 AND L35)

L37 77 DUP REM L36 (55 DUPLICATES REMOVED)
 ANSWERS '1-38' FROM FILE HCAPLUS
 ANSWERS '39-40' FROM FILE MEDLINE
 ANSWER '41' FROM FILE EMBASE
 ANSWERS '42-76' FROM FILE BIOSIS
 ANSWER '77' FROM FILE WPIX

L38 33 SEA ABB=ON PLU=ON L36 AND ALZH?
L39 18 DUP REM L38 (15 DUPLICATES REMOVED)
 ANSWERS '1-10' FROM FILE HCAPLUS
 ANSWERS '11-17' FROM FILE BIOSIS
 ANSWER '18' FROM FILE WPIX

FILE 'REGISTRY' ENTERED AT 16:26:34 ON 20 DEC 2006
D QUE STAT L6

FILE 'HCAPLUS' ENTERED AT 16:27:12 ON 20 DEC 2006
D QUE NOS L11

FILE 'MARPAT' ENTERED AT 16:27:31 ON 20 DEC 2006
D QUE L21

FILE 'WPIX' ENTERED AT 16:28:01 ON 20 DEC 2006
D QUE L28

FILE 'HCAPLUS, MARPAT, WPIX' ENTERED AT 16:28:17 ON 20 DEC 2006
L40 30 DUP REM L11 L21 L28 (7 DUPLICATES REMOVED)
 ANSWERS '1-12' FROM FILE HCAPLUS
 ANSWERS '13-29' FROM FILE MARPAT
 ANSWER '30' FROM FILE WPIX
D L40 IBIB ABS HITSTR 1-12
D L40 IBIB ABS QHIT 13-29
D L40 IBIB ABS HITSTR 30

FILE 'BEILSTEIN' ENTERED AT 16:33:21 ON 20 DEC 2006
D QUE L19
D L19 IDE ALLREF 1-2

FILE 'HCAPLUS, MEDLINE, EMBASE, BIOSIS, WPIX' ENTERED AT 16:34:25 ON 20
DEC 2006
D QUE L39
D L39 IBIB ABS TOT